Exploring microRNA Biology using Integrative Bioinformatics by Pomyen, Yotsawat
Exploring microRNA Biology using 
Integrative Bioinformatics  
 
 
 
By 
Yotsawat Pomyen 
 
 
 
A thesis submitted in fulfilment of requirements for the degree of 
Doctor of Philosophy of Imperial College London 
 
 
 
 
 
 
Computational and Systems Medicine  
Department of Surgery and Cancer  
Imperial College London 
2014 
  
  
2 
Copyright Declaration 
 
The copyright of this thesis rests with the author and is made available under a 
Creative Commons Attribution Non-Commercial No Derivatives licence. 
Researchers are free to copy, distribute or transmit the thesis on the condition 
that they attribute it, that they do not use it for commercial purposes and that 
they do not alter, transform or build upon it. For any reuse or redistribution, 
researchers must make clear to others the licence terms of this work.  
  
3 
Statement of originality 
 
 
I hereby declare that all the works in this thesis is the product of my own original 
work, and to the best of my knowledge the material in this thesis has not been 
submitted to any other academic institution for any degree. The works of others used 
in this thesis are fully acknowledged according to academic standard practices.  
  
  
4 
Abstract 
Deregulation of energy metabolism is one of the emerging hallmarks of cancer 
required for proliferation and metastasis. MicroRNAs are small RNA molecules that 
have crucial roles in the regulation of biological processes in organisms, including  
metabolism. Due to recent discovery of miRNAs in humans, roles of miRNAs in  
metabolism of tumour cells, and effects these have on cancer patients, are still obscure 
and in need of expansion. Currently, experimental and computational data on the 
miRNAs are being analysed by a wide range of statistical methods; however, these 
methods in their original forms posses many limitations. Therefore, new ways of 
utilising these statistical methods are needed in order to unravel the roles of miRNAs 
in cancer metabolism. In this thesis, the roles of a specific miRNA, miR-22, and the 
three metabolic target genes were investigated through the use of classical statistical 
methods, revealed that miR-22, the metabolic target genes, and the interactions 
between them, were beneficial to survival outcome of breast cancer patients. 
Furthermore, novel combinations of the conventional statistical methods were 
invented in order to investigate the global miRNA regulations on metabolic target 
genes. These new procedures were demonstrated by using publicly available data sets. 
In one analysis, it was found that miRNAs could be divided into six clusters 
according to the metabolic target genes through a novel combination of statistical 
methods. A new statistical method was also invented to provide a generalised means 
to test for clustering based on sets of correlations.  
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1.1 Dysregulated metabolism is one of the established hallmarks of 
cancer 
In 2000, Hanahan & Weinberg published a seminal work on the hallmarks of cancer, 
which are the six main characteristics that cancer cells have in common (Hanahan & 
Weinberg 2000). Eleven years later, the same authors published an updated article, 
including four more hallmarks that cancer cells would have to acquire in order to 
support proliferative capacity. One of those four hallmarks is the capability of the 
cancer to modify or reprogram the energy metabolism of the cell (Hanahan & 
Weinberg 2011). It is widely known that cancer cells have very different requirements 
compared to normal cells in terms of metabolism. Otto Warburg was the first to 
observe that cancer cells have abnormal energy metabolism (Koppenol et al. 2011I). 
It has been proposed that cancer cells use a “glycolytic phenotype” or aerobic 
glycolysis, in which the cancer cells largely choose for an inefficient way to produce 
energy from glucose even under sufficient oxygen supply, because the cells can divert 
intermediate metabolites from the glycolysis to generate other essential biomolecules 
for the new daughter cells (Heiden et al. 2009). Main components required in any 
cells that can be synthesized from glycolysis intermediates include nucleotides, amino 
acids, and lipids. Since energy metabolism mainly occurs in mitochondria, biological 
pathways within the mitochondria will be altered to accommodate the modified 
metabolite requirement for highly proliferative cells such as cancer cells (Ward & 
Thompson 2012; Seyfried et al. 2014). 
1.2  c-Myc is an oncogene heavily involved in cancer cell metabolism 
Transcription factor c-Myc is a proto-oncogene that plays a very important role in cell 
malignancy, especially in modifying cell metabolism (Cairns et al. 2011; Miller et al. 
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2012). c-Myc can activate or inhibit a wide range of genes that are involved in cell 
metabolism, including energy metabolism, nucleotide biosynthesis, lipid synthesis 
and mitochondrial biosynthesis (Dang 2013). A myriad of genes that control these 
biological pathways are under the control of this transcription factor, which means 
that slight change in the expression of c-Myc can produce huge metabolic 
consequences in the cells, leading to carcinogenesis. However, protein-coding genes 
are not the only type of genes that are under the regulation of c-Myc. Recently, 
several studies have identified another class of genes that is also under the sphere of 
influence of this transcription factor, which are non-coding microRNA genes or 
miRNAs (Chen et al. 2012; Psathas & Thomas-Tikhonenko 2014). Currently, several 
miRNAs have been identified to be under c-Myc control. There have been substantial 
evidence that c-Myc regulates processes, through miRNAs, that are crucial for 
carcinogenesis, including cell cycle progression, apoptosis, angiogenesis, metastasis, 
and metabolism (Psathas & Thomas-Tikhonenko 2014). Therefore, by identifying 
microRNAs under this transcription factor, which in turn regulate metabolic enzymes 
that have vital roles in cancer, a more complete picture of how cellular energetics 
works could be unraveled.  
1.3 miRNA roles in cancer metabolism  
Since the discovery of the first miRNA in C. elegans in 1993, thousands of miRNAs 
were identified, through various means, in all kinds of organisms, ranging from virus 
to animals and plants. After the discovery of the let-7 miRNA family, which has 
homologs in humans, an explosion of miRNA-related findings was soon took place in 
the biomedical research community, including cancer research. Several miRNAs have 
been identified to play various roles in all sorts of cancer hallmarks, ranging from 
tumour development (Malumbres 2013), invasion and metastasis (Garzon et al. 2009; 
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Melo & Esteller 2011), angiogenesis (Melo & Esteller 2011), and proliferation 
(Esquela-Kerscher & Slack 2006). An emerging cancer hallmark of reprogramming 
energy metabolism also has several miRNAs that were identified to have important 
roles (Chen et al. 2012; Dumortier et al. 2013; Tomasetti et al. 2014). Metabolic 
pathways that have been identified to be affected by miRNA dysregulation are 
glycolysis, TCA cycle, lipid metabolism, amino acid metabolism, most of them are 
taking place in mitochondria (Tomasetti et al. 2014; Dumortier et al. 2013). 
Therefore, the understanding of miRNA in cancer metabolism is far from complete 
and is also becoming more complex with the growing number of newly discovered 
metabolic targets of miRNAs (Rottiers & Näär 2012).  
1.4 What is microRNA?  
microRNAs (miRNAs) are a class of short, non-coding RNA molecules, 
approximately 20 – 30 nucleotides in length, that regulate gene expression in 
eukaryotes from plants to worms to humans. The first microRNA, lin-4, was 
discovered in Caenorhabditis elegans in 1993. The expression of the gene lin-4 is 
required in C. elegans larvae to progress from early development stage of L1 to late 
stage L1. It was found that antisense binding of lin-4 in 3’UTR of lin-14 could 
regulate the expression of lin-14, a gene that is highly expressed during the early L1 
developmental stage L1 of worm larvae, so that it can complete specific growth 
pattern in the late L1 stage and then progress to L2 stage (Lee et al. 1993). It was also 
independently confirmed that the repression of lin-14 occurred post-transcriptionally, 
and only the binding in 3’UTR is sufficient for the repression (Wightman et al. 1993).  
Although lin-4 was the first miRNA to be discovered, the sequence of lin-4 was not 
conserved cross other species. It was not until 2000 that the let-7 miRNA was 
discovered in C. elegans (Reinhart et al. 2000), and was also found that the sequence 
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of let-7 was conserved in other metazoan, from flies, mouse, and humans (Pasquinelli 
et al. 2000). The orthologs of lin-4, miR-125, were found later in mouse (Lagos-
Quintana et al. 2002) and human (Sempere et al. 2004).   
1.5 Genomic location of microRNA  
There are two main classes of microRNAs divided according to their genomic 
location, which are intergenic and intragenic microRNAs. An intergenic microRNA is 
a microRNA that has an independent transcription unit without a host gene. Intergenic 
microRNA can be subdivided into monocistronic with a single primary transcript of 
microRNA such as miR-210 (Zhang et al. 2009), bicistronic, i.e. two adjacent primary 
transcripts of microRNA such as miR-222/211 cluster (Di Leva et al. 2010), and 
polycistronic with multiple primary transcripts of microRNAs in the same 
transcription unit such as miR-17/92 cluster with six different microRNAs 
(Mogilyansky & Rigoutsos 2013) 
An intragenic microRNA is a microRNA that is located in the intron or exon of 
another gene. The host gene of an intragenic microRNA can be either a noncoding or 
coding gene. Therefore, there are four possible genomic locations that intragenic 
microRNAs can be located, which are: intronic of a noncoding gene such as miR-
15a/16-1 in DLEU gene (Veronese et al. 2014); intronic of a coding gene such as 
miR-26a in CTDSP2 gene (Zhu et al. 2012); exonic of a noncoding gene such as miR-
155 in BIC gene (Elton et al. 2013); and exonic of a coding gene such as miR-985 in 
CACNG8 gene (Kim et al. 2009);  
A study had calculated number of intragenic miRNAs to be approximately 48% 
(~43% intronic and ~5% exonic miRNAs), the rest 52% are intergenic miRNAs 
(Hinske et al. 2010). 
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1.6 Biogenesis of microRNA in animals 
Typically, biogenesis of microRNAs usually begins by transcription from genomic 
DNA to generate primary miRNA sequence, or pri-miRNA (Bartel 2004; Kim et al. 
2009). The canonical pathway for miRNA biogenesis (Figure 1.1A) is accomplished 
through RNA polymerase II in the nucleus (Ameres & Zamore 2013), although some 
miRNAs can also be transcribed by RNA polymerase III (Borchert et al. 2006). The 
length of pri-miRNA can be range from several hundred base pairs to several 
thousands base pairs, which forms hairpin-structured stem loops from the transcript 
(Bartel 2004; Kim 2005). In the canonical pathway of miRNA biogenesis, 
heterodimer of endonuclease RNAse III Drosha and DGCR8 (DiGeorge Syndrome 
critical region 8) called the microprocessor complex then crops the primary transcript 
of miRNA at the stem loops, releasing one or more precursor miRNAs or pre-
miRNAs according to pri-miRNA (Ameres & Zamore 2013). In an alternative 
miRNA biogenesis pathway (Figure 1.1B), a hairpin structure resembles pre-miRNA, 
which called a mirtron can be produced from host gene of miRNA through alternative 
splicing by spliceosome, by passing the need for microprocessor complex (Carthew & 
Sontheimer 2009; Kim et al. 2009). Next, the hairpin structure of pre-miRNA or 
mirtron, now 60-100 nucleotides, is exported out of the nucleus to cytoplasm by a 
complex of nucleo/cytoplasmic transporter exportin-5 (XPO5) and Ran-GTP (He & 
Hannon 2004; Ha & Kim 2014). After the transport out of the nucleus, pre-miRNA 
will then be further cleaved at the stem loop structure by another complex of 
endonuclease Dicer, TAR RNA-binding protein (TRBP) and protein activator of the 
interferon (PACT, also know PRKRA), and argonaute protein (AGO), resulting in a 
double-stranded miRNA-miRNA* duplex approximately 22 nucleotides (Kim et al. 
2009; Ameres & Zamore 2013; Ha & Kim 2014). The miRNA-miRNA* duplex is 
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then loaded onto AGO protein, which is followed by the liberation of miRNA* strand, 
and forms mature RNA-induced silencing complex (RISC), with mature miRNA 
sequence as the guide strand for mRNA target recognition (Kim et al. 2009; Ha & 
Kim 2014). Some small pre-miRNAs can bypass the dicing process, in which the pre-
miRNA is directly loaded onto the AGO protein and undergo maturation process into 
a mature RISC (Kim et al. 2009; Ameres & Zamore 2013; Ha & Kim 2014).  
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Figure 1.1 miRNA biogenesis pathways. A) Canonical miRNA biogenesis pathway. 
miRNA biogenesis starts with RNA transcription to produce primary miRNA 
molecule (pri-miRNA), then the secondary structure (hairpin loop) is then cropped by 
Drosha and DGCR8 proteins to produce precursor miRNA (pre-miRNA). The pre-
miRNA is then exported out of the nucleus by Exportin-5 (XPO5) protein. After the 
export, pre-miRNA is further processed by Dicer protein. The mature miRNA 
sequence is finally loaded onto AGO protein, resulting in RNA-induced silencing 
complex (RISC). This figure is adapted from Kim et al. 2009. 
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1.7 Mechanisms of actions of miRNA 
Several groups have been trying to ascertain how miRNA regulate the target genes, 
but there is no unifying theory of how miRNA suppress the expression of the target 
mRNAs (He & Hannon 2004; Pillai et al. 2007; Liu 2008; Sun et al. 2010; Eulalio et 
al. 2008; Ameres & Zamore 2013; Sarkies & Miska 2014). A recent study on kinetic 
signatures of mechanisms of actions of miRNA has gathered nine different 
mechanisms, and proposed a unifying model of how gene expression repression is 
carried out by a miRNA (Morozova et al. 2012). These nine mechanisms of actions of 
miRNA are:  
1. Cap-40S inhibition – inhibition of translational initiation by cap-40S 
association with miRISC  
2. 60S joining inhibition – inhibition of translational initiation by recruiting 
eukaryotic initiation factor 6 (eIF6) protein to prevent association between 
40S-60S ribosome subunits  
3. Inhibition of elongation  
4. Ribosome drop-off (premature termination) 
5. Cotranslational protein degradation  
6. Sequestration in P-bodies 
7. mRNA decay (degradation or destabilisation) 
8. mRNA cleavage 
9. Transcriptional inhibition (miRNA-mediated chromatin reorganisation 
following by gene silencing) 
  
Chapter 1 
 
27 
1.8 Experimental methods for miRNA target identification  
Since the first miRNA was identified back in 1993, there has been numerous 
advances on how the targets of miRNA are identified. Currently, these methods are 
widely used to experimentally identify (or validate) the miRNA-target interaction:  
1. Genetic screening – identification of mutated genes that rescue miRNA loss-
of-function phenotype  
2. Gene expression profiling after miRNA transfection/inhibition – comparing 
differentially expression genes after overexpression or inhibition of a certain 
miRNA 
3. Translation (or polysome) profiling after miRNA transfection/inhibition – 
mRNAs undergoing elongation process by ribosomes are trapped by 
cyclohexamide, and then separated out by sucrose-gradient centrifugation.  
4. Immunoprecipitation-based methods – mRNA transcripts are crosslinked with 
the miRISC proteins (typically AGO or TNRC6) by UV light then the 
crosslinked molecules are separated out by immunoprecipitation (crosslinking 
and immunoprecipitation or CLIP). The transcripts are then identified by 
microarray or sequencing. This category can be subdivided into four different 
methods: 
a. High-throughput sequencing of RNA isolated by CLIP (HITS-CLIP), 
where the transcripts obtained from immunoprecipitation undergo 
high-throughput sequencing (or deep sequencing or next-generation 
sequencing).  
b. Photoactivatable ribonucleoside-enhanced CLIP (PAR-CLIP), where 
photoactive 4-thiouridine is used as RNA substrate in RNA synthesis 
step.  
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c. Crosslinking, immunoprecipitation and sequencing of hybrids 
(CLASH), where CLIP process is followed by ligation miRNA to the 
target sites within the miRISC.  
d. Individual-nucleotide resolution CLIP (iCLIP), where reverse 
transcriptase is used to block the polymerization that takes place before 
the crosslinking.  
5. Biotin-tagged pull-down – miRNA is tagged with biotin at the 3’ end and the 
miRNA-mRNA complex is then captured by streptavidin beads, which are 
then purified and the mRNA sequences analysed.  
6. Proteomic-based methods – protein profiles are determined after miRNA 
transfection/inhibition. This category can be subdivided into two methods:  
a. Stable isotope labelling with amino acids in cell culture (SILAC), 
where protein profiles are measured by high-throughput mass 
spectrometry in the two samples (normal vs miRNA 
transfected/inhibited) that are labelled by different isotopes. 
b. Two-dimensional differentiation in-gel electrophoresis (2D-DIGE), 
where two samples (normal vs miRNA transfected/inhibited) are 
labelled with different fluorescent dyes then undergo iso-electric 
focusing and SDS-PAGE, and the protein spots are finally identified 
by mass spectrometry. 
7. Direct target cleavage detection – high-throughput sequencing is performed 
globally on the product of a modified 5’ RNA ligase mediated-rapid 
amplification of cDNA ends (5’ RLM-RACE). This method is called parallel 
analysis of RNA ends (PARE) or degradom-seq or genome-wide mapping of 
uncapped transcripts (GMUCT).  
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These method were extensively reviewed by Thomson et al., 2011; Martinez-Sanchez 
& Murphy, 2013; and Hausser & Zavolan, 2014. 
1.9 Several features used in miRNA target prediction algorithms 
Before the advances on the experimental methods of target identification reviewed in 
the previous section, there was no economically viable means to globally identify the 
targets of miRNA. Researchers were resorting to a bottom-up approach, where only a 
handful of genes or miRNAs can be tested at a time. Therefore, bioinformatics 
algorithms and tools based-on unique characteristics (or features) of miRNA target 
recognition sites and/or miRNA-mRNA complex were invented to facilitate miRNA 
target identification. These algorithms and tools are immensely valuable to 
biomedical researchers because the researchers can use these tools to focus their work 
on likely candidates, and do not waste their precious time and resources to 
unnecessarily testing genes that might not be target of the miRNAs of their choice.  
Several miRNA target prediction algorithms are online resources, and most of them 
are freely available. There are a number of reviews that introduce each algorithm 
regarding their main capabilities, methodologies, performances, and the differences 
between them (Hammell 2010; Saito & Saetrom 2010; Witkos et al. 2011; Peterson et 
al. 2014; Ritchie & Rasko 2014). These reviews mostly focused on the ‘features’ that 
the algorithms used in order to predict the target genes of miRNAs. Based on these 
reviews, common features that miRNA prediction software used to identify target 
genes are as follows: 
1. Seed sequence complementarity – most of miRNA target prediction software 
require the target sites to have at least 6 or 7 nucleotides ‘seed’ matched to the 
first 2-7 or 2-8 nucleotides starting at 5’ end of mature miRNA sequence.   
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2. Conservation among species – another feature that most miRNA target 
prediction algorithms used to assess potential target sites. If the target sites are 
conserved among several species, then they are considered evolutionarily 
important to living organisms.  
3. miRNA:mRNA duplex thermodynamic stability or free energy – if a 
miRNA:mRNA duplex has low minimum (Gibbs) free energy, it is considered 
to be highly stable (or favourable) duplex, and thus more likely to be a real 
interaction.  
4. Target site accessibility – mRNA secondary structure affects the binding of 
the miRISC to the target site. In this regard, minimum free energy can be 
calculated to assess whether the target site is accessible, and indeed a 
functional target site.  
5. Target site abundance – to achieve effective targeting, a mRNA usually has 
more than one miRNA target sites for a miRNA. Some groups suggested that 
multiple target sites might result in additive or even synergistic effects.  
6. miRNA:mRNA interaction types – certain types of miRNA:mRNA 
interactions are more likely to be used. Nevertheless, there exist several non-
canonical site types for miRNA:mRNA interactions. These site types are:  
a. 6-mer: a site with perfect Watson-Crick match between 2-7 nucleotide 
seed sequence at 5’ end of miRNA. This site only has modest 
regulatory effect on the target. 
b. 7mer-A1: a site with perfect Watson-Crick match between 2-7 
nucleotide seed sequence at 5’ end of miRNA and has an A across 
from nucleotide 1 of miRNA. It was proposed that the A is recognised 
by miRISC.  
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c. 7mer-m8: a site with perfect Watson-Crick match between 2-8 
nucleotide seed sequence at 5’ end of miRNA. This is the most 
abundance site types in the genomes and considered to be highly 
conserved among species. 
d. 3’-supplementary: a site with additional Watson-Crick base-pairing at 
nucleotides 13-16 from 5’ end of miRNA. This site type is rare in the 
genome. 
e. 3’-compensatory: a site that has a mismatch in the seed region 
(nucleotides 2-7) with additional Watson-Crick base-paring at 
nucleotides 13-16 from 5’ end of miRNA, which thought to 
compensate the mismatch in the seed region. This site type is rare in 
the genome.  
7. Target site location – target sites of miRNAs are usually residing in 3’ 
untranslated region (UTR), but recently there are emerging evidence that 
miRNA target sites can be in 5’UTR, or even on the open reading frames 
(ORFs) of the target genes. 
8. miRNA:mRNA expression profiles – the target genes and miRNAs usually 
have negative correlation between them. With this fact, some algorithms take 
into account the expression profiles of the miRNAs and the target mRNAs in 
order to increase the accuracy of the predictions. It should be noted that this is 
not a main feature, and only a few algorithms incorporated this approach into 
the calculation. 
1.10 Commonly used miRNA prediction algorithms 
As previously mentioned in the previous section, there are quite a number of miRNA 
target prediction software, implementing different methodologies and take into 
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account different number of features in the prediction methods. However, there are 
only a few that have been used extensively by researchers and worth mentioning in 
this study. These miRNA prediction software are as follow:  
1. TargetScan – a prediction algorithm based on stringent seed pairing and target 
site conservation (Friedman et al. 2009).  
2. miRanda – this tool considers three main features in the target predictions, 
which are stringent seed match, site conservation and minimum free energy 
(John et al. 2004).  
3. DIANA-microT – one of several tools that consider a bulge in the seed match 
and require 7-9 nucleotides long to supplement or compensate the bulge 
(Reczko et al. 2012).  
4. PITA – Probability of interaction by target accessibility (PITA) uses the site 
accessibility as the main feature in the target prediction. This tool also 
considers other features in the prediction (Kertesz et al. 2007).  
5. PicTar – This algorithm is the first one to include the co-expression between 
miRNA and the target genes. The potential target sites are identified through 
sequence alignment and scored by using Hidden-Markov Model (HMM) 
(Krek et al. 2005).  
6. RNAhybrid – Uses the minimum free energy between miRNAs (small RNAs) 
and mRNAs (large RNAs) duplex as the main feature. The first algorithm that 
use statistical models to assess the features that the algorithm takes into 
account, which are seed match, minimum free energy and target site 
abundance (Rehmsmeier et al. 2004).  
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7. RNA22 – Uses pattern recognition technique to search for potential target sites 
in mRNAs and then identify the miRNAs that could form duplex with the 
target sites from minimum free energy (Miranda et al. 2006). 
There was a comprehensive review comparing these target prediction algorithms on 
the basis of precision, sensitivity, and the ratio between predicted targets and 
experimentally validated targets, and showed that these target prediction software 
have comparable performance (Alexiou et al. 2009).  
1.11 Emerging miRNA that might play a significant role in cancer: miR-
22  
MiR-22 is an exonic miRNA, which is transcribed from a host gene called MIR22HG 
residing on the short arm of chromosome 17 in human, and has the genomic location 
at 1,617,197-1,617,281 according to UCSC Genome Browser human genome version 
hg19 (Karolchik et al. 2014). MiR-22 was previously found to be under the positive 
feedback loop of transcription factor c-Myc (Chang et al. 2008; J Xiong et al. 2010; 
Polioudakis et al. 2013), but another study showed that c-Myc might be a negative 
regulator of miR-22 (Kong et al. 2014). This miRNA has been shown to have 
potentially protective effects in neurodegenerative disease (Jovicic et al. 2013) and a 
cardiomyocyte hypertrophy regulator in heart tissue (Huang et al. 2013). Recent 
studies showed that the role of miR-22 in cancer is controversial, with conflicting 
evidence that miR-22 is a tumour-suppressor gene (J Xiong et al. 2010; Jianhua 
Xiong et al. 2010; Zhang et al. 2010; Zhang et al. 2012; X. Li et al. 2014) and an 
oncogene (Song, Ito, et al. 2013; Song, Poliseno, et al. 2013). Several hallmarks in 
multiple cancer types identified to be under the regulation of miR-22 are cancer cell 
invasion and metastasis (Li et al. 2010; Guo et al. 2013), apoptosis , cancer stem cell 
(Song, Ito, et al. 2013), cell cycle progression (Ting et al. 2010; Ling et al. 2012; D. 
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Xu et al. 2011), and cancer cell proliferation (Lenkala et al. 2014; Polioudakis et al. 
2013). However, another hallmark that is currently under explored for miR-22 is 
cancer cell metabolism. 
1.12 Breast cancer and miR-22: conflicting evidence  
The role of miR-22 in several types of cancer is controversial as has been shown in 
the previous section, especially in breast cancer. In early work, miR-22 was suggested 
to be a tumour-suppressor gene in breast cancer. However, several recent studies 
yielded different results. Two of the very first breast cancer-related studies on miR-22 
were that miR-22 repressed the expression of Estrogen receptor α (ERα), and thereby 
inhibited proliferation of breast cancer cell line MCF-7SH and in patient samples 
(Pandey & Picard 2009; Jianhua Xiong et al. 2010). Nevertheless, another study 
showed that miR-22 was not statistically associated with ERα expression in breast 
cancer tissues from patients (Yoshimoto et al. 2011). In another study, miR-22 was 
found to be suppressing the growth and cell invasiveness of breast cancer, both in in 
vitro and in vivo models through reprogramming of the senescent pathway by directly 
targeting SIRT1, Sp1, and CDK6 genes (D. Xu et al. 2011). Another recently 
published study showed that Sp1 was also suppressing the promoter region of miR-22. 
Taking into account the study by Xu et al. (2011), miR-22 is in a feed back loop 
control with Sp1 and the transcription factor c-Myc (Kong et al. 2014). Another c-
Myc-related finding in the miR-22 breast cancer study was that miR-22 
downregulates c-Myc binding protein (MYCBP), and therefore suppressing the 
activity of c-Myc by depletion of its binding protein partner (J Xiong et al. 2010). 
Although it was found in another cancer cell line, c-Myc was found to be directly 
promoting miR-22 expression in cervical cancer cell line (Polioudakis et al. 2013). 
MiR-22 was also found to be repressing other two oncogenes, epidermal growth 
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factor receptor 3 (ERBB3 or HER3) and ecotropic viral integration site 1 (EVI-1) in 
five different breast cancer cell lines, which in turn reduce the activity of PI3K/AKT 
signalling pathway and also reduce the metastatic potential of those breast cancer cell 
lines (Patel et al. 2011). Another twist in the breast cancer-related story of miR-22 
came in 2013, in which a study showed that miR-22 promotes cancer stemness and 
metastasis (through EMT) through chromatin remodeling via a demethylation of 
another tumour-suppressor gene miR-200 in the in vivo models (Song, Poliseno, et al. 
2013). There is no consensus reached for the exact roles of miR-22 in breast cancer. 
As for the roles of miR-22 in emerging hallmark like energy metabolism, there is no 
study linking miR-22 to any metabolic target. Therefore, this is a very interesting 
aspect of miR-22 that should be explored in order to fill the gap for the role of miR-22 
in cancer metabolism.  
1.13 The overall extent of miRNA regulation for the metabolic target 
genes is still unknown 
Despite the growing number of metabolic genes being discovered to be direct targets 
of several miRNAs and multiple miRNA predicted target databases, there are very 
few studies trying to probe the extent of metabolic consequences from miRNA 
control. The reasons for the lack of this kind of study are as follow: 
1. The real target genes of miRNAs and exact roles of miRNAs on the metabolic 
target genes are not completely understood. This renders most of the attempts 
to model the interactions between miRNAs and the (predicted or 
experimentally verified) target genes less useful than it should be.  
2. The multiple levels of interactions between metabolic genes, proteins, 
metabolites, and the miRNAs involved are so complex that there is no 
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computational or statistical approaches that can accommodate all of the 
variables at once.  
3. Even using only two layers of data, either miRNA-mRNA, or miRNA-
metabolites combinations, the models generated will still be very complex and 
comprise of many assumptions and constraints, render the usefulness of the 
model to be limited or very specific to fixed conditions (Resendis-Antonio et 
al. 2015).  
Nevertheless, a few studies have been attempting to perform a global analysis of 
miRNA-metabolic association. One study by Tibiche & Wang (2008) was trying to 
find regulatory patterns of miRNAs on metabolic enzymes by mapping the miRNAs 
onto metabolic pathways according to miRNA predicted target genes. This study 
identified the ‘Hub nodes’ that are highly connected and ‘cut points’ that are the rate-
limiting points for metabolite flows, and found that these hub nodes and cut points 
were under the control of miRNAs more than expected by chance. Although the 
approach was a very simple one, one should be cautious of the result of the study 
because of the fact that the most of the predicted targets of miRNAs might be false 
positives. Another study was using network-based Bayesian model called Gaussian 
Graphical Model (GGM) to model the correlation between miRNA, mRNA and 
patient survival time (Wang et al. 2013). One drawback of this study was that by 
using correlation between miRNA and mRNA, true targets of miRNAs that might not 
be correlated due to systematic errors of the data would be missed in the analysis. 
Another drawback of this approach is that it is a complex method and cumbersome to 
implement.  
Therefore, a new statistical approach that is simpler to implement and able to reduce 
the chance of false positives in the pool of predicted target genes, and a novel 
Chapter 1 
 
37 
combination of classical statistical methods to verify the findings from such approach 
is needed in order to better understand the interaction bewteen the miRNAs and target 
genes under the regulation of miRNAs, especially the metabolic target genes.  
1.14 Hypothesis of the thesis 
A better understanding of the biology of miRNAs can be achieved through integration 
of two types of biological data by using novel combinations of conventional statistical 
methods.  
1.15 The aims of this thesis 
1. Ascertain the role of miR-22 and the metabolic target genes under miR-22 
regulation in survival outcome of breast cancer patients 
2. Explore the global network of miRNA regulation on metabolic target genes by 
using statistical approach 
3. Create a novel statistical procedure for data integration from combination of 
two classical statistical methods. 
 
1.16 Statistical methods used in this thesis  
Several classical statistical methods are used throughout this thesis in order to answer 
specific and broader research questions that were explored about the miRNA biology 
and metabolism. The implementation of the statistical methods in this thesis were 
ranging from purely exploratory, i.e. simply use the methods to answer a specific 
question, to a method development, i.e. inventing new ways to use classical statistical 
methods to unravel novel information from old data sets.  
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1.16.1 Spearman’s Rank correlation   
Rank correlation is a nonparametric statistical dependence test between two variables. 
This type of test does not assume that the variables are normally distributed. The 
Spearman’s rank correlation in particular can be considered a nonparametric version 
of Pearson’s product moment correlation (or Pearson correlation) (Kendall & Gibbons 
1990). The main difference between these two tests is that the Pearson correlation 
probes the linear dependence of the two quantitative variables, while the Spearman’s 
rank correlation probes the dependence of the two variables using the ranks between 
data in the two variables. Spearman’s rank correlation is essentially Pearson 
correlation on the ranks of the two variables. In this thesis, the Spearman’s rank 
correlation was used to determine the degree of association between two variables in 
order to avoid making assumptions on the distribution of the data. This method was 
utilised extensively in the Chapter 2 and 4. The Spearman Rho (ρ) can be calculated 
by the following equation:  
! = 1− 6 !!!!(!! − 1) 
where di is the difference between ranks of the two variables, and n is the number of 
samples in a variable.  
1.16.2 Kaplan-Meier estimate and Log-rank test 
When collecting the survival data of multiple patients, it is difficult to start data 
collection at the same exact time for all the patients. It is impossible for the researcher 
to be able to trace all the patients to the very end of the study period, especially in the 
study of disease such as cancer, where patients might be out of the study, either by 
death or just disappear from the study. Kaplan-Meier estimate is a method that 
calculates the probabilities of occurrence of an event, e.g. death, cancer relapse, 
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metastasis, etc., at a certain point in time (Kleinbaum & Klein 2005a). Each 
probability at one point in time is multiplied to each and everyone of the probability 
together to yield the final estimate. There are three assumptions on the data, which are 
1) a patient who is censored (i.e. lost-to-follow up) has the same survival prospect as 
other patients at a specified time point, 2) survival probabilities of every patient is the 
same, either recruited early or late in the study, and 3) event happened at the time 
specified. A survival probability at any time point is calculated by the following 
equation:  
!! = !#!!"#$%&'!!!"#$%!!"!!ℎ!!!"#$" − #!!"#$!"#$!!"#!!!"!!ℎ!!!"#$!!"#$%!#!!"#$%&'!!!"#$%!!"!!ℎ!!!"#$"!  
To determine if the two or more KM estimates are statistically different, Log-Rank 
test is used to test the hypothesis that the KM estimates between groups are not 
different. Log-rank test is calculated by summing the ratio between squared of 
summed observed number of events minus the summed expected number of events in 
each group and the summed expected number of events in the group (Kleinbaum & 
Klein 2005a). The equation for Log-rank test statistic is the following equation:  
!"# − !"#$!!"#!!!"#"$!"$% = !! + !! !!!#!"#$%&!  
The log-rank statistic is approximately Chi-square with the degree of freedom equal 
to the number of groups minus 1. Therefore, the p-value from the log-rank test can be 
determined from Chi-square distribution table based on the significant level required. 
1.16.3 Cox proportional hazard model for hazard ratio calculation 
Cox proportional hazard model (or Cox regression) is another survival analysis 
method based on regression model. The Cox regression models the incidence or 
hazard ratio, i.e. the numbers of new events per population at-risk per unit time 
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(Kleinbaum & Klein 2005a). The hazard function is the probability that if a person 
survives to a time point t, the person will experience the event in the next time point. 
Let h(t | X1i, X2i, … , XKi) be the hazard function of ith person at a time point t, where i 
= 1, 2, … , n and X1i, X2i, … , XKi denote K predictors. h0(t) denotes the baseline 
hazard function at time point t, where all the predictors equal 0. The hazard ratio h(t) / 
h0(t) can be expressed as a hazard function at time t as follow:  ℎ ! !!!∗ ,!!!∗ ,… ,!!"∗ℎ! !|!!! ,!!! ,… ,!!" = !e(!!!!!!!!!!!!...!!!!!") 
The usefulness of the Cox model is that the baseline hazard does not have to be 
specified in order to estimate the predictor β.  
1.16.4 Meta-analysis 
Meta-analysis is a statistical technique used for combining the results from different 
and individual studies in order to increase the statistical power of the estimated effect 
from interventions (in the case of clinical trials of drug or treatments) or specific 
molecular entities (in the case of gene expression measurements). This thesis used a 
random effect model proposed by Cochran (1954) to combine the estimates from 
individual studies. The weighted estimator mw can be calculated from the following 
equation: 
!! = !!!!! !!!  
where yi is the effect from i-th study, and wi is the weight of i-th study. The weight of 
each study can be calculated by the following equation:  
!! = 1(!! + !!!) 
where t2 is inter-study variance estimate, and !!! is sampling variance from i-th study. 
The inter-study variance is calculated from the following equation:  
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!! = !"# 0, 1! − 1 (!! − !)! − 1! !!!!!  
where k is the number of studies, and ! is the mean of effect estimates from all the 
studies. 
1.16.5 Data normalisation  
In high-throughput gene expression experiments, by microarray or high-throughput 
sequencing, there are usually variations that arise from the process of the experiments 
rather than from the underlying biological differences between samples. Such 
variations (or biases) include non-uniformity in the hybridization process, scanner 
settings, the time of the experiments, ambient environment during the experiments, 
experimentation batches, and variations from different operators/experimenters. These 
variations can be minimised or removed by a process called normalisation. This thesis 
used microarray data generated from a specific single-channel microarray platform 
called Affymetrix GeneChip, which are short oligonucleotide arrays constructed using 
photolithography technology and used RNA from only one sample to be hybridised to 
the microarray. The process of normalisation in this type of microarray is used 
interchangeably with the term pre-processing, which includes three steps of 
background noise correction, normalisation, and probe level summarisation. The 
method that was used to normalise the microarrays in this thesis is called GCRMA 
(GC-content, Robust Multichip Average). GCRMA corrects the background noise in 
the microarray by using probe sequence information to take into account the GC-
content in the sequence to calculate non-specific binding in the probe. Next, GCRMA 
normalises the data by using quantile normalisation, which is a non-parametric 
statistical method that transforms the different data distributions between samples to 
be identical in every samples. Finally, the probes that measure the same gene, which 
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is collectively called a probe set, is summarised by using Tukey Median polish 
algorithm, where the median of each probe from every sample (row median) and the 
median of each sample from every probe (column median) are calculated, then 
calculate the median of medians for each row and column and finally add these 
median of medians together to yield a grand effect on each sample. This procedure is 
repeated until the sample median becomes zero for all the samples.  
The RNA high-throughput sequencing or next generation sequencing or RNA-seq 
experiments also suffer from same biases as the microarray experiments. However, 
the quantile normalisation that performs well in removing the biases in microarray 
data was found to be not suitable in high-throughput sequencing. The main reason 
being that the quantile normalisation tends to classify weakly expressed genes as 
differentially expressed, thereby increase the false-positive rate in the analysis (Dillies 
et al. 2013). Another commonly used approach in RNA-seq data normalisation is 
called read per kilobase per million mapped reads or RPKM, which rescales the gene 
counts based on the library size and the length of the gene. Unfortunately, this 
approach introduces bias in the per-gene variance, which in turn also increase the 
false-positive rate from weakly expressed genes similar to quantile normalisation 
(Dillies et al. 2013). This thesis, therefore, utilised another approach called trimmed 
mean of M-values or TMM normalisation. TMM calculates a nomalisation factor, 
which is defined as a weighted trimmed mean of the log ratios between test samples 
and a reference sample (Robinson & Oshlack 2010). This method was found to 
perform better than RPKM and quantile normalisation in differential expressed gene 
analysis in the real samples (Dillies et al. 2013). 
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1.16.6 Cochran-Armitage trend test 
Cochran-Armitage trend test is used to test whether there is an association between 
two categories in one variable and two or more categories (ordinal) in another 
variable. The data can be formulated in to a 2 x k contingency table, where the two-
category variable is the response variable that has binomial distribution and the 
ordinal variable is the explanatory variable. The null hypothesis of this test is that 
there is no association (or trend) between these two variables. The test statistic for the 
Cochran-Amitage trend test has Chi-squared distribution with the degree of freedom 
equals 1 (the number of two response categories in response variable minus one).  
1.16.7 Jaccard index and Jaccard distance  
Similarity between two sets can be compared by a similarity measure called the 
Jaccard index, defined by the ratio between the intersection of the two sets and the 
union of the two sets (Levandowsky & Winter 1971). The Jaccard index can be 
expressed in the form of the following equation:  
! !,! = ! ∩ !! ∪ !  
Distance between sets is the one-complement of the Jaccard index in the form of the 
following equation:  !! !,! = 1− !(!,!) 
The Jaccard distance is used as the distance metric to compare the distance (or 
dissimilarity) between two miRNAs families based on the predicted target genes that 
the two miRNAs have in common.  
1.16.8 Hierarchical clustering  
Clustering is an unsupervised classification technique extensively used in data 
mining. The main objective of the clustering is to group the data, which can be 
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objects, records or observations, into classes of similar kinds. A cluster can be defined 
as a group of data that are similar to other objects in the cluster and dissimilar to the 
objects in other clusters. The similarity (or dissimilarity) of the data can be measured 
by a variety of metrics, such as correlation coefficients, distance between the data in 
the Euclidean space (i.e. Euclidean distance), or the Jaccard distance. Hierarchical 
clustering is an algorithm that uses recursive steps in order to group the data, either 
through a partitioning (divisive methods) or combining (agglomerative methods) of 
existing clusters. Agglomerative hierarchical clustering (a bottom-up approach) needs 
a criterion, which is termed linkage, in order to determine the distance between the 
data and group the data into clusters (Larose 2005). Several linkages for grouping the 
data are:  
1. Single linkage or the nearest-neighbour criterion, where the minimum distance 
between each data points from two clusters determines the distance between 
two clusters. 
2. Complete linkage or the farthest-neighbour criterion, where the maximum 
distance between each data points from two clusters determines the distance 
between the two clusters.  
3. Average linkage, where the average distance between data points from two 
clusters determines the distance between the two clusters. 
4. Ward’s linkage, where a predefined objective function is used to create 
clusters that maximise the similarity between the data in the clusters being 
combined, and also maximise the external separation between other clusters. 
This thesis will utilise an agglomerative clustering algorithm based on Ward’s 
criterion.  
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1.16.9 Over-representation analysis or Fisher’s Exact test 
In a situation of sampling without replacement, to test whether occurrences of a 
certain number of objects in one class by random sampling from a universe of two 
classes of objects is more than expected by chance, the problem can be formulated 
into a 2 x 2 contingency table as follow:  
  Selected by  random sampling  
  Yes No Total 
Member of 
class A 
Yes a b n1 
No c d n2 
 Total m1 m2 N 
  
This analysis of determining if the number in cell a is more than expected by chance 
is called over-representation analysis. The statistical test used to determine the 
probability value from this type of analysis is a categorical data analysis method 
called Fisher’s exact test or hypergeometric test, derived from the name of the p-value 
distribution of the problem, which is called the hypergeometric distribution (Leonard 
2000). The p-value from the 2 x 2 contingency table is a cumulative distribution 
function of the p-value, and can be calculated by using the following equation:  
! ! ≥ ! = !1− !! !!!!!!!!!!!
!
!!!  
where p(i ≥ x) is the cumulative probability of obtaining the number of objects, a, that 
are both selected by random sampling and members of class A, !! = ! !!!! !!! ! is a 
binomial coefficient, N is the total number of objects, n1 is the number of objects in 
the class A, and m1 is the number of randomly selected objects by random sampling.  
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1.16.10 Multiple hypothesis testing  
In high-throughput gene expression analysis, each gene is subjected to individual 
hypothesis testing for differential expression between two conditions with small 
sample size. The number of the genes measured in one experiment usually exceeds 
10,000 genes. The goal of multiple hypothesis testing procedures is to control the 
number of false-positives from individual hypothesis testing. Family-wise error rate 
(FWER) multiple hypothesis testing procedure such as Bonferroni correction tests if 
there is one or more false positives in all the hypotheses being tested. This FWER 
procedure is considered too stringent in biological experiments, since the number of 
truly differentially expressed genes is unknown. Another multiple hypothesis testing 
procedure called false discovery rate (FDR) calculates the probability of expected 
false-positive proportion at a certain pre-specified level. Commonly used FDR 
correction procedure is the Benjamini-Hochberg correction procedure (Benjamini & 
Hochberg 1995), where the proportion of expected false positives E(Q) is defined as 
follow:  ! ! = !!! ! 
where, m0 is the number of true null hypothesis from individual hypothesis testing, m 
is the total number of hypotheses being tested, and α is the level of error rate desired 
to control. This thesis used Benjamini-Hochberg FDR correction procedure in all of 
the multiple hypothesis testing.  
1.16.11 Shannon’s information entropy 
In information theory, entropy is the amount of information or uncertainty in the data. 
For a discrete random variable X with a certain probability distribution, the entropy of 
the probability distribution of the variable H(X) is defined as follow:  
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! ! = − !(!!) !log!(!!)!  
where xi is the i-th random variable, and log is natural logarithm. This concept of 
information entropy was proposed by Shannon (1948). This thesis used the concept to 
determine the information entropy in the data in order to find the maximum contrast 
in the data, by calculating a Shannon entropy-like score based on this equation.   
 
  
 
 
 
 
 
 
 
Chapter 2 : Roles of miR-22 in metabolic 
regulation and survival outcome of breast 
cancer patients
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2.1 Introduction  
As part of an ongoing effort to identify miRNAs that regulate metabolism in tumour 
cells, previous work in our laboratory identified miR-22 as a possible post-
transcriptional regulator of three metabolic genes, MTHFD2, ACLY, and ELOVL6. An 
initial bioinformatics analysis using correlation analysis and O2-PLS modeling of 
molecular profiles from the NCI-60 cell line panel identified several miRNAs in 
which the expression were strongly correlated to metabolite levels: of these miR-22 
had the highest variance explained by cross validation in the model (Figure 2.1A).  
 
Figure 2.1 O2-PLS modeling of metabolite-miRNA associations in the NCI-60 
panel (From Koufaris et al., submitted). A) O2-PLS model correlated component 
‘loadings’ and individual variable cross validated predicted explained variance (Q2) 
for miRNAs. B) O2-PLS model correlated component ‘loadings’ and Q2 for 
metabolites. C) Heatmap showing univariate Pearson correlation of selected miRNAs 
with metabolites in the NCI-60 panel. D) Pearson correlations of miRNAs identified 
from multivariate model with MYC mRNA expression across the NCI-60 panel. 
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The models also identified several statistically significant metabolites, which were 
intermediates in biological pathways such as glycolysis, TCA cycle, one-carbon 
metabolism, lipid metabolism and nucleotide metabolism (Figure 2.1B-C). The set of 
metabolite-associated miRNA were also highly correlated to c-Myc expression 
consistent with regulation of these microRNAs by c-Myc (Figure 2.1D). Further 
bioinformatic analysis identified miR-22 predicted target genes consistent across three 
or more target prediction algorithms that were down regulated in two independent 
studies of the effects of miR-22 transfection. This analysis yielded seven target genes, 
in which two were metabolic target genes both involved in fatty acid synthesis: 
ELOVL6 and ACLY (Figure 2.2A-B). Another metabolic target gene identified by 
overlapping output from multiple target prediction software was MTHFD2, involved 
in mitochondrial one-carbon metabolism. This gene was of interest since a high 
degree of negative correlation between miR-22 and the metabolite S-(5’-adenosyl)-L-
methioine (SAM), an intermediate in the one-carbon metabolism was observed 
(Figure 2.1C). A series of experiments conducted in breast cancer cell line MCF-7 
confirmed that these three metabolic genes were indeed the genuine targets of post-
transcriptional regulation of miR-22 (Figure 2.2C-D and Figure 2.3A-D). Hence, it 
was hypothesised that miR-22 and the target genes might have effects on the survival 
outcome of the breast cancer patients. This study aim was to determine the extent that 
these three metabolic target genes have on the survival outcome of breast cancer 
patients, and effect modification of miR-22 on the three target genes in vivo, by using 
the miRNA and mRNA expression profiles measured by microarray and next 
generation sequencing (NGS) experiments from publicly available breast cancer data 
sets.  
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Figure 2.2 miR-22 represses fatty acid synthesis and elongation by direct 
targeting of ACLY and ELOVL6 (From Koufaris et al., submitted). A) 
Identification of putative miR-22 direct targets, identifying common targets among 
genes from two independent studies with 1.5-fold downregulation after miR-22 
transfection of ES2 cells, MCF-7 cells, and genes predicted to be miR-22 targets by 
three or more target prediction algorithms. B) Scheme of de novo synthesis and 
elongation of fatty acid and involvement of ACLY and ELOVL6 in these pathways. 
C) qRT-PCR detection of ACLY and ELOVL6 mRNA in MCF-7 cells transfected with 
either miR-22 mimic, or a negative control (scramble) after 48 hours. Data are 
normalised to β-actin and shown as mean ± s.e.m., n=3. *p <0.05. D) Immunoblotting 
analysis of ACLY and ELOVL6 in miR-22-transfected MCF-7 cells after 48 hours.  
2.2 Materials and methods 
The data used in this study were all retrieved from publicly available sources. The 
breast cancer data sets used can be divided into two main groups, one which reports 
directly levels of the mature miR-22 and another which examined expression of the 
miR-22 host gene (MIR22HG), a potential surrogate marker of mature miR-22 
expression. More details of these data can be found in the results section. The 
correlation coefficient metric used throughout this study was Spearman’s rank 
correlation coefficient (Spearman ρ). The combined correlation coefficients were 
calculated by a vote counting procedure proposed by Bushman & Wang (1995).  
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Figure 2.3 The mitochondrial enzyme MTHFD2 is repressed by miR-22 and 
affects one-carbon metabolism in cancer cells (From Koufaris et al., submitted). 
A) Representative immunoblots for MTHFD2 in MCF-7 transfected with miR-22 
mimic. B) qRT-PCR for MTHFD2. Data were normalised to β-actin. C)Validation of 
direct targeting of MTHFD2 by miR-22 using a luciferase reporter assay. Vector 
containing the luciferase reporter harboring the wildtype 3’UTR of gene (WT) or the 
3’UTR with specific mutation of miR-22 binding sites (MUT) were co-transfected 
with miR-22 or negative mimic control oligonucleotide into MCF-7 cells. D) Scheme 
of mf mammalian mitochondrial one-carbon metabolism and the metabolic role of 
MTHFD2. All data are shown as mean ± s.e.m., n = 3. ** p<0.01. *** p<0.001.  
Survival analyses were performed using Kaplan-Meier estimator to create survival 
curves from the follow-up data (Kleinbaum & Klein 2005a). The Cox proportional 
hazards model was used to calculate the hazard ratio of the gene of interest on the 
survival data (Kleinbaum & Klein 2005b). Meta-analysis was performed using 
random effect model on the Cox proportional hazard estimates (Cochran 1954), and 
using Fisher’s method on the log-rank p-values associated with Cox proportional 
hazard estimates (Whitlock 2005). The Cochran-Armitage test for trend was used to 
test if the association between miR-22 and the target genes resulted in effect 
modification (Armitage 1955). All statistical calculations and plots were performed in 
R statistical environment version 3.0 with the following packages: survival for 
Kaplan-Meier estimates, Cox proportional hazard estimates and associated log-rank 
p-values calculations, and all KM-plots in survival analyses; survcomp and rmeta for 
combining Cox proportional estimates and log-rank p-values, and all forest plots in 
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meta-analyses; and coin for Cochran-Armitage test for trend p-values calculations in 
effect modification determination between miR-22 and the target genes. 
 
2.3 Results 
2.3.1 Correlation between the expression of the mature miR-22 gene product and 
the host gene MIR22HG mRNA 
To test if expression of the host gene MIR22HG (previously known as C17orf91) was 
sufficiently associated to levels of the mature miR-22 to act as a surrogate marker, 
Spearman’s Rank correlation coefficient (Rho or ρ) between mature miR-22 and the 
host gene was calculated for several data sets where expression data on both were 
available (Table 2.1). Overall, very high degrees of agreement were observed. 
Spearman’s ρ ranged from 0.4-0.53, and all ρ were statistically significant. Given 
these observations, in several independent data sets, it was decided that MIR22HG 
could be used as a surrogate for mature miR-22 expression. 
2.3.2 Normalisation effect on correlation coefficients of in vivo data sets 
Variation in the platforms used in measuring both mature miR-22 and the host genes 
(i.e. high-throughput sequencing and microarray technologies) did not have 
significant effect on the correlation. However, data normalisation on high-throughput 
sequencing data did have a very significant effect on the correlation coefficient. The 
current normalisation method employed in most miRNA-seq data analysis with 
multiple samples is read per kilobase per million (RPKM), which normalises each 
miRNA species based on their transcript length on each sample.  
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Table 2.1 Spearman’s rank correlation coefficients between mature miR-22 and 
the host gene. 
 Data set Spearman’s ρ FDR adjusted p-value 
NCI-60 data 
miR-Israel Lab x Gx-GeneLogic (HG-U133) 0.528 2.71E-5 
miR-Israel Lab x Gx-GeneLogic (HG-U95A) 0.424 8.00E-4 
miR-Weinstein Lab x Gx-GeneLogic (HG-U133) 0.398 0.002 
miR-Weinstein Lab x Gx-GeneLogic (HG-U95A) 0.396 0.002 
Breast 
Cancer data 
(TCGA) 
miR-UNC (miRNAseq + HiSeq2000) x Gx-
BCGSC (HiSeq2000)   0.512 < 2.20E-16 
For in vitro (NCI-60) data sets, mature miR-22 was measured by RT-PCR (Israel Lab [Gaur et al., 
2007]) or custom spotted microarray (Weinstein Lab [Blower et al., 2007]), and the host gene 
expression was measured by two separate Affymetrix microarray designs. NCI-60 microarray 
experiments were carried out by GeneLogic, Inc (Shankavaram et al. 2007). For TCGA data set, both 
mature miR-22 and the host gene were measured by high-throughput sequencing platforms by Illumina 
(The Cancer Genome Atlas Network 2012). 
 
Nevertheless, in this study, it was found that the standard RPKM normalised mRNA 
and miRNA lead to underestimation of correlation between mature miR-22 and the 
target genes. Table 2.2 and Table 2.3 show the correlation coefficients after RPKM- 
and TMM-normalised between mature miR-22 and the three target genes from Farazi 
et al. (2011) and TCGA breast cancer data sets, respectively. For both data sets, the 
TMM-normalised data yielded statistically significant and higher negative correlation 
coefficients than RPKM-normalised data, except for ELOVL6 in Farazi et al. data set. 
The ρ between miR-22 and the three metabolic target genes, MTHFD2, ACLY, and 
ELOVL6, from Farazi et al. data set using RPKM-normalised data were -0.24, -0.14 
and -0.19, respectively, and for TMM-normalised data the ρ were, -0.33, -0.17 and -
0.07, respectively. For TCGA data set, the ρ for RPKM-normalised data were -0.07, 
0.06 and -0.04, and the ρ for TMM-normalised data were -0.29, -0.06 and -0.11, for 
MTHFD2, ACLY and ELOVL6, respectively. This clearly showed that normalisation 
of miRNA-seq data was affecting the differential miRNA analysis.  
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Table 2.2 Correlation coefficients comparison between RPKM- and TMM-
normalised of Farazi et al. (2010) breast cancer data set. 
Gene 
RPKM-normalised TMM-normalised 
Spearman’s ρ p-value Spearman’s ρ p-value 
MTHFD2 -0.24 0.002 -0.33 2.11E-5 
ACLY -0.14 0.07 -0.17 0.02 
ELOVL6 -0.19 0.01 -0.07 0.35 
 
Table 2.3 Correlation coefficients comparison between RPKM- and TMM-
normalised of TCGA breast cancer data set. 
Gene 
RPKM-normalised TMM-normalised 
Spearman’s ρ p-value Spearman’s ρ p-value 
MTHFD2 -0.07 0.15 -0.29 2.20E-16 
ACLY 0.06 0.23 -0.06 0.02 
ELOVL6 -0.04 0.46 -0.11 0.0003 
 
2.3.3 Correlation between mature miR-22 and metabolites – in vitro data sets 
Using microRNA and metabolite data sets based on NCI-60 cell panel, miR-22 has 
strong and negative correlations with several metabolites. The metabolites with 
strongest negative correlation coefficients with miR-22 were trans-4-hydroxy-L-
proline (hydroxyproline), S-(5’-adenosyl)-L-methionine (SAM), 5’-S-methyl-5’-
thioadenosine (MTA), and citric acid. Table 2.4 shows Spearman’s Rank correlations 
and adjusted p-values between miR-22 from two independent microRNA array data 
sets based on NCI-60 cell panel and the three metabolites. Hydroxyproline is the 
metabolite of amino acid proline, and both are major components in collagen proteins 
and connective tissues in human. SAM is the major donor of methyl groups for most 
biosynthetic methylation processes in the cells. Synthesis and recycling of SAM is 
coupled with another metabolic pathway, which is the folate-dependent one-carbon 
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metabolism. MTA is the substrate for adenine synthesis, which is a substrate for 
adenosine synthesis, a building block of DNA, and also a one-carbon (methylation) 
pathway metabolite. Citric acid or citrate is a substrate in the TCA cycle and fatty 
acid biosynthesis.  
Table 2.4 Correlation between miR-22 and metabolites from in vitro data sets. 
Metabolite 
Sokilde et al. (2011) Liu et al. (2010) 
Spearman’s ρ FDR adjusted p-value Spearman’s ρ 
FDR adjusted 
p-value 
Hydroxyproline -0.657 1.98E-5 -0.504 0.009 
SAM -0.630 1.98E-5 -0.415 0.03 
MTA -0.599 5.97E-5 -0.331 0.08 
Citric acid -0.588 7.80E-5 -0.434 0.02 
Strongest negative correlation coefficients between miR-22 (Søkilde et al. 2011; Liu et al. 2010) and 
metabolites (National Cancer Institute 2014) from data sets based on NCI-60 cell panel. 
 
Another metabolic gene predicted to be a target of miR-22 by at least three 
microRNA target prediction software was methylenetetrahydrofolate 
dehydrogenase/cyclohydrolase (MTHFD2). This gene is the mitochondrial 
bifunctional enzyme in the SAM cycle, which was found to be a rate limiting step for 
synthesising 5,10-methylenetetrahydrofolate, a substrate for purine biosynthesis 
(Pawelek & MacKenzie 1998).  
 
These results confirmed the previous work of our group that these metabolites have 
high degree of negative correlations with miR-22, and rationalised the three metabolic 
target genes that were proposed to be under the regulation of miR-22.  
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2.3.4 Correlation between miR-22 and the three metabolic target genes – in vivo 
data sets  
To test the hypothesis that ACLY, MTHFD2, and ELOVL6 were the targets of miR-22 
in vivo, the correlation between the miR-22 expression and mRNA levels of these 
targets in a series of tumour data sets were calculated. The expressions of these 
metabolic target genes were extracted from breast cancer patient data sets from 
several breast cancer studies. The selected data sets for this work were based on the 
studies used in the Kaplan-Meier plotter website (kmplotter.com). The criteria for 
data sets to be selected were as follow: 1) survival data [i.e. relapse-free follow-up 
time] were available and 2) the gene expression platform used was Affymetrix HG-
U133 family. The survival data, i.e. the relapse-free period of the patients, were used 
for subsequent survival analyses. The gene used as the surrogate of miR-22 
expression was MIR22HG (previously known as C17orf91), which was presented in 
the Affymetrix HG-U133 family GeneChip platform. In total, nine breast cancer data 
sets from eight breast cancer studies were selected for this study. Affymetrix probeset 
names for MIR22HG and the target genes are shown in Table 2.5. Note that where 
multiple probesets were available, the probesets reported for the target genes of miR-
22 were the best performing probesets, i.e. the ones that give the highest correlations 
and/or highest hazard ratios in subsequent survival analyses. This was based on the 
presumption that noise in these data sets were more likely to reduce a true correlation 
than create a false positive.  
 
 Two mature microRNA data sets were used in this work. First data set is from 
The Cancer Genome Atlas (TCGA) project. Briefly, TCGA is a comprehensive data 
repository for several cancers with multiple molecular measurements by microarray 
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technology or high-throughput sequencing technology. The breast cancer data used in 
this analysis consist of mature microRNAs and gene expression measured by high-
throughput sequencing and survival data (follow-up time and vital status) of the 
patients. The second data set is from Farazi et al. (2010), a collection of microRNA 
and gene expression of 161 breast carcinomas and 6 cell lines with survival data. 
microRNA expression was measured by high-throughput sequencing and gene 
expression was measured by custom spotted microarray. Table 2.6 summarises the 
number of samples in each data set that was used in this study. 
 
The results of the correlation analyses are shown in Table 2.7. miR-22 was negatively 
correlated with c-Myc (Spearman’s ρ ranged from 0.003 to -0.46), consistent with 
previous findings that miR-22 is regulated by this transcription factor. miR-22 was 
also negatively correlated with its target genes that have been previously identified by 
microRNA target prediction software and confirmed by cell culture experiment. The 
trend was clear that miR-22 is negatively correlated with these target genes, albeit 
with non-statistically significant p-values in majority of the cases. Spearman’s Rho 
for ACLY, MTHFD, and ELOVL6 were ranging from -0.02 to -0.25, -0.08 to -0.33, 
and 0.0006 to -0.32, respectively. Combined correlation coefficients between miR-22 
and the target genes were also calculated by using the combining sample correlation 
coefficients and vote counts procedure (Bushman & Wang 1995). It was evidently 
clear from the combined correlation coefficients that these target genes were 
negatively correlated with the miR-22, and that these target genes were possibly the 
real targets for post-transcriptional repression by miR-22 in vivo. The combined 
Spearman’s ρ [with 95% confidence interval] for MTHFD2, ACLY, and ELOVL6 
were -0.24 [-0.20, -0.28], -0.07 [-0.03, -0.11], and -0.11 [-0.08, -0.15], respectively.  
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Figure 2.4 shows the relationship between mature miR-22 expression and the three 
metabolic target genes in detail. The patients in each data set were divided into four 
bins according to mature miR-22 expression quartiles (the first quartile and fourth 
quartile are the lowest and highest mature miR-22 expression, respectively), and the 
boxes and whiskers showed the expression level of its target genes in each bin. For 
MTHFD2, the median expression in each bin decreases with higher miR-22 
expression, which is also evidence that miR-22 might be associated with MTHFD2 in 
vivo. The cell culture performed within Keun group (Figure 2.3A-C) showed that 
MTHFD2 was repressed by miR-22, which confirmed that the association is genuine. 
For ACLY and ELOVL6, visual inspection did not show associations between the 
genes and miR-22 (Figure 2.4).  
Table 2.5 Probeset names of MIR22HG and the target genes from Affymetrix 
GeneChip platforms used in breast cancer studies. 
Gene Symbol Selected probeset name Affymetrix GeneChip platforms 
MIR22HG 214696_at HG-U133A, HG-U133plus2 
MTHFD2 201761_at HG-U133A, HG-U133plus2 
ACLY 201128_s_at HG-U133A, HG-U133plus2 
ELOVL6 204256_at HG-U133A, HG-U133plus2 
c-MYC 202431_s_at HG-U133A, HG-U133plus2 
Note that there are multiple probesets for ACLY and ELOVL6 and only best performing probesets were 
selected for these two genes for correlation and subsequent survival analyses. 
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Table 2.6 Number of samples from data sets used in this studies. 
Data set Number of samples 
Median*/mean^ age 
at diagnosis (years) 
Median*/mean^ 
Follow-up time 
 (years) 
Number of events 
(relapse) 
Mature  
miR-22 
TCGA 1126 NA 2.7^ [0-18.6] 37 
Farazi et al. 
(2010)+ 161 50^ [26-83] 7.1^ [0.6-17.8] 31 
miR-22  
host gene 
 
GSE1456 159 58^ [42-75] 6.2^ [0.2-8.4] 40 
GSE16391 55 59^ [46-78] 3^ [0.9-5.4] 55 
GSE2034 286 54^ [32-70] 6.4^ [0.1-14.2] 107 
GSE2990 102 58^ [32-86] 7^ [0.02-14.5] 40 
GSE3494 251 62^ [28-93] 7.1^ [0.08-12.7] 61 
GSE6532 
(GPL570) 87 NA 12.7* [NA] 28 
GSE6532 
(GP96) 72 NA 6.1* [NA] 19 
GSE7390 198 47* [NA] 14* [NA] 51 
GSE9195 77 63^ [42-82] 12.5^ [NA] 10 
+ number of samples with microRNA measurement is 185 but samples with corresponding gene 
expression is 161.  
^ marks the data with mean values.  
* marks the data with median values. NA = Not available.  
 
 
Table 2.7 Correlation coefficients (Spearman's ρ) between mature miR-22 or the 
host genes and the target genes. 
Data set 
Possible miR-22 Target genes  
MTHFD2 ACLY ELOVL6 c-MYC  
Mature 
miR-22 
TCGA -0.2932 -0.0647 -0.108 -0.1666  
Farazi et al. (2010) -0.3301 -0.1746 -0.0732 -0.2531  
miR-22 host 
gene 
 
GSE1456 -0.1939 -0.2599 -0.1206 -0.2876  
GSE16391 -0.1508 -0.0997 0.0738 -0.4639 p-value 
GSE2034 -0.1232 -0.0253 -0.1801 0.069 < 0.001 
GSE2990 -0.2481 -0.1549 -0.1415 -0.2163 < 0.01 
GSE3494 -0.3289 -0.0350 -0.1222 -0.0163 < 0.05 
GSE6532 (GPL570) -0.1677 -0.0659 -0.2029 -0.1418  
GSE6532 (GP96) -0.2003 -0.1028 -0.2727 0.0034  
GSE7390 -0.0891 -0.0419 -0.0006 -0.1786  
GSE9195 -0.3159 -0.0219 -0.3256 0.0163  
Combined correlation -0.24 -0.07 -0.11 -0.13  
[95% confidence interval] [-0.20, -0.28] [-0.03, -0.11] [-0.08, -0.15] [-0.09, -0.17]  
P-value levels associated with the correlation coefficients are shown on the right of the table. The 
combined correlation coefficients were calculated by using the combining sample correlation 
coefficients and vote counts procedure (Bushman & Wang 1995). 
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2.3.5 Patient survival outcome based on expression in upper and lower tertiles of 
MIR22HG and the metabolic target genes – individual in vivo data sets  
Mature miR-22, the host gene MIR22HG, and its three target genes were used to 
perform survival analysis on the data sets with follow-up information of the patients. 
The main hypothesis of this study was that miR-22 and/or the three metabolic target 
genes have important roles in survival outcome of breast cancer patients. To this end, 
mature miR-22, MIR22HG, and the metabolic target genes were subjected to survival 
analysis by calculating survival functions using Kaplan-Meier estimator, based on 
previously mentioned variables. Each variable was divided into high and low 
expression groups according to the expression tertiles (i.e. the patients were divided 
into three equal bins). High expression group is the patients with the genes in upper 
tertile, whereas the low expression group is the patients with the genes in lower 
tertile. Survival curves were then plotted for the high and low groups in each data set. 
Figure 2.5, Figure 2.6, Figure 2.7, and Figure 2.8 show survival curves from 
individual data sets between high and low expression of MIR22HG, MTHFD2, ACLY 
and ELOVL6, respectively. The hazard ratio (HR) calculated by Cox proportional 
hazards model with 95% confidence intervals (CI) and associated log-rank p-values 
for each data set is shown at the bottom right corner of each plot. 
 
Chapter 2 
 
62 
 
Figure 2.4 Box plots of miR-22 target genes expressions according to expression 
quartiles of mature miR-22 from two breast cancer data sets. Correlation 
coefficients and associated p-values between miR-22 target genes and mature miR-22 
are corresponded to table 2.7. 
 
The data showed that on individual data sets level, the majority of data sets do not 
yield any statistically significant results at p-value threshold of 0.05. For MIR22HG, 
only three data sets have statistically significant results. These three data sets showed 
that breast cancer patients with high expression of MIR22HG have better survival 
outcome than the patients with low MIR22HG expression (Figure 2.5). The data sets 
(with log-rank p-value) with statistically significant results for MIR22HG were 
GSE16391 (0.03), GSE3494 (0.002), and GSE6532.GPL96 (0.001).  The opposite 
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trends were observed in the analyses on the three target genes of miR-22. Where the 
data sets yield statistically significant results, all the patient groups with low 
expressions of MTHFD2 and ELOVL6 have better survival outcome than those with 
high expression of these two genes (Figure 2.6 and Figure 2.8, respectively). The 
data sets with statistically significant results (with log-rank p-value) for MTHFD2 
were GSE2034 (0.02) and GSE3494 (0.02), and for ELOVL6 were GSE2034 (0.005), 
GSE3494 (0.005) and GSE6532.GPL570 (0.03). For ACLY, there is no data set with 
statistically significant result at the p-value threshold of 0.05 (Figure 2.7). The results 
from individual data sets could not give a conclusive answer whether the miR-22 host 
gene and the target genes can be used as predictors for survival outcome of breast 
cancer patients.  
2.3.6 Patient survival outcome based on expression in upper and lower tertiles of 
miR-22 host gene and the metabolic target genes – all in vivo data sets 
combined 
The expression of miR-22 host gene, i.e. MIR22HG, and its target genes, i.e. 
MTHFD2, ACLY and ELOVL6, from each data set was divided into tertiles. Next, 
samples in each data set in upper and lower tertiles were labeled as high and low 
according to their expression values. Finally, samples in upper and lower tertiles from 
nine data sets were combined into one data set, together with its follow-up and vital 
status information of each sample. These combined data sets were then subjected to 
survival analysis. Figure 2.9 shows the survival curves of the combined data sets on 
MIR22HG, MTHFD2, ACLY and ELOVL6. 
 
For MIR22HG, MTHFD2 and ELOVL6, the results are statistically significant at the 
p-value threshold of 0.05. The results suggest that breast cancer patients with high 
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expression of MIR22HG and low expression of MTHFD2 and ELOVL6 have better 
survival outcome than the patients with low expression of MIR22HG and high 
expression of MTHFD2 and ELOVL6 (Figure 2.9A, B and D). From the survival 
analysis, high expression of MIR22HG has a protective effect in the breast cancer 
patients, with hazard ratio of 0.78 (95 % confidence interval [CI] = 0.63 – 0.97), log-
rank p-value = 0.027. High expression of MTHFD2 and ELOVL6 has the opposite 
effect on the survival outcome of breast cancer patients. Patients with high expression 
of MTHFD2 have a hazard ratio of 1.54 (95% CI = 1.24 – 1.92), log-rank p-value = 
0.0001. Patients with high expression of ELOVL6 have a hazard ratio of 1.58 (95% = 
1.29 – 1.95), log-rank p-value = 1.35 x 10-5. For ACLY, the result is not statistically 
significant at the same level of p-value cut-off (Figure 2.9C). 
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Figure 2.5 Survival curves of nine data sets for MIR22HG. The survival curves 
were calculated by using Kaplan-Meier estimator based on relapse-free survival time 
of the patients. The patients were divided by tertiles of MIR22HG expression. X axis 
is follow up time before censored in days and y axis is relapsed-free survival (RFS) 
probability calculated by Kaplan-Meier estimator. Blue and red lines represent 
survival probability trajectories of patients with high and low expression of 
MIR22HG, respectively. Vertical bars are censored times of patients. Hazard ratio for 
patients with high MIR22HG expression, with 95% confidence interval in square 
brackets, and its associated log-rank p-value of each data set is on the lower right 
corner of the each plot. 
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Figure 2.6 Survival curves of nine data sets for MTHFD2. The survival curves 
were calculated by using Kaplan-Meier estimator based on relapse-free survival time 
of the patients. The patients were divided by tertiles of MTHFD2 expression. X axis is 
follow up time before censored in days and y axis is relapsed-free survival (RFS) 
probability calculated by Kaplan-Meier estimator. Blue and red lines represent 
survival probability trajectories of patients with high and low expression of MTHFD2, 
respectively. Vertical bars are censored times of patients. Hazard ratio for patients 
with high MTHFD2 expression, with 95% confidence interval in square brackets, and 
its associated log-rank p-value of each data set is on the lower right corner of the each 
plot.  
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Figure 2.7 Survival curves of nine data sets for ACLY. The survival curves were 
calculated by using Kaplan-Meier estimator based on relapse-free survival time of the 
patients. The patients were divided by tertiles of ACLY expression. X axis is follow up 
time before censored in days and y axis is relapsed-free survival (RFS) probability 
calculated by Kaplan-Meier estimator. Blue and red lines represent survival 
probability trajectories of patients with high and low expression of ACLY, 
respectively. Vertical bars are censored times of patients. Hazard ratio for patients 
with high ACLY expression, with 95% confidence interval in square brackets, and its 
associated log-rank p-value of each data set is on the lower right corner of the each 
plot. 
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Figure 2.8 Survival curves of nine data sets for ELOVL6. The survival curves were 
calculated by using Kaplan-Meier estimator based on relapse-free survival time of the 
patients. The patients were divided by tertiles of ELOVL6 expression. X axis is follow 
up time before censored in days and y axis is relapsed-free survival (RFS) probability 
calculated by Kaplan-Meier estimator. Blue and red lines represent survival 
probability trajectories of patients with high and low expression of ELOVL6, 
respectively. Vertical bars are censored times of patients. Hazard ratio for patients 
with high ELOVL6 expression, with 95% confidence interval in square brackets, and 
its associated log-rank p-value of each data set is on the lower right corner of the each 
plot. 
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Figure 2.9 Survival curves from all data sets combined for MIR22HG and the 
three metabolic target genes. A) MIR22HG, B) MTHFD2, C) ACLY, D) ELOVL6. 
The survival curves were calculated by using Kaplan-Meier estimator based on 
relapse-free survival time of the patients. The patients were divided by tertiles of 
MIR22HG and the three target genes expressions. X axes are follow up time before 
censored in days and y axes are relapsed-free survival (RFS) probability calculated by 
Kaplan-Meier estimator. Blue and red lines represent survival probability trajectories 
of patients with high and low expression of MIR22HG and the three target genes, 
respectively. Vertical bars are censored times of patients. Hazard ratio for patients 
with high MIR22HG and the three target genes expression, with 95% confidence 
interval in square brackets, and its associated log-rank p-value of each data set is on 
the lower right corner of the each plot. 
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2.3.7 Meta-analysis 
Because the combined KM analysis did not take into account the sizes of the different 
studies, the hazard ratios of MIR22HG and the metabolic target genes found by the 
combined KM analyses might be over- or underestimated. In order to compare and 
combine the effect of MIR22HG and the target genes on the survival outcome of the 
breast cancer patients from multiple data sets, taking into account the different effect 
sizes from different data sets, meta-analysis was used to combine the results from 
several breast cancer studies. The data sets were subjected to meta-analysis using 
random effects model. Forest plots were created to illustrate the effects that the genes 
have on patient survival outcome. Overall hazard ratios and associated log-rank p-
values were calculated from Cox proportional hazards model between high and low 
expression groups divided by upper and lower tertiles expression of those genes. 
Figure 2.10 shows forest plots on meta-analysis for MIR22HG, MTHFD2, ACLY, and 
ELOVL6.  
 
The meta-analyses yielded the results similar to the survival analyses in the previous 
section, where MIR22HG, MTHFD2 and ELOVL6 were statistically significant at p-
value cut-off of 0.05. From meta-analyses (Figure 2.10), high expression of 
MIR22HG has a protective effect on the survival outcome of breast cancer patients, 
with the hazard ratio of 0.68 (95% CI = 0.47 – 0.98), log-rank p-value = 0.001 
(Figure 2.10A). High expressions of MTHFD2 and ELOVL6 have adverse health 
effect on the survival outcome of the breast cancer patients (Figure 2.10B and D). 
The hazard ratio of patients with high expression of MTHFD2 is 1.58 (95% CI = 1.27 
– 1.95), log-rank p-value = 0.019. The hazard ratio of patients with high expression of 
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ELOVL6 is 1.54 (95% CI = 1.25 – 1.88), log-rank p-value = 0.004. For ACLY, the 
result from meta-analysis was not statistically significant (Figure 2.10C).  
 
Figure 2.10 Meta-analyses of MIR22HG and the three metabolic target genes. To 
compare the differences between data sets, the forest plots were generated based on 
hazard ratios (HRs) and associated 95% CIs from the data sets. To achieve higher 
statistical power from more samples, the overall hazard ratios were calculated by 
using random-effects model. The boxes and the whiskers indicate HRs and 95% 
confidence intervals of separate studies, and sizes of the boxes signify the effect sizes 
of the studies. The diamond represents overall HR of MIR22HG and the three 
metabolic target genes and [upper and lower 95% confidence interval] on both ends of 
the diamond: A) MIR22HG, 0.68 [0.47-0.98], log-rank p-value = 0.001, n = 857; B) 
MTHFD2, 1.58 [1.27-1.95], log-rank p-value = 0.019, n = 1088; C) ACLY, 1.17 [0.92-
1.50], log-rank p-value = 0.16, n= 1088; and D) ELOVL6, 1.54 [1.25-1.88], log-rank 
p-value = 0.004, n = 1134. 
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2.3.8 Effect modification between miR-22 and the metabolic target genes 
Although miR-22 and the metabolic target genes on their own might have effects on 
the patient survival outcome, a combined effect between miR-22 and one of its target 
genes might even be stronger than the effect of miR-22 or the target genes on their 
own. Therefore, the effect modification of miR-22 on the three metabolic target genes 
on patient survival outcome were investigated. MIR22HG (for data sets from 
Kmplotter webtool) and mature miR-22 expression (from TCGA data set) were 
divided into three groups according to their expression tertiles, which are upper, 
middle and lower tertiles. The target genes, i.e. MTHFD2 ACLY and ELOVL6, were 
divided into two groups (high and low) according to upper and lower tertiles. Patients 
were then divided into six categories according to the expression of miR-22 and one 
of its target genes. Table 2.8 shows the categories of the patients according to miR-22 
and one of the metabolic target genes expression. Finally, survival curves were 
plotted for each target genes, comparing survival outcome between high and low 
expression groups in each expression tertile of miR-22.  
 
In order to test whether or not the expression of miR-22 target genes in different miR-
22 expression tertiles were statistically associated with the survival outcome of the 
breast cancer patients, Cochran-Armitage test for trend was used to calculate the 
probability of the association being occurred at random. For the data sets from 
Kmplotter webtool, MIR22HG was used as the surrogate for mature miR-22. 
 
The effect modification of miR-22 on the three metabolic target genes found to be 
statistically significant were between miR-22+MTHFD2 and miR-22+ELOVL6, with 
association p-values calculated by Cochran-Armitage trend test equal 0.001 and 3.46 
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x 10-5, respectively. The hazard ratios for breast cancer patients that have high 
expression of these two target genes were increased after combining the effect of 
having low expression of miR-22. The hazard ratio of the patients who have high 
MTHFD2 expression and low miR-22 expression was 1.72 (95% CI = 1.19 – 2.5), 
log-rank p-value = 0.003 (Figure 2.11). The hazard ratio of the patients with high 
expression of ELOVL6 and low expression of miR-22 was 2.44 (95% CI = 1.64 – 
3.63), log-rank p-value = 6.21 x 10-6 (Figure 2.13). The effect modification of miR-
22 was stronger for ELOVL6 than MTHFD2 and the effect gradually lessen the lower 
expression groups of the metabolic target genes, albeit not statistically significant. 
However, the survival outcome of the patients with low expression of miR-22 were 
similar in every group of the metabolic target genes expressions for both MTHFD2 
and ELOVL6, suggesting that the high expression of miR-22 was associated with the 
breast cancer patient survival outcome.  
The effect modification of miR-22 on ACLY, however, was not statistically 
significant, and combining the low expression of miR-22 did not significantly alter 
the hazard ratio for the patients with high expression of ACLY (Figure 2.12). 
Table 2.8 Patient categories based on miR-22 expression tertiles and miR-22 
target genes expression. 
Patient  
Category 
miR-22 expression 
(MIR22HG and mature miR-22) 
miR-22 target genes expression 
(MTHFD2, ACLY and ELOVL6) 
1 Upper tertile 
Lower Tertile  
(Low expression group) 2 Middle tertile 
3 Lower tertile 
4 Upper tertile 
Upper tertile  
(High expression group) 5 Middle tertile 
6 Lower tertile 
The categories with the same shading are used to calculate the hazard ratios for having high expression 
of target genes. 
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Based on the data presented, it is evident that miR-22 is a post-transcriptional 
regulator of MTHFD2 and ELOVL6, but not ACLY in vivo. The interaction between 
miR-22 and these two metabolic target genes also has real effect on the survival 
outcome of the breast cancer patients, which means that miR-22 and the two 
metabolic target genes MTHFD2 and ELOVL6 might have significant clinical 
relevance in the future.  
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Figure 2.11 Effect modification of miR-22 on MTHFD2. A survival curve of 
combined data set for MTHFD2 shows survival trajectories of breast cancer patients 
in different MIR22HG expression tertiles. The survival curve was calculated by using 
Kaplan-Meier estimator based on relapse-free survival time of the patients. U, M and 
L for miR-22 are survival trajectories for breast cancer patients in upper, middle and 
lower tertiles, respectively. H and L for MTHFD2 are high and low expression group 
of breast cancer patients based on upper and lower tertiles of MTHFD2. Hazard ratios 
were calculated for the patients with high expression of MTHFD2 in each miR-22 
expression tertile. On the top right corner is a forest plot comparing hazard ratios of 
breast cancer patients with high MTHFD2 expression (divided by upper and lower 
tertiles) between miR-22 expression tertiles. 
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Figure 2.12 Effect modification of miR-22 on ACLY. A survival curve of 
combined data set for ACLY shows survival trajectories of breast cancer patients in 
different MIR22HG expression tertiles. U, M and L for miR-22 are survival 
trajectories for breast cancer patients in upper, middle and lower tertiles, respectively. 
H and L for ACLY are high and low expression group of breast cancer patients based 
on upper and lower tertiles of ACLY. Hazard ratios were calculated for the patients 
with high expression of ACLY in each miR-22 expression tertile. On the top right 
corner is a forest plot comparing hazard ratios of breast cancer patients with high 
ACLY expression (divided by upper and lower tertiles) between miR-22 expression 
tertiles. 
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Figure 2.13 Effect modification of miR-22 on ELOVL6. A survival curve of 
combined data set for ELOVL6 shows survival trajectories of breast cancer patients in 
different miR-22 expression tertiles. U, M and L for miR-22 are survival trajectories 
for breast cancer patients in upper, middle and lower tertiles, respectively. H and L for 
ELOVL6 are high and low expression group of breast cancer patients based on upper 
and lower tertiles of ELOVL6. Hazard ratios were calculated for the patients with high 
expression of ELOVL6 in each miR-22 expression tertile. On the top right corner is a 
forest plot comparing hazard ratios of breast cancer patients with high ELOVL6 
expression (divided by upper and lower tertiles) between miR-22 expression tertiles. 
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2.4 Discussion 
2.4.1 MIR22HG as the surrogate of mature miR-22  
The use of MIR22HG as the surrogate for mature miR-22 expression was justified by 
the fact that the correlation coefficients between the two in several independent data 
sets were very high (see Table 2.1). The NCI-60 in vitro data sets comprises of 59 
different cancer cell lines, and therefore, the correlation from this data sets should be 
able to provide an accurate estimate of MIR22HG and the mature sequence. Several 
studies also confirmed that mammalian miRNAs usually correlate well with the host 
genes (Baskerville & Bartel 2005; Ruike et al. 2008), especially miR-22 (Rodriguez 
et al. 2004; Wang et al. 2011), and that the host gene could be used as a surrogate for 
mature miRNA expression (Gennarino et al. 2009). However, some studies suggested 
that, in some cell-specific contexts, host genes expressions are not reflecting those of 
their mature sequences (Sikand et al. 2009; Biasiolo et al. 2011). The causes for the 
inconsistency in host gene-mature sequence relationship might be due to:  
polymorphisms in the miRNA transcripts, affecting the biogenesis of the miRNA (Ha 
& Kim 2014); epigenetic control by DNA methylation and/or histone modification 
(Davis & Hata 2009; Ha & Kim 2014); and level of transcription factor c-Myc and the 
exact roles of c-Myc in cell-specific contexts of miR-22 transcription  (J Xiong et al. 
2010; Polioudakis et al. 2013; Kong et al. 2014). Nevertheless, MIR22HG is not the 
active molecule that is incorporated into the miRISC, which acts on the target genes. 
It is possible that MIR22HG transcript might be under all of the previously mentioned 
transcriptional controls and might not reflect the extent of the mature species.  
Another drawback of using MIR22HG as a surrogate for mature miR-22 is the 
possibility of existence of alternatively spliced variants of the MIR22HG transcript. 
MIR22HG has four exons in the pri-miR-22 (Slezak-Prochazka et al. 2013), and it 
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was found that the longer isoform of miR-22 is more effective than the shorter 
isoform in target repression (Nam et al. 2014). Therefore, the measured MIR22HG 
might not be an accurate estimate of mature miR-22 from the possibility that the 
MIR22HG measured did not measure the correct isoform of miR-22 by the 
microarray. As far as alternative splicing of miRNA is concerned, a recent report 
showed that the alternative splicing process itself negatively regulated the precursor 
miRNA levels (Melamed et al. 2013). It should also be noted that miR-22 is an exonic 
miRNA, which is different from majority of miRNAs that are intronic miRNAs. 
Currently there is no report on the overall extent of correlation between exonic 
miRNAs and the host genes. Unfortunately, the mature miR-22 breast cancer data set 
of Farazi et al. (2010) did not have MIR22HG (or C17orf91) measurement for in vivo 
correlation assessment to definitely confirm that MIR22HG and mature miR-22 is 
correlated.  
2.4.2 Normalisation is a crucial step for differential miRNA comparison  
The effect of normalisation for high-throughput sequencing has an impact on the 
values of mature miRNAs expression. Although the way high-throughput sequencing 
of RNA (whether mRNA or miRNA) are usually normalised, i.e. RPKM or read per 
kilobase exon model per million mapped reads (Mortazavi et al. 2008), provides good 
estimate of most of the miRNA species present in different samples, there are 
growing number of studies suggested that RPKM is not suitable for differential 
expression analysis (Bullard et al. 2010; Robinson & Oshlack 2010; Sun & Zhu 2012; 
Dillies et al. 2013). This might be due to the fact that there were different number of 
counts between different samples (Garmire & Subramaniam 2012). However, there 
are only a few studies comparing the effects and suitability of RNA-seq data 
normalisation and the results are still inconclusive, and it is even more controversial 
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in the case of miRNA-seq data normalisation. Currently there is also no high-
throughput mRNA and miRNA data sets that have both mature miR-22 and the host 
gene, MIR22HG, which can be used for a definitive test on the extent of the effect of 
normalisation. 
2.4.3 Correlation does not equal causation  
The correlation between miR-22 and the metabolic target genes, especially MTHFD2 
and ELOVL6, were quite convincing that these two genes might be affecting the 
survival outcome of breast cancer patients the most. However, it was not the case for 
ACLY, and the target gene of miR-22 with the strongest effect on the patient survival 
outcome was neither MTHFD2 or ACLY, but ELOVL6. Despite the lowest correlation 
with miR-22 (Table 2.7), ELOVL6 affected the patient survival outcome the most 
(Figure 2.9), especially when the effect of ELOVL6 was modified by miR-22 
expression (Figure 2.10).  The effect of ELOVL6 on patient survival outcome was the 
strongest when the patients also in the miR-22 high expression group. On the other 
hand, ELOVL6 does not affect the survival outcome in the patient with miR-22 low 
expression, suggesting the effect modification of miR-22 on ELOVL6. MTHFD2 also 
showed similar trend as ELOVL6, albeit at a lesser extent (Figure 2.11). Several 
approaches have been developed to identify effect modification among miRNAs or 
between miRNAs and their target genes based on their sequences (Yoon & De 
Micheli 2005) or their expression profiles (Boross et al. 2009; J. Xu et al. 2011; Y. Li 
et al. 2014), but the approach used in this study is simpler than the methods 
previously mentioned. However, this approach is quite limited on the number of 
miRNA and mRNA that can be tested in the analysis. As the number of miRNA 
and/or mRNA is increasing, the category numbers of the samples will also be 
increasing, which will complicate the analysis. Also the number of samples in each 
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category will be decreasing, lessen the power of the analysis. Nevertheless, the 
approach in this study is suitable for targeted identification of the effect modification 
relationship between miRNA-mRNA because the number of samples used, which 
gives more power for the analysis.  
2.4.4 High expression of miR-22 is beneficial to breast cancer patients  
The results from this study suggested that miR-22 is beneficial to the breast cancer 
patients, possibly through the suppression of the metabolic target genes MTHFD2, 
and ELOVL6. These metabolic target genes of miR-22 have very important roles in 
cancer progression, especially in breast cancer. By suppressing these metabolic target 
genes, miR-22 is indirectly linked to several aspects of metabolic control in breast 
cancer.  
A very recent study showed that patients with high expression of the protein product 
of MTHFD2 have poorer survival outcome than the patients with low or no MTHFD2 
expression (Liu et al. 2014). Another study showed that MTHFD2 expression was 
increased in many types of cancer cells, and suppressing MTHFD2 expression caused 
apoptosis in most of the cancer cell lines tested in the study, which imply that 
MTHFD2 is needed for cancer cell proliferation and viability (Nilsson et al. 2014). 
Another study identified miR-9 as another post-transcriptional regulator of MTHFD2, 
and showed that MTHFD2 depletion has a proliferative effect with overexpression of 
miR-9 (Selcuklu et al. 2012). A MTHFD2 knock down experiment impaired cell 
migration and invasion into extracellular matrix in breast cancer cell lines (Lehtinen 
et al. 2013). Despite the weak evidence observed for an interaction between ACLY 
and miR-22, ACLY is also clearly important in cancer. It was found recently that 
ACLY gene product ATP citrate lyase (ACLY) has a role in reversing the epithelial-
mesenchymal transition (EMT) process in non-small cell lung cancer cell lines and 
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human mammary breast cancer lines, thereby promoting cell differentiation and 
reduction of cancer stem cells (Hanai et al. 2013). Furthermore, decreased ACLY 
leads to suppressed growth and/or apoptosis by blocking the triglyceride elongation 
process (Migita et al. 2014). The expression of ELOVL6 was recently found to be 
down-regulated in mammary epithelial cells, promoting the cell differentiation 
process, and the low expression of ELOVL6 was also found to be beneficial for breast 
cancer patients survival outcome (Dória et al. 2014). Note that previously mentioned 
study used the same data sets that were also used in this study. Another recent study 
showed that decrease ELOVL6 reduce cell proliferation in liver cancer (Shiau et al. 
2014).  All these studies were in line with the previous findings in the Keun group 
laboratory and this study.  
The effect modification of miR-22 on ELOVL6 might be of interest in breast cancer 
therapy. This study showed that breast cancer patients with low expression of 
ELOVL6 and high expression of miR-22 have the best survival outcome compared to 
other groups of patients. A combination therapy that enhances miR-22 expression and 
lower ELOVL6 expression might be beneficial to the breast cancer patients, although 
the molecular mechanism of the therapy would have to be clearly elucidated. Other 
metabolic target genes of miR-22, which remain to be discovered in the future, might 
also help in the understanding of the roles of miR-22 in breast cancer.  
2.4.5 The exact roles of miR-22 in cancer still remain controversial 
Despite previously mentioned studies that were in line with the analysis presented 
here, there were also evidence that miR-22 is an oncogene, particularly in breast 
cancer (Song, Poliseno, et al. 2013). In this particular study, xenograft mouse models 
were used and identified another target gene, Ten eleven translocation 2 (TET2), 
which in turn inhibits demethylation of the promoter of a tumour suppressor miR-200 
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and promotes invasiveness and metastasis through EMT initiation. This study also 
showed that triple negative breast cancer (TNBC) patients with high expression of 
miR-22 have poorer survival outcome.  
It is possible that miR-22 can regulate different processes through different sets of 
target genes. Although TET2 is not a metabolic gene, it regulates another miRNA by 
remodeling the epigenetic landscape of the promoter of miR-200, suppressing the 
expression of this miRNA and in turn upregulate the transcription factors Zeb1, Zeb2 
and SIP1 triggering the EMT process. It is also possible that miR-22 might behave 
differently in the in vitro and in vivo environments. Many studies previously 
described were mostly done in cancer cell lines, which might not be a representative 
environment for what is taking place in the actual human or other organisms. This 
goes to show that more experiments, especially in vivo studies such as mouse 
xenografts should be performed to ascertain the definitive roles of miR-22 and the 
mechanisms that it operates.  
It was also a limitation of this study that the hormone status, estrogen receptor alpha 
(ER-α), progesterone receptor (PR), and human epidermal growth factor receptor 2 
(HER2 or ERBB2), were omitted, and patients were not divided based on hormone 
receptor status. The reason was partly due to the fact that some of the breast cancer 
data sets do not have hormone receptor status available. The breast cancer data that 
was used in Song, Poliseno, et al. (2013) study was among a few studies that have 
complete hormone receptor statuses. However, this data set has only around 200 
samples, and after excluding other hormone receptors positive samples, the samples 
used in the study were hardly representative of the population. Another explanation is 
that TNBC are usually very heterogeneous samples, with completely different gene 
expression profiles among the TNBC samples. It is possible that in TNBC, miR-22 
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will behave completely different, and act as an oncogene instead of a tumour 
suppressor. A very recent study showed that miR-22 was expressed differently in 
different cell types (Nam et al. 2014). Therefore, it is possible that even in the same 
cell types but with different context (differentiated cell or stem cell-like phenotypes), 
miR-22 might be expressed differently. Nevertheless, only with more studies, 
complete with all the hormone receptor status, the question of whether miR-22 is 
indeed an oncogene in TNBC can be revealed. Evidently, miR-22 has multiple target 
genes, with different roles in cancer, and should be studied more thoroughly to 
elucidate the exact mechanisms of actions for the benefit of the breast cancer 
sufferers.  
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3.1 Introduction 
Metabolic control by miRNAs is poorly understood relative to transcriptional control 
of mRNAs. Because miRNAs directly suppress or are involved in degradation of 
mRNA, the relationship of miRNA-mRNA is more obvious than that of miRNA-
metabolite. Metabolic pathways are potentially now more complicated than ever 
because of this additional layer of control by miRNAs. Currently there are very few 
attempts in global analysis of miRNA-associated metabolic consequences. This might 
be due to the fact that miRNA-mRNA relationship is already more complex than 
expected. One way of reducing the complexity between miRNA-gene-metabolite 
networks is to find a subset of miRNAs that potentially target the same groups of 
genes, and then focus the analysis on the pathway level to limit the scope of miRNAs, 
genes, and metabolites that are involved in the analysis. This approach is a top-down 
approach; the opposite way compared to the approach used in the chapter 2 where the 
hypothesis was specifically generated by focusing on one specific set of miRNA-gene 
interactions (bottom-up approach). In this study, all microRNA families and their 
predicted target genes were used to calculate the proportions of probable sets of 
predicted metabolic targets between every pair of miRNA families to find miRNA 
clusters that have similar predicted metabolic target genes. The predicted metabolic 
genes in these miRNA clusters were then used in pathway analysis to find pathways 
that might be associated with these miRNA clusters.  
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3.2 Materials and methods 
The PCT scores are the probability of preferentially conserved targeting of an mRNA 
by a miRNA family. The PCT score was defined as the expected signal-to-background 
ratio of a miRNA target site in an mRNA, calculated through branch-length score 
from multiple species alignment of the target site (Friedman et al. 2009). Predicted 
conserved target genes and associated PCT scores of miRNA families, release 6.2 
(June 2012) are retrieved on 7 October 2013 from TargetScan website 
(Bioinformatics and research computing 2012). In total, there are 87 miRNA families 
presented in TargetScan based on seed sequences of miRNAs. The PCT scores were 
used as the weights for the weighted Jaccard index later. Metabolic gene list was 
retrieved from a study of human metabolic reconstruction RECON 1 list (Duarte et al. 
2007). The overlapped predicted target genes from two miRNA families were 
trimmed down to metabolic genes only according RECON 1 metabolic gene list. The 
Jaccard index is a similarity metric used for measuring the difference between two 
sets, X and Y, which is the ratio of overlapped members between X and Y of all the 
members in X and Y (Levandowsky & Winter 1971) and can be expressed in the 
following equation: 
! = ! !! ∩ !!!! ∪ !!  (1) 
where J is the Jaccard index, and CX and CY are the numbers of members in set X and 
Y, respectively. Jaccard distance is a dissimilarity metric derived from the Jaccard 
index used for measuring the distance between the two sets, which can be expressed 
as follow:  !! = 1− ! (2) 
where dJ is the Jaccard distance. In this study, a weighted Jaccard index (Sethi & 
Alagiriswamy 2010) was used to calculate the similarity between two miRNA 
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families. Instead of simply counting the number of overlapped predicted target genes 
between two miRNA families, PCT score of each predicted target gene was used as the 
weight to take into account the probability of that predicted target gene being a real 
target for a certain miRNA. The weighted Jaccard index can be expressed as follow: 
!! = ! !! ∩ !!!!!!!!!!!! ∪ !!!!!!  (3) 
where Jw is weighted Jaccard index, WX and WY are the weights of the members in sets 
X and Y, respectively, which in this case set X and Y are sets of predicted gene targets 
from two miRNA families and WX and WY are the PCT scores of predicted target genes 
from two miRNA families. Weighted Jaccard distance of all miRNA family pairs was 
calculated from the weighted Jaccard index to produce the distance matrix between all 
miRNA families for the hierarchical clustering analysis. Hierarchical clustering was 
performed using Ward’s minimum variance method or Ward’s linkage (Ward 1963), 
where objective function is to obtain minimum distance between the miRNAs in the 
clusters. The clusters of miRNAs were defined by Dynamic Hybrid algorithm from R 
package ‘Dynamic Tree Cut’ (Langfelder et al. 2008). Pathway analysis was 
performed on predicted target gene lists of each miRNA family pair by using over-
representation analysis (ORA) on KEGG pathway database (Kanehisa & Goto 2000). 
Finally, the number of pathways that are associated with miRNA families in each 
cluster was tested by ORA, to ascertain whether or not the number of pathways 
occurred more than expected by chance. The p-values associated with the over-
represented pathways in each cluster was subjected to multiple hypothesis testing 
using the Benjamini-Hochberg false discovery rate procedure (Benjamini & Hochberg 
1995). The pathways with FDR-adjusted p-value less than 0.05 were retained. All 
statistical calculations were performed in R statistical packages version 2.12. KEGG 
database was accessed through KEGGREST package (Tenenbaum 2013). Jaccard 
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distance matrices were produced by R package ‘NeatMap’ (Rajaram & Oono 2010). 
Figure 3.1 illustrates the analysis as a flow chart. 
3.3 Results 
3.3.1 Basic statistics  
Most of predicted target genes of miRNAs are evolutionarily conserved among 
mammals and the 3’UTR of those target genes are under selective pressure to be 
under the control of miRNAs. The estimate of the proportion of protein-coding genes 
under the control of miRNAs is more than 60% (Friedman et al. 2009). In this 
analysis, a crude estimate of the number of genes under the control of miRNAs is 
around 82%, based on the number of conserved predicted target genes in the current 
release of TargetScan database (Release 6.2, June 2012) and the estimated number of 
protein-coding genes of 20,687 genes (The ENCODE Project Consortium 2012). The 
number of overlapped metabolic genes based on RECON 1 metabolic network 
reconstruction study (Duarte et al. 2007) is around 8% of the predicted target genes. 
Table 3.1 summarises the basic statistics of the raw data used in this study. The 
number of predicted target genes present in the database and the number of metabolic 
predicted target genes for each of the miRNA family are summarised in Table 3.2.  
Table 3.1 Summary of basic statistics on the data used in this study. 
 Number of Genes 
Predicted protein-coding genes (ENCODE project) 20,678 
Predicted target genes under miRNA control (TargetScan) 17,088 
Metabolic genes (RECON 1)* 1,480 
Overlapped between TargetScan and RECON 1 genes 1358 
*The original number of metabolic genes in RECON 1 is 1496 genes. The genes that are note included 
in the calculation are due to the depreciated gene symbols (i.e. has been renamed or dropped) in the 
HUGO nomenclature.
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Figure 3.1 Flow chart illustrating overall of the analysis. The genes used in the calculation were metabolic genes only. 
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miR$23abc/23b$3p 0.00 0.63 0.78 0.78 0.84 0.73 0.75 0.63 0.57 0.67 0.76 0.64 0.70 0.64 0.70 0.68 0.61 0.83 0.59 0.64 0.63 0.77 0.74 0.67 0.72 0.65 0.73 0.80 0.61 0.65 0.62 0.61 0.63 0.77 0.66 0.65 0.75 0.75 0.75 0.76 0.75 0.67 0.66 0.60 0.60 0.61 0.68 0.79 0.73 0.81 0.75 0.74 0.83 0.74 0.78 0.62 0.90 0.67 0.84 0.76 0.64 0.71 0.74 0.63 0.68 0.72 0.71 0.71 0.57 0.65 0.81 0.78 0.74 0.79 0.77 0.78 0.62 0.72 0.64 0.95 0.94 0.99 0.70 0.96 0.98 0.92 0.95
miR$218/218a 0.63 0.00 0.71 0.81 0.77 0.75 0.82 0.72 0.67 0.69 0.73 0.69 0.73 0.77 0.68 0.69 0.70 0.79 0.60 0.71 0.68 0.75 0.69 0.73 0.68 0.67 0.74 0.71 0.64 0.69 0.70 0.64 0.72 0.81 0.67 0.72 0.73 0.67 0.65 0.73 0.75 0.69 0.72 0.67 0.72 0.65 0.68 0.80 0.70 0.79 0.72 0.73 0.82 0.77 0.79 0.69 0.96 0.67 0.84 0.79 0.72 0.74 0.69 0.75 0.68 0.69 0.81 0.76 0.67 0.64 0.74 0.79 0.73 0.78 0.72 0.84 0.68 0.72 0.70 0.95 0.95 0.99 0.74 1.00 0.98 0.97 0.98
miR$338/338$3p 0.78 0.71 0.00 0.82 0.78 0.75 0.75 0.73 0.72 0.66 0.70 0.73 0.74 0.77 0.77 0.72 0.72 0.83 0.70 0.68 0.72 0.74 0.75 0.73 0.77 0.73 0.74 0.76 0.75 0.72 0.74 0.68 0.76 0.77 0.75 0.80 0.74 0.75 0.81 0.83 0.76 0.73 0.73 0.73 0.75 0.76 0.77 0.76 0.71 0.80 0.79 0.74 0.87 0.77 0.83 0.75 0.89 0.64 0.89 0.79 0.72 0.72 0.75 0.73 0.74 0.73 0.79 0.79 0.73 0.71 0.75 0.86 0.72 0.79 0.79 0.83 0.76 0.72 0.71 0.89 0.92 0.98 0.80 0.92 0.96 0.98 0.91
miR$219$5p/508/508$3p/4782$3p 0.78 0.81 0.82 0.00 0.83 0.81 0.81 0.83 0.78 0.79 0.87 0.78 0.83 0.86 0.75 0.82 0.78 0.84 0.77 0.87 0.85 0.84 0.75 0.83 0.78 0.82 0.84 0.81 0.70 0.76 0.86 0.81 0.77 0.90 0.80 0.88 0.79 0.71 0.76 0.79 0.81 0.75 0.80 0.82 0.86 0.67 0.82 0.84 0.87 0.83 0.85 0.76 0.81 0.82 0.83 0.84 0.94 0.84 0.85 0.84 0.79 0.82 0.81 0.79 0.84 0.88 0.87 0.84 0.82 0.75 0.81 0.83 0.82 0.82 0.81 0.83 0.78 0.78 0.83 0.99 0.98 1.00 0.82 1.00 1.00 0.98 0.98
miR$490$3p 0.84 0.77 0.78 0.83 0.00 0.76 0.81 0.72 0.71 0.71 0.85 0.78 0.78 0.82 0.78 0.82 0.81 0.88 0.75 0.81 0.80 0.82 0.81 0.78 0.79 0.77 0.78 0.83 0.76 0.78 0.74 0.79 0.79 0.72 0.74 0.81 0.82 0.77 0.79 0.83 0.77 0.77 0.76 0.75 0.81 0.77 0.81 0.73 0.78 0.83 0.80 0.78 0.86 0.78 0.85 0.75 0.94 0.77 0.81 0.83 0.73 0.78 0.80 0.78 0.79 0.87 0.84 0.84 0.77 0.72 0.80 0.85 0.77 0.84 0.78 0.80 0.81 0.76 0.81 0.92 0.88 0.95 0.77 0.93 0.95 0.91 0.94
miR$499$5p 0.73 0.75 0.75 0.81 0.76 0.00 0.79 0.71 0.72 0.74 0.78 0.76 0.82 0.80 0.78 0.78 0.76 0.83 0.76 0.75 0.73 0.78 0.74 0.81 0.75 0.74 0.84 0.79 0.70 0.74 0.67 0.80 0.77 0.80 0.75 0.78 0.76 0.71 0.75 0.78 0.81 0.73 0.75 0.71 0.75 0.73 0.76 0.77 0.81 0.79 0.79 0.74 0.75 0.74 0.78 0.75 0.91 0.73 0.77 0.78 0.68 0.82 0.77 0.75 0.75 0.79 0.80 0.76 0.71 0.69 0.80 0.79 0.81 0.79 0.74 0.17 0.75 0.79 0.77 0.91 0.90 0.94 0.71 0.94 0.94 0.91 0.90
miR$503 0.75 0.82 0.75 0.81 0.81 0.79 0.00 0.82 0.80 0.68 0.82 0.79 0.54 0.78 0.74 0.79 0.77 0.81 0.77 0.80 0.82 0.77 0.80 0.81 0.78 0.78 0.74 0.76 0.76 0.73 0.79 0.76 0.80 0.91 0.84 0.81 0.74 0.72 0.80 0.77 0.79 0.71 0.83 0.76 0.82 0.78 0.79 0.86 0.75 0.79 0.84 0.82 0.84 0.79 0.84 0.78 0.92 0.77 0.86 0.84 0.79 0.76 0.75 0.78 0.84 0.76 0.91 0.83 0.78 0.73 0.77 0.89 0.73 0.81 0.80 0.90 0.78 0.81 0.82 0.94 0.94 0.97 0.82 0.97 0.97 0.97 0.93
miR$25/32/92abc/363/363$3p/367 0.63 0.72 0.73 0.83 0.72 0.71 0.82 0.00 0.68 0.64 0.79 0.70 0.73 0.76 0.68 0.66 0.69 0.79 0.64 0.76 0.69 0.76 0.62 0.77 0.67 0.67 0.78 0.65 0.62 0.69 0.71 0.64 0.68 0.86 0.75 0.60 0.68 0.71 0.70 0.70 0.77 0.70 0.65 0.70 0.64 0.61 0.71 0.83 0.76 0.78 0.70 0.74 0.78 0.73 0.83 0.66 0.95 0.76 0.84 0.74 0.72 0.69 0.68 0.71 0.68 0.75 0.83 0.78 0.65 0.67 0.78 0.83 0.71 0.79 0.80 0.76 0.63 0.78 0.78 0.96 0.93 0.97 0.68 0.96 0.97 0.96 0.99
miR$26ab/1297/4465 0.57 0.67 0.72 0.78 0.71 0.72 0.80 0.68 0.00 0.67 0.76 0.71 0.72 0.77 0.66 0.68 0.58 0.73 0.63 0.74 0.69 0.70 0.68 0.74 0.65 0.65 0.72 0.65 0.59 0.60 0.70 0.62 0.64 0.79 0.68 0.73 0.69 0.67 0.65 0.66 0.73 0.63 0.70 0.68 0.65 0.58 0.66 0.81 0.69 0.81 0.71 0.65 0.73 0.76 0.72 0.66 0.95 0.71 0.74 0.74 0.67 0.71 0.67 0.70 0.63 0.78 0.75 0.72 0.60 0.64 0.71 0.74 0.70 0.81 0.77 0.86 0.66 0.73 0.70 0.95 0.95 0.97 0.67 0.96 0.97 0.96 0.96
miR$24/24ab/24$3p 0.67 0.69 0.66 0.79 0.71 0.74 0.68 0.64 0.67 0.00 0.71 0.67 0.65 0.68 0.67 0.64 0.64 0.78 0.65 0.64 0.66 0.66 0.74 0.69 0.65 0.66 0.72 0.65 0.64 0.64 0.66 0.58 0.66 0.77 0.72 0.75 0.73 0.70 0.70 0.77 0.71 0.60 0.72 0.65 0.70 0.63 0.64 0.78 0.63 0.76 0.72 0.69 0.82 0.77 0.75 0.70 0.89 0.63 0.77 0.80 0.67 0.66 0.74 0.70 0.70 0.67 0.72 0.75 0.67 0.66 0.70 0.81 0.62 0.75 0.72 0.80 0.68 0.72 0.64 0.87 0.91 0.96 0.72 0.91 0.97 0.94 0.96
miR$22/22$3p 0.76 0.73 0.70 0.87 0.85 0.78 0.82 0.79 0.76 0.71 0.00 0.75 0.74 0.74 0.74 0.74 0.76 0.90 0.73 0.72 0.73 0.81 0.75 0.75 0.72 0.76 0.77 0.74 0.73 0.72 0.74 0.71 0.77 0.83 0.76 0.83 0.77 0.74 0.80 0.83 0.78 0.67 0.73 0.75 0.81 0.77 0.70 0.84 0.74 0.77 0.87 0.79 0.92 0.80 0.77 0.78 0.92 0.67 0.88 0.80 0.72 0.71 0.79 0.72 0.75 0.75 0.82 0.81 0.74 0.71 0.79 0.84 0.73 0.81 0.80 0.88 0.76 0.81 0.77 0.95 0.95 0.99 0.76 0.97 0.99 0.97 0.95
miR$9/9ab 0.64 0.69 0.73 0.78 0.78 0.76 0.79 0.70 0.71 0.67 0.75 0.00 0.70 0.77 0.63 0.72 0.63 0.82 0.65 0.75 0.74 0.70 0.75 0.73 0.69 0.69 0.73 0.65 0.60 0.68 0.69 0.65 0.68 0.85 0.70 0.75 0.75 0.72 0.72 0.76 0.73 0.56 0.74 0.66 0.69 0.61 0.68 0.87 0.71 0.76 0.80 0.73 0.82 0.75 0.80 0.75 0.92 0.69 0.82 0.75 0.74 0.72 0.71 0.68 0.70 0.77 0.77 0.77 0.67 0.71 0.80 0.80 0.70 0.75 0.75 0.83 0.70 0.67 0.72 0.91 0.95 0.98 0.73 0.95 0.98 0.94 0.98
miR$15abc/16/16abc/195** 0.70 0.73 0.74 0.83 0.78 0.82 0.54 0.73 0.72 0.65 0.74 0.70 0.00 0.75 0.70 0.71 0.68 0.83 0.67 0.72 0.72 0.74 0.79 0.72 0.74 0.72 0.61 0.74 0.69 0.68 0.74 0.65 0.74 0.86 0.75 0.78 0.78 0.73 0.74 0.76 0.76 0.61 0.79 0.69 0.74 0.68 0.71 0.87 0.74 0.78 0.83 0.81 0.88 0.79 0.82 0.75 0.94 0.70 0.86 0.82 0.74 0.76 0.76 0.75 0.79 0.75 0.82 0.85 0.67 0.71 0.78 0.86 0.57 0.82 0.80 0.89 0.78 0.76 0.69 0.94 0.95 0.98 0.78 0.98 0.98 0.98 0.97
let$7/98/4458/4500 0.64 0.77 0.77 0.86 0.82 0.80 0.78 0.76 0.77 0.68 0.74 0.77 0.75 0.00 0.67 0.71 0.71 0.79 0.71 0.82 0.74 0.68 0.72 0.73 0.76 0.69 0.78 0.70 0.66 0.71 0.79 0.70 0.72 0.89 0.86 0.79 0.77 0.67 0.68 0.76 0.77 0.69 0.80 0.74 0.73 0.68 0.67 0.79 0.78 0.75 0.76 0.74 0.84 0.83 0.82 0.81 0.94 0.71 0.83 0.82 0.81 0.71 0.66 0.77 0.76 0.75 0.79 0.83 0.70 0.67 0.79 0.83 0.72 0.81 0.85 0.88 0.78 0.82 0.74 0.98 0.95 0.99 0.76 1.00 0.99 0.99 0.98
miR$7/7ab 0.70 0.68 0.77 0.75 0.78 0.78 0.74 0.68 0.66 0.67 0.74 0.63 0.70 0.67 0.00 0.71 0.65 0.83 0.65 0.71 0.68 0.75 0.72 0.71 0.74 0.66 0.71 0.72 0.69 0.68 0.69 0.61 0.75 0.75 0.68 0.67 0.75 0.74 0.74 0.74 0.77 0.71 0.71 0.68 0.71 0.69 0.70 0.79 0.72 0.75 0.71 0.70 0.84 0.78 0.84 0.67 0.89 0.65 0.82 0.81 0.70 0.72 0.74 0.68 0.70 0.76 0.78 0.80 0.67 0.70 0.74 0.81 0.70 0.78 0.80 0.79 0.71 0.75 0.71 0.93 0.93 0.97 0.70 0.95 0.97 0.92 0.96
miR$1ab/206/613 0.68 0.69 0.72 0.82 0.82 0.78 0.79 0.66 0.68 0.64 0.74 0.72 0.71 0.71 0.71 0.00 0.69 0.79 0.68 0.71 0.72 0.72 0.74 0.68 0.68 0.71 0.74 0.74 0.67 0.68 0.71 0.66 0.71 0.81 0.70 0.77 0.73 0.74 0.74 0.75 0.74 0.67 0.74 0.68 0.71 0.67 0.71 0.81 0.69 0.77 0.78 0.73 0.82 0.76 0.79 0.74 0.92 0.69 0.81 0.79 0.74 0.74 0.73 0.74 0.72 0.71 0.78 0.75 0.66 0.68 0.76 0.80 0.72 0.77 0.73 0.84 0.72 0.72 0.69 0.96 0.95 0.99 0.73 0.96 0.97 0.96 0.99
miR$17/17$5p/20ab/20b$5p/93/106ab** 0.61 0.70 0.72 0.78 0.81 0.76 0.77 0.69 0.58 0.64 0.76 0.63 0.68 0.71 0.65 0.69 0.00 0.79 0.61 0.70 0.68 0.73 0.71 0.71 0.69 0.66 0.72 0.60 0.49 0.38 0.68 0.63 0.62 0.79 0.68 0.70 0.71 0.66 0.61 0.70 0.74 0.52 0.74 0.64 0.68 0.56 0.64 0.79 0.67 0.77 0.71 0.72 0.81 0.75 0.77 0.68 0.92 0.68 0.78 0.76 0.59 0.70 0.69 0.67 0.65 0.74 0.74 0.72 0.60 0.62 0.75 0.76 0.63 0.78 0.76 0.78 0.63 0.72 0.63 0.92 0.93 0.95 0.69 0.94 0.95 0.93 0.95
miR$18ab/4735$3p 0.83 0.79 0.83 0.84 0.88 0.83 0.81 0.79 0.73 0.78 0.90 0.82 0.83 0.79 0.83 0.79 0.79 0.00 0.78 0.82 0.78 0.80 0.82 0.81 0.79 0.79 0.84 0.80 0.73 0.79 0.79 0.78 0.79 0.85 0.82 0.83 0.81 0.81 0.83 0.86 0.84 0.81 0.78 0.78 0.82 0.79 0.84 0.75 0.81 0.82 0.84 0.80 0.86 0.80 0.84 0.79 0.91 0.78 0.88 0.84 0.80 0.76 0.82 0.79 0.83 0.84 0.84 0.84 0.77 0.73 0.80 0.88 0.82 0.81 0.86 0.85 0.78 0.78 0.83 0.93 0.90 0.98 0.76 0.97 0.99 0.93 0.96
miR$27abc/27a$3p 0.59 0.60 0.70 0.77 0.75 0.76 0.77 0.64 0.63 0.65 0.73 0.65 0.67 0.71 0.65 0.68 0.61 0.78 0.00 0.66 0.64 0.73 0.72 0.69 0.69 0.68 0.72 0.73 0.59 0.65 0.69 0.39 0.67 0.82 0.69 0.67 0.70 0.68 0.66 0.71 0.75 0.63 0.72 0.68 0.68 0.60 0.65 0.83 0.67 0.82 0.71 0.69 0.83 0.78 0.77 0.65 0.95 0.66 0.83 0.76 0.72 0.69 0.70 0.65 0.72 0.72 0.80 0.77 0.62 0.65 0.76 0.82 0.68 0.81 0.75 0.83 0.64 0.71 0.65 0.94 0.94 0.99 0.69 0.97 0.97 0.95 0.98
miR$29abcd 0.64 0.71 0.68 0.87 0.81 0.75 0.80 0.76 0.74 0.64 0.72 0.75 0.72 0.82 0.71 0.71 0.70 0.82 0.66 0.00 0.72 0.78 0.75 0.78 0.69 0.66 0.77 0.70 0.70 0.72 0.76 0.68 0.73 0.86 0.74 0.84 0.76 0.69 0.65 0.73 0.73 0.68 0.83 0.75 0.71 0.67 0.66 0.84 0.69 0.74 0.79 0.70 0.87 0.84 0.86 0.76 0.96 0.69 0.82 0.77 0.70 0.75 0.74 0.72 0.76 0.77 0.82 0.82 0.72 0.68 0.76 0.81 0.70 0.85 0.80 0.86 0.75 0.82 0.74 0.91 0.91 0.99 0.75 0.97 0.96 0.99 0.99
miR$30abcdef/30abe$5p/384$5p 0.63 0.68 0.72 0.85 0.80 0.73 0.82 0.69 0.69 0.66 0.73 0.74 0.72 0.74 0.68 0.72 0.68 0.78 0.64 0.72 0.00 0.74 0.76 0.73 0.69 0.70 0.75 0.69 0.65 0.68 0.73 0.65 0.68 0.86 0.74 0.80 0.71 0.73 0.70 0.81 0.73 0.65 0.74 0.69 0.66 0.63 0.70 0.84 0.70 0.81 0.74 0.73 0.83 0.84 0.83 0.76 0.96 0.73 0.85 0.82 0.72 0.73 0.67 0.72 0.72 0.81 0.82 0.77 0.64 0.68 0.81 0.81 0.70 0.76 0.79 0.84 0.64 0.79 0.71 0.96 0.95 0.98 0.71 0.97 0.98 0.97 0.97
miR$31 0.77 0.75 0.74 0.84 0.82 0.78 0.77 0.76 0.70 0.66 0.81 0.70 0.74 0.68 0.75 0.72 0.73 0.80 0.73 0.78 0.74 0.00 0.81 0.74 0.71 0.67 0.78 0.78 0.72 0.73 0.67 0.73 0.74 0.78 0.70 0.82 0.79 0.74 0.78 0.78 0.77 0.70 0.78 0.59 0.76 0.74 0.71 0.78 0.70 0.76 0.80 0.69 0.88 0.82 0.76 0.78 0.92 0.69 0.82 0.83 0.72 0.73 0.77 0.77 0.74 0.78 0.77 0.83 0.76 0.66 0.79 0.88 0.74 0.81 0.79 0.84 0.75 0.74 0.72 0.93 0.93 0.97 0.68 0.96 0.97 0.91 0.96
miR$33ab/33$5p 0.74 0.69 0.75 0.75 0.81 0.74 0.80 0.62 0.68 0.74 0.75 0.75 0.79 0.72 0.72 0.74 0.71 0.82 0.72 0.75 0.76 0.81 0.00 0.80 0.73 0.68 0.75 0.78 0.67 0.70 0.70 0.73 0.73 0.72 0.74 0.76 0.75 0.71 0.70 0.71 0.71 0.73 0.69 0.73 0.67 0.71 0.75 0.71 0.72 0.73 0.72 0.78 0.73 0.70 0.75 0.65 0.86 0.72 0.75 0.79 0.65 0.68 0.71 0.70 0.70 0.75 0.78 0.72 0.71 0.70 0.80 0.72 0.79 0.79 0.75 0.75 0.68 0.76 0.72 0.91 0.95 1.00 0.65 0.92 1.00 0.95 0.95
miR$34ac/34bc$5p/449abc/449c$5p 0.67 0.73 0.73 0.83 0.78 0.81 0.81 0.77 0.74 0.69 0.75 0.73 0.72 0.73 0.71 0.68 0.71 0.81 0.69 0.78 0.73 0.74 0.80 0.00 0.71 0.69 0.70 0.68 0.66 0.69 0.70 0.66 0.75 0.80 0.72 0.83 0.74 0.75 0.75 0.76 0.75 0.64 0.76 0.68 0.75 0.67 0.72 0.79 0.68 0.80 0.80 0.75 0.82 0.80 0.82 0.75 0.94 0.70 0.84 0.80 0.76 0.72 0.73 0.72 0.72 0.76 0.76 0.81 0.72 0.66 0.77 0.80 0.70 0.80 0.80 0.86 0.72 0.71 0.72 0.95 0.94 0.98 0.73 0.98 0.98 0.94 0.98
miR$143/1721/4770 0.72 0.68 0.77 0.78 0.79 0.75 0.78 0.67 0.65 0.65 0.72 0.69 0.74 0.76 0.74 0.68 0.69 0.79 0.69 0.69 0.69 0.71 0.73 0.71 0.00 0.68 0.75 0.67 0.67 0.67 0.70 0.67 0.76 0.78 0.71 0.73 0.77 0.73 0.73 0.76 0.75 0.68 0.73 0.67 0.75 0.68 0.71 0.80 0.67 0.78 0.73 0.67 0.84 0.77 0.81 0.67 0.93 0.68 0.79 0.80 0.69 0.71 0.73 0.72 0.72 0.73 0.76 0.78 0.67 0.67 0.74 0.78 0.75 0.76 0.77 0.82 0.68 0.75 0.73 0.94 0.93 0.96 0.72 0.94 0.96 0.92 0.95
miR$145 0.65 0.67 0.73 0.82 0.77 0.74 0.78 0.67 0.65 0.66 0.76 0.69 0.72 0.69 0.66 0.71 0.66 0.79 0.68 0.66 0.70 0.67 0.68 0.69 0.68 0.00 0.72 0.71 0.62 0.68 0.67 0.68 0.69 0.83 0.68 0.74 0.72 0.69 0.66 0.73 0.70 0.65 0.71 0.66 0.66 0.61 0.68 0.81 0.59 0.75 0.71 0.73 0.76 0.74 0.76 0.67 0.92 0.69 0.80 0.78 0.67 0.69 0.65 0.72 0.68 0.73 0.79 0.75 0.65 0.67 0.75 0.78 0.68 0.75 0.76 0.83 0.58 0.72 0.70 0.92 0.92 0.99 0.70 0.93 0.97 0.91 0.97
miR$103a/107/107ab 0.73 0.74 0.74 0.84 0.78 0.84 0.74 0.78 0.72 0.72 0.77 0.73 0.61 0.78 0.71 0.74 0.72 0.84 0.72 0.77 0.75 0.78 0.75 0.70 0.75 0.72 0.00 0.73 0.68 0.70 0.68 0.71 0.76 0.83 0.73 0.82 0.81 0.71 0.77 0.75 0.75 0.66 0.78 0.68 0.80 0.71 0.74 0.81 0.74 0.79 0.82 0.78 0.87 0.82 0.84 0.76 0.93 0.71 0.83 0.84 0.66 0.75 0.72 0.73 0.76 0.80 0.79 0.81 0.71 0.68 0.83 0.86 0.66 0.83 0.77 0.87 0.76 0.76 0.73 0.94 0.96 0.98 0.76 0.98 0.97 0.96 0.96
miR$122/122a/1352 0.80 0.71 0.76 0.81 0.83 0.79 0.76 0.65 0.65 0.65 0.74 0.65 0.74 0.70 0.72 0.74 0.60 0.80 0.73 0.70 0.69 0.78 0.78 0.68 0.67 0.71 0.73 0.00 0.64 0.55 0.71 0.71 0.76 0.74 0.66 0.79 0.70 0.68 0.70 0.77 0.70 0.64 0.68 0.68 0.77 0.73 0.74 0.64 0.68 0.69 0.79 0.73 0.75 0.74 0.68 0.71 0.75 0.73 0.65 0.81 0.62 0.67 0.74 0.72 0.71 0.78 0.70 0.76 0.73 0.67 0.76 0.78 0.73 0.78 0.65 0.75 0.73 0.66 0.76 0.68 0.83 1.00 0.69 1.00 1.00 0.87 0.59
miR$129$5p/129ab$5p 0.61 0.64 0.75 0.70 0.76 0.70 0.76 0.62 0.59 0.64 0.73 0.60 0.69 0.66 0.69 0.67 0.49 0.73 0.59 0.70 0.65 0.72 0.67 0.66 0.67 0.62 0.68 0.64 0.00 0.51 0.62 0.61 0.62 0.79 0.65 0.65 0.73 0.68 0.68 0.69 0.73 0.55 0.67 0.62 0.65 0.55 0.67 0.80 0.69 0.76 0.72 0.72 0.76 0.74 0.75 0.66 0.91 0.68 0.76 0.76 0.61 0.71 0.69 0.61 0.69 0.73 0.74 0.70 0.60 0.65 0.77 0.75 0.68 0.75 0.72 0.75 0.64 0.70 0.63 0.94 0.94 0.97 0.67 0.95 0.96 0.94 0.96
miR$93/93a/105/106a** 0.65 0.69 0.72 0.76 0.78 0.74 0.73 0.69 0.60 0.64 0.72 0.68 0.68 0.71 0.68 0.68 0.38 0.79 0.65 0.72 0.68 0.73 0.70 0.69 0.67 0.68 0.70 0.55 0.51 0.00 0.68 0.65 0.68 0.82 0.66 0.77 0.72 0.68 0.67 0.73 0.74 0.53 0.69 0.67 0.72 0.63 0.68 0.80 0.69 0.72 0.72 0.69 0.76 0.75 0.78 0.69 0.90 0.71 0.80 0.77 0.59 0.67 0.72 0.68 0.70 0.72 0.76 0.74 0.66 0.67 0.74 0.73 0.64 0.75 0.75 0.81 0.67 0.72 0.71 0.90 0.92 0.95 0.69 0.92 0.94 0.91 0.94
miR$96/507/1271 0.62 0.70 0.74 0.86 0.74 0.67 0.79 0.71 0.70 0.66 0.74 0.69 0.74 0.79 0.69 0.71 0.68 0.79 0.69 0.76 0.73 0.67 0.70 0.70 0.70 0.67 0.68 0.71 0.62 0.68 0.00 0.67 0.70 0.85 0.69 0.80 0.72 0.68 0.69 0.73 0.69 0.61 0.76 0.28 0.68 0.68 0.68 0.83 0.69 0.77 0.72 0.71 0.79 0.75 0.81 0.73 0.91 0.64 0.84 0.79 0.70 0.70 0.72 0.75 0.69 0.72 0.78 0.76 0.64 0.64 0.79 0.85 0.72 0.78 0.77 0.77 0.71 0.78 0.71 0.91 0.91 0.95 0.75 0.92 0.99 0.91 0.99
miR$128/128ab 0.61 0.64 0.68 0.81 0.79 0.80 0.76 0.64 0.62 0.58 0.71 0.65 0.65 0.70 0.61 0.66 0.63 0.78 0.39 0.68 0.65 0.73 0.73 0.66 0.67 0.68 0.71 0.71 0.61 0.65 0.67 0.00 0.67 0.71 0.68 0.67 0.72 0.71 0.69 0.77 0.72 0.61 0.71 0.67 0.69 0.59 0.64 0.81 0.69 0.79 0.72 0.70 0.87 0.76 0.77 0.67 0.91 0.63 0.83 0.80 0.70 0.65 0.73 0.65 0.71 0.69 0.73 0.72 0.60 0.66 0.81 0.82 0.65 0.77 0.79 0.88 0.68 0.71 0.62 0.92 0.93 1.00 0.73 0.94 0.97 0.96 0.96
miR$141/200a 0.63 0.72 0.76 0.77 0.79 0.77 0.80 0.68 0.64 0.66 0.77 0.68 0.74 0.72 0.75 0.71 0.62 0.79 0.67 0.73 0.68 0.74 0.73 0.75 0.76 0.69 0.76 0.76 0.62 0.68 0.70 0.67 0.00 0.80 0.69 0.73 0.79 0.73 0.74 0.74 0.78 0.67 0.75 0.68 0.66 0.64 0.74 0.82 0.73 0.80 0.72 0.75 0.79 0.78 0.82 0.69 0.96 0.76 0.81 0.78 0.72 0.75 0.75 0.67 0.73 0.76 0.80 0.77 0.67 0.72 0.76 0.81 0.76 0.79 0.80 0.82 0.67 0.73 0.72 0.93 0.93 0.99 0.77 0.96 0.98 0.95 0.98
miR$142$3p 0.77 0.81 0.77 0.90 0.72 0.80 0.91 0.86 0.79 0.77 0.83 0.85 0.86 0.89 0.75 0.81 0.79 0.85 0.82 0.86 0.86 0.78 0.72 0.80 0.78 0.83 0.83 0.74 0.79 0.82 0.85 0.71 0.80 0.00 0.81 0.86 0.81 0.71 0.75 0.79 0.83 0.78 0.85 0.80 0.78 0.80 0.80 0.86 0.88 0.80 0.79 0.81 0.82 0.86 0.81 0.76 0.97 0.82 0.87 0.81 0.79 0.85 0.75 0.85 0.83 0.84 0.80 0.79 0.81 0.70 0.82 0.72 0.83 0.77 0.81 0.88 0.75 0.88 0.83 0.98 0.98 1.00 0.78 0.99 1.00 1.00 0.98
miR$135ab/135a$5p 0.66 0.67 0.75 0.80 0.74 0.75 0.84 0.75 0.68 0.72 0.76 0.70 0.75 0.86 0.68 0.70 0.68 0.82 0.69 0.74 0.74 0.70 0.74 0.72 0.71 0.68 0.73 0.66 0.65 0.66 0.69 0.68 0.69 0.81 0.00 0.74 0.77 0.66 0.67 0.73 0.75 0.68 0.75 0.68 0.72 0.67 0.66 0.84 0.74 0.76 0.82 0.73 0.81 0.73 0.82 0.72 0.95 0.69 0.84 0.79 0.70 0.73 0.68 0.74 0.71 0.78 0.87 0.74 0.68 0.66 0.82 0.83 0.72 0.79 0.72 0.83 0.70 0.75 0.74 0.96 0.95 0.97 0.76 0.96 0.96 0.95 0.95
miR$137/137ab 0.65 0.72 0.80 0.88 0.81 0.78 0.81 0.60 0.73 0.75 0.83 0.75 0.78 0.79 0.67 0.77 0.70 0.83 0.67 0.84 0.80 0.82 0.76 0.83 0.73 0.74 0.82 0.79 0.65 0.77 0.80 0.67 0.73 0.86 0.74 0.00 0.82 0.76 0.75 0.81 0.77 0.71 0.80 0.78 0.73 0.66 0.74 0.88 0.79 0.81 0.80 0.81 0.83 0.80 0.81 0.76 0.98 0.75 0.86 0.83 0.79 0.74 0.76 0.75 0.75 0.83 0.82 0.80 0.69 0.71 0.85 0.85 0.80 0.85 0.80 0.86 0.75 0.78 0.79 0.97 0.94 1.00 0.80 0.98 1.00 0.99 0.99
miR$139$5p 0.75 0.73 0.74 0.79 0.82 0.76 0.74 0.68 0.69 0.73 0.77 0.75 0.78 0.77 0.75 0.73 0.71 0.81 0.70 0.76 0.71 0.79 0.75 0.74 0.77 0.72 0.81 0.70 0.73 0.72 0.72 0.72 0.79 0.81 0.77 0.82 0.00 0.67 0.73 0.77 0.80 0.77 0.74 0.73 0.73 0.75 0.73 0.74 0.73 0.79 0.78 0.74 0.80 0.75 0.80 0.64 0.86 0.73 0.80 0.74 0.68 0.76 0.76 0.73 0.74 0.83 0.83 0.78 0.75 0.67 0.72 0.75 0.80 0.79 0.78 0.82 0.68 0.75 0.74 0.90 0.91 0.97 0.71 0.90 0.96 0.86 0.89
miR$216a 0.75 0.67 0.75 0.71 0.77 0.71 0.72 0.71 0.67 0.70 0.74 0.72 0.73 0.67 0.74 0.74 0.66 0.81 0.68 0.69 0.73 0.74 0.71 0.75 0.73 0.69 0.71 0.68 0.68 0.68 0.68 0.71 0.73 0.71 0.66 0.76 0.67 0.00 0.41 0.74 0.69 0.71 0.70 0.68 0.70 0.70 0.73 0.67 0.70 0.74 0.76 0.71 0.75 0.72 0.77 0.68 0.83 0.69 0.73 0.74 0.64 0.67 0.72 0.67 0.68 0.76 0.77 0.72 0.68 0.68 0.77 0.71 0.79 0.79 0.69 0.73 0.68 0.74 0.71 0.86 0.84 0.99 0.69 0.91 0.94 0.79 0.92
miR$216b/216b$5p 0.75 0.65 0.81 0.76 0.79 0.75 0.80 0.70 0.65 0.70 0.80 0.72 0.74 0.68 0.74 0.74 0.61 0.83 0.66 0.65 0.70 0.78 0.70 0.75 0.73 0.66 0.77 0.70 0.68 0.67 0.69 0.69 0.74 0.75 0.67 0.75 0.73 0.41 0.00 0.77 0.75 0.71 0.76 0.70 0.66 0.68 0.73 0.75 0.69 0.81 0.71 0.76 0.84 0.74 0.79 0.66 0.91 0.74 0.81 0.76 0.63 0.72 0.69 0.69 0.73 0.79 0.75 0.78 0.67 0.69 0.75 0.75 0.78 0.83 0.77 0.79 0.68 0.72 0.73 0.93 0.90 0.96 0.70 0.95 0.93 0.89 0.91
miR$217 0.76 0.73 0.83 0.79 0.83 0.78 0.77 0.70 0.66 0.77 0.83 0.76 0.76 0.76 0.74 0.75 0.70 0.86 0.71 0.73 0.81 0.78 0.71 0.76 0.76 0.73 0.75 0.77 0.69 0.73 0.73 0.77 0.74 0.79 0.73 0.81 0.77 0.74 0.77 0.00 0.80 0.79 0.77 0.71 0.64 0.71 0.79 0.77 0.72 0.81 0.77 0.75 0.84 0.77 0.84 0.67 0.92 0.80 0.81 0.80 0.69 0.81 0.75 0.77 0.68 0.88 0.81 0.81 0.72 0.70 0.80 0.85 0.79 0.82 0.78 0.83 0.68 0.78 0.79 0.92 0.91 0.96 0.72 0.98 0.96 0.93 0.97
miR$146ac/146b$5p 0.75 0.75 0.76 0.81 0.77 0.81 0.79 0.77 0.73 0.71 0.78 0.73 0.76 0.77 0.77 0.74 0.74 0.84 0.75 0.73 0.73 0.77 0.71 0.75 0.75 0.70 0.75 0.70 0.73 0.74 0.69 0.72 0.78 0.83 0.75 0.77 0.80 0.69 0.75 0.80 0.00 0.76 0.77 0.69 0.79 0.76 0.76 0.75 0.71 0.78 0.78 0.76 0.84 0.79 0.81 0.75 0.85 0.72 0.80 0.77 0.71 0.72 0.73 0.76 0.73 0.81 0.80 0.79 0.69 0.69 0.77 0.80 0.76 0.78 0.77 0.85 0.74 0.75 0.75 0.89 0.91 0.95 0.77 0.95 0.95 0.92 0.95
miR$150/5127 0.67 0.69 0.73 0.75 0.77 0.73 0.71 0.70 0.63 0.60 0.67 0.56 0.61 0.69 0.71 0.67 0.52 0.81 0.63 0.68 0.65 0.70 0.73 0.64 0.68 0.65 0.66 0.64 0.55 0.53 0.61 0.61 0.67 0.78 0.68 0.71 0.77 0.71 0.71 0.79 0.76 0.00 0.72 0.62 0.69 0.67 0.69 0.79 0.68 0.76 0.76 0.71 0.83 0.75 0.78 0.70 0.91 0.66 0.78 0.79 0.66 0.69 0.77 0.66 0.72 0.71 0.73 0.75 0.63 0.67 0.75 0.79 0.62 0.80 0.76 0.75 0.70 0.64 0.62 0.89 0.92 0.97 0.72 0.94 0.97 0.91 0.95
miR$153 0.66 0.72 0.73 0.80 0.76 0.75 0.83 0.65 0.70 0.72 0.73 0.74 0.79 0.80 0.71 0.74 0.74 0.78 0.72 0.83 0.74 0.78 0.69 0.76 0.73 0.71 0.78 0.68 0.67 0.69 0.76 0.71 0.75 0.85 0.75 0.80 0.74 0.70 0.76 0.77 0.77 0.72 0.00 0.73 0.71 0.67 0.73 0.80 0.81 0.80 0.75 0.68 0.74 0.73 0.77 0.75 0.89 0.78 0.87 0.79 0.72 0.71 0.67 0.69 0.71 0.79 0.83 0.74 0.70 0.70 0.79 0.81 0.79 0.78 0.78 0.86 0.69 0.77 0.73 0.95 0.95 1.00 0.68 0.97 0.97 0.95 0.97
miR$182 0.60 0.67 0.73 0.82 0.75 0.71 0.76 0.70 0.68 0.65 0.75 0.66 0.69 0.74 0.68 0.68 0.64 0.78 0.68 0.75 0.69 0.59 0.73 0.68 0.67 0.66 0.68 0.68 0.62 0.67 0.28 0.67 0.68 0.80 0.68 0.78 0.73 0.68 0.70 0.71 0.69 0.62 0.73 0.00 0.66 0.64 0.69 0.80 0.70 0.76 0.71 0.69 0.79 0.74 0.77 0.71 0.92 0.67 0.84 0.77 0.73 0.71 0.70 0.76 0.67 0.73 0.76 0.77 0.65 0.61 0.75 0.83 0.70 0.74 0.74 0.82 0.71 0.74 0.68 0.93 0.91 0.98 0.68 0.94 0.99 0.93 0.97
miR$200bc/429/548a 0.60 0.72 0.75 0.86 0.81 0.75 0.82 0.64 0.65 0.70 0.81 0.69 0.74 0.73 0.71 0.71 0.68 0.82 0.68 0.71 0.66 0.76 0.67 0.75 0.75 0.66 0.80 0.77 0.65 0.72 0.68 0.69 0.66 0.78 0.72 0.73 0.73 0.70 0.66 0.64 0.79 0.69 0.71 0.66 0.00 0.60 0.69 0.82 0.74 0.79 0.73 0.74 0.76 0.77 0.82 0.69 0.92 0.73 0.81 0.76 0.73 0.75 0.68 0.72 0.67 0.74 0.80 0.75 0.62 0.67 0.82 0.81 0.78 0.80 0.78 0.82 0.66 0.78 0.74 0.93 0.93 0.94 0.71 0.94 0.94 0.92 0.96
miR$203 0.61 0.65 0.76 0.67 0.77 0.73 0.78 0.61 0.58 0.63 0.77 0.61 0.68 0.68 0.69 0.67 0.56 0.79 0.60 0.67 0.63 0.74 0.71 0.67 0.68 0.61 0.71 0.73 0.55 0.63 0.68 0.59 0.64 0.80 0.67 0.66 0.75 0.70 0.68 0.71 0.76 0.67 0.67 0.64 0.60 0.00 0.69 0.80 0.72 0.81 0.73 0.73 0.80 0.75 0.81 0.64 0.93 0.70 0.83 0.76 0.66 0.71 0.72 0.66 0.67 0.74 0.76 0.75 0.57 0.67 0.81 0.79 0.70 0.82 0.77 0.80 0.61 0.71 0.63 0.95 0.95 0.97 0.71 0.96 0.97 0.93 0.97
miR$204/204b/211 0.68 0.68 0.77 0.82 0.81 0.76 0.79 0.71 0.66 0.64 0.70 0.68 0.71 0.67 0.70 0.71 0.64 0.84 0.65 0.66 0.70 0.71 0.75 0.72 0.71 0.68 0.74 0.74 0.67 0.68 0.68 0.64 0.74 0.80 0.66 0.74 0.73 0.73 0.73 0.79 0.76 0.69 0.73 0.69 0.69 0.69 0.00 0.80 0.71 0.79 0.75 0.72 0.82 0.77 0.81 0.68 0.94 0.64 0.78 0.81 0.69 0.72 0.75 0.72 0.72 0.71 0.76 0.76 0.66 0.68 0.77 0.79 0.71 0.79 0.79 0.82 0.69 0.75 0.70 0.94 0.92 0.99 0.69 0.97 0.97 0.93 0.96
miR$196abc 0.79 0.80 0.76 0.84 0.73 0.77 0.86 0.83 0.81 0.78 0.84 0.87 0.87 0.79 0.79 0.81 0.79 0.75 0.83 0.84 0.84 0.78 0.71 0.79 0.80 0.81 0.81 0.64 0.80 0.80 0.83 0.81 0.82 0.86 0.84 0.88 0.74 0.67 0.75 0.77 0.75 0.79 0.80 0.80 0.82 0.80 0.80 0.00 0.83 0.74 0.79 0.75 0.77 0.78 0.79 0.80 0.93 0.82 0.81 0.84 0.82 0.80 0.68 0.79 0.80 0.81 0.85 0.79 0.82 0.71 0.66 0.80 0.84 0.74 0.83 0.80 0.82 0.81 0.84 0.95 0.96 1.00 0.77 0.97 0.97 1.00 1.00
miR$199ab$5p 0.73 0.70 0.71 0.87 0.78 0.81 0.75 0.76 0.69 0.63 0.74 0.71 0.74 0.78 0.72 0.69 0.67 0.81 0.67 0.69 0.70 0.70 0.72 0.68 0.67 0.59 0.74 0.68 0.69 0.69 0.69 0.69 0.73 0.88 0.74 0.79 0.73 0.70 0.69 0.72 0.71 0.68 0.81 0.70 0.74 0.72 0.71 0.83 0.00 0.76 0.69 0.76 0.86 0.80 0.83 0.70 0.96 0.68 0.82 0.85 0.70 0.67 0.70 0.72 0.68 0.70 0.80 0.82 0.70 0.67 0.69 0.84 0.69 0.84 0.79 0.86 0.71 0.75 0.70 0.92 0.91 1.00 0.70 0.93 1.00 0.92 0.96
miR$193/193b/193a$3p 0.81 0.79 0.80 0.83 0.83 0.79 0.79 0.78 0.81 0.76 0.77 0.76 0.78 0.75 0.75 0.77 0.77 0.82 0.82 0.74 0.81 0.76 0.73 0.80 0.78 0.75 0.79 0.69 0.76 0.72 0.77 0.79 0.80 0.80 0.76 0.81 0.79 0.74 0.81 0.81 0.78 0.76 0.80 0.76 0.79 0.81 0.79 0.74 0.76 0.00 0.77 0.73 0.87 0.81 0.81 0.76 0.87 0.76 0.84 0.81 0.79 0.79 0.79 0.79 0.73 0.78 0.84 0.86 0.78 0.73 0.73 0.83 0.79 0.85 0.81 0.84 0.78 0.78 0.79 0.92 0.87 0.94 0.75 0.94 0.94 0.89 0.89
miR$194 0.75 0.72 0.79 0.85 0.80 0.79 0.84 0.70 0.71 0.72 0.87 0.80 0.83 0.76 0.71 0.78 0.71 0.84 0.71 0.79 0.74 0.80 0.72 0.80 0.73 0.71 0.82 0.79 0.72 0.72 0.72 0.72 0.72 0.79 0.82 0.80 0.78 0.76 0.71 0.77 0.78 0.76 0.75 0.71 0.73 0.73 0.75 0.79 0.69 0.77 0.00 0.81 0.78 0.74 0.77 0.70 0.95 0.74 0.80 0.79 0.68 0.80 0.71 0.78 0.66 0.77 0.79 0.75 0.75 0.72 0.79 0.78 0.79 0.82 0.77 0.84 0.65 0.80 0.75 0.96 0.95 1.00 0.71 0.96 1.00 0.96 0.96
miR$183 0.74 0.73 0.74 0.76 0.78 0.74 0.82 0.74 0.65 0.69 0.79 0.73 0.81 0.74 0.70 0.73 0.72 0.80 0.69 0.70 0.73 0.69 0.78 0.75 0.67 0.73 0.78 0.73 0.72 0.69 0.71 0.70 0.75 0.81 0.73 0.81 0.74 0.71 0.76 0.75 0.76 0.71 0.68 0.69 0.74 0.73 0.72 0.75 0.76 0.73 0.81 0.00 0.84 0.72 0.78 0.77 0.87 0.72 0.76 0.79 0.68 0.71 0.74 0.74 0.71 0.82 0.79 0.79 0.72 0.62 0.74 0.76 0.76 0.79 0.77 0.83 0.77 0.75 0.76 0.90 0.90 0.98 0.77 0.98 0.98 0.92 0.97
miR$190/190ab 0.83 0.82 0.87 0.81 0.86 0.75 0.84 0.78 0.73 0.82 0.92 0.82 0.88 0.84 0.84 0.82 0.81 0.86 0.83 0.87 0.83 0.88 0.73 0.82 0.84 0.76 0.87 0.75 0.76 0.76 0.79 0.87 0.79 0.82 0.81 0.83 0.80 0.75 0.84 0.84 0.84 0.83 0.74 0.79 0.76 0.80 0.82 0.77 0.86 0.87 0.78 0.84 0.00 0.80 0.84 0.77 0.94 0.83 0.82 0.84 0.78 0.87 0.79 0.82 0.83 0.87 0.84 0.77 0.84 0.77 0.79 0.82 0.88 0.81 0.80 0.81 0.78 0.81 0.85 0.90 0.91 0.98 0.74 0.93 0.92 0.94 0.92
miR$223 0.74 0.77 0.77 0.82 0.78 0.74 0.79 0.73 0.76 0.77 0.80 0.75 0.79 0.83 0.78 0.76 0.75 0.80 0.78 0.84 0.84 0.82 0.70 0.80 0.77 0.74 0.82 0.74 0.74 0.75 0.75 0.76 0.78 0.86 0.73 0.80 0.75 0.72 0.74 0.77 0.79 0.75 0.73 0.74 0.77 0.75 0.77 0.78 0.80 0.81 0.74 0.72 0.80 0.00 0.83 0.76 0.93 0.77 0.86 0.76 0.76 0.70 0.73 0.77 0.75 0.84 0.79 0.77 0.77 0.69 0.77 0.83 0.81 0.80 0.77 0.85 0.74 0.78 0.77 0.95 0.92 1.00 0.76 0.97 0.97 0.98 0.95
miR$383 0.78 0.79 0.83 0.83 0.85 0.78 0.84 0.83 0.72 0.75 0.77 0.80 0.82 0.82 0.84 0.79 0.77 0.84 0.77 0.86 0.83 0.76 0.75 0.82 0.81 0.76 0.84 0.68 0.75 0.78 0.81 0.77 0.82 0.81 0.82 0.81 0.80 0.77 0.79 0.84 0.81 0.78 0.77 0.77 0.82 0.81 0.81 0.79 0.83 0.81 0.77 0.78 0.84 0.83 0.00 0.75 0.91 0.78 0.86 0.84 0.79 0.79 0.82 0.79 0.78 0.82 0.85 0.80 0.78 0.73 0.75 0.79 0.82 0.85 0.78 0.86 0.72 0.76 0.80 0.90 0.94 0.97 0.77 0.90 0.96 0.96 0.96
miR$101/101ab 0.62 0.69 0.75 0.84 0.75 0.75 0.78 0.66 0.66 0.70 0.78 0.75 0.75 0.81 0.67 0.74 0.68 0.79 0.65 0.76 0.76 0.78 0.65 0.75 0.67 0.67 0.76 0.71 0.66 0.69 0.73 0.67 0.69 0.76 0.72 0.76 0.64 0.68 0.66 0.67 0.75 0.70 0.75 0.71 0.69 0.64 0.68 0.80 0.70 0.76 0.70 0.77 0.77 0.76 0.75 0.00 0.93 0.72 0.87 0.72 0.72 0.72 0.75 0.75 0.66 0.79 0.81 0.78 0.66 0.64 0.74 0.78 0.74 0.81 0.77 0.87 0.30 0.76 0.74 0.97 0.95 0.99 0.71 0.97 0.99 0.96 0.98
miR$187 0.90 0.96 0.89 0.94 0.94 0.91 0.92 0.95 0.95 0.89 0.92 0.92 0.94 0.94 0.89 0.92 0.92 0.91 0.95 0.96 0.96 0.92 0.86 0.94 0.93 0.92 0.93 0.75 0.91 0.90 0.91 0.91 0.96 0.97 0.95 0.98 0.86 0.83 0.91 0.92 0.85 0.91 0.89 0.92 0.92 0.93 0.94 0.93 0.96 0.87 0.95 0.87 0.94 0.93 0.91 0.93 0.00 0.91 0.95 0.93 0.94 0.94 0.89 0.95 0.91 0.96 0.90 0.96 0.94 0.87 0.85 0.91 0.90 0.87 0.92 0.94 0.95 0.92 0.91 0.90 0.85 0.87 0.93 0.88 0.88 0.91 0.90
miR$125a$5p/125b$5p/351/670/4319 0.67 0.67 0.64 0.84 0.77 0.73 0.77 0.76 0.71 0.63 0.67 0.69 0.70 0.71 0.65 0.69 0.68 0.78 0.66 0.69 0.73 0.69 0.72 0.70 0.68 0.69 0.71 0.73 0.68 0.71 0.64 0.63 0.76 0.82 0.69 0.75 0.73 0.69 0.74 0.80 0.72 0.66 0.78 0.67 0.73 0.70 0.64 0.82 0.68 0.76 0.74 0.72 0.83 0.77 0.78 0.72 0.91 0.00 0.79 0.79 0.78 0.70 0.68 0.72 0.77 0.66 0.76 0.76 0.67 0.64 0.72 0.78 0.67 0.75 0.77 0.82 0.69 0.75 0.72 0.87 0.95 0.96 0.75 0.95 0.98 0.94 0.97
miR$192/215 0.84 0.84 0.89 0.85 0.81 0.77 0.86 0.84 0.74 0.77 0.88 0.82 0.86 0.83 0.82 0.81 0.78 0.88 0.83 0.82 0.85 0.82 0.75 0.84 0.79 0.80 0.83 0.65 0.76 0.80 0.84 0.83 0.81 0.87 0.84 0.86 0.80 0.73 0.81 0.81 0.80 0.78 0.87 0.84 0.81 0.83 0.78 0.81 0.82 0.84 0.80 0.76 0.82 0.86 0.86 0.87 0.95 0.79 0.00 0.85 0.79 0.88 0.76 0.83 0.88 0.93 0.82 0.84 0.84 0.74 0.76 0.81 0.85 0.85 0.83 0.81 0.84 0.84 0.84 0.91 0.93 1.00 0.78 0.95 0.98 0.95 0.96
miR$221/222/222ab/1928 0.76 0.79 0.79 0.84 0.83 0.78 0.84 0.74 0.74 0.80 0.80 0.75 0.82 0.82 0.81 0.79 0.76 0.84 0.76 0.77 0.82 0.83 0.79 0.80 0.80 0.78 0.84 0.81 0.76 0.77 0.79 0.80 0.78 0.81 0.79 0.83 0.74 0.74 0.76 0.80 0.77 0.79 0.79 0.77 0.76 0.76 0.81 0.84 0.85 0.81 0.79 0.79 0.84 0.76 0.84 0.72 0.93 0.79 0.85 0.00 0.74 0.79 0.82 0.79 0.79 0.87 0.85 0.81 0.71 0.73 0.85 0.84 0.82 0.83 0.81 0.86 0.74 0.79 0.77 0.94 0.93 0.97 0.75 0.97 0.97 0.97 0.93
miR$130ac/301ab/301b/301b$3p** 0.64 0.72 0.72 0.79 0.73 0.68 0.79 0.72 0.67 0.67 0.72 0.74 0.74 0.81 0.70 0.74 0.59 0.80 0.72 0.70 0.72 0.72 0.65 0.76 0.69 0.67 0.66 0.62 0.61 0.59 0.70 0.70 0.72 0.79 0.70 0.79 0.68 0.64 0.63 0.69 0.71 0.66 0.72 0.73 0.73 0.66 0.69 0.82 0.70 0.79 0.68 0.68 0.78 0.76 0.79 0.72 0.94 0.78 0.79 0.74 0.00 0.62 0.67 0.57 0.64 0.80 0.82 0.77 0.69 0.65 0.79 0.74 0.71 0.80 0.73 0.79 0.68 0.77 0.72 0.94 0.94 0.97 0.68 0.95 0.97 0.95 0.92
miR$148ab$3p/152 0.71 0.74 0.72 0.82 0.78 0.82 0.76 0.69 0.71 0.66 0.71 0.72 0.76 0.71 0.72 0.74 0.70 0.76 0.69 0.75 0.73 0.73 0.68 0.72 0.71 0.69 0.75 0.67 0.71 0.67 0.70 0.65 0.75 0.85 0.73 0.74 0.76 0.67 0.72 0.81 0.72 0.69 0.71 0.71 0.75 0.71 0.72 0.80 0.67 0.79 0.80 0.71 0.87 0.70 0.79 0.72 0.94 0.70 0.88 0.79 0.62 0.00 0.72 0.65 0.73 0.74 0.81 0.71 0.70 0.66 0.72 0.80 0.71 0.82 0.74 0.87 0.70 0.76 0.71 0.92 0.93 0.96 0.68 0.93 0.96 0.94 0.97
miR$425/425$5p/489 0.74 0.69 0.75 0.81 0.80 0.77 0.75 0.68 0.67 0.74 0.79 0.71 0.76 0.66 0.74 0.73 0.69 0.82 0.70 0.74 0.67 0.77 0.71 0.73 0.73 0.65 0.72 0.74 0.69 0.72 0.72 0.73 0.75 0.75 0.68 0.76 0.76 0.72 0.69 0.75 0.73 0.77 0.67 0.70 0.68 0.72 0.75 0.68 0.70 0.79 0.71 0.74 0.79 0.73 0.82 0.75 0.89 0.68 0.76 0.82 0.67 0.72 0.00 0.66 0.73 0.79 0.81 0.78 0.67 0.69 0.78 0.74 0.78 0.78 0.79 0.80 0.69 0.70 0.70 0.91 0.89 0.95 0.66 0.92 0.94 0.91 0.90
miR$19ab 0.63 0.75 0.73 0.79 0.78 0.75 0.78 0.71 0.70 0.70 0.72 0.68 0.75 0.77 0.68 0.74 0.67 0.79 0.65 0.72 0.72 0.77 0.70 0.72 0.72 0.72 0.73 0.72 0.61 0.68 0.75 0.65 0.67 0.85 0.74 0.75 0.73 0.67 0.69 0.77 0.76 0.66 0.69 0.76 0.72 0.66 0.72 0.79 0.72 0.79 0.78 0.74 0.82 0.77 0.79 0.75 0.95 0.72 0.83 0.79 0.57 0.65 0.66 0.00 0.72 0.77 0.85 0.78 0.66 0.67 0.77 0.83 0.72 0.77 0.79 0.85 0.68 0.73 0.73 0.96 0.95 1.00 0.70 0.96 0.96 0.96 0.99
miR$132/212/212$3p 0.68 0.68 0.74 0.84 0.79 0.75 0.84 0.68 0.63 0.70 0.75 0.70 0.79 0.76 0.70 0.72 0.65 0.83 0.72 0.76 0.72 0.74 0.70 0.72 0.72 0.68 0.76 0.71 0.69 0.70 0.69 0.71 0.73 0.83 0.71 0.75 0.74 0.68 0.73 0.68 0.73 0.72 0.71 0.67 0.67 0.67 0.72 0.80 0.68 0.73 0.66 0.71 0.83 0.75 0.78 0.66 0.91 0.77 0.88 0.79 0.64 0.73 0.73 0.72 0.00 0.78 0.76 0.75 0.67 0.65 0.72 0.76 0.75 0.77 0.77 0.81 0.64 0.74 0.72 0.97 0.94 0.97 0.69 0.97 0.97 0.95 0.95
miR$138/138ab 0.72 0.69 0.73 0.88 0.87 0.79 0.76 0.75 0.78 0.67 0.75 0.77 0.75 0.75 0.76 0.71 0.74 0.84 0.72 0.77 0.81 0.78 0.75 0.76 0.73 0.73 0.80 0.78 0.73 0.72 0.72 0.69 0.76 0.84 0.78 0.83 0.83 0.76 0.79 0.88 0.81 0.71 0.79 0.73 0.74 0.74 0.71 0.81 0.70 0.78 0.77 0.82 0.87 0.84 0.82 0.79 0.96 0.66 0.93 0.87 0.80 0.74 0.79 0.77 0.78 0.00 0.85 0.85 0.71 0.71 0.81 0.90 0.74 0.80 0.84 0.89 0.76 0.74 0.76 0.95 0.96 0.99 0.79 0.98 0.99 0.97 0.97
miR$140/140$5p/876$3p/1244 0.71 0.81 0.79 0.87 0.84 0.80 0.91 0.83 0.75 0.72 0.82 0.77 0.82 0.79 0.78 0.78 0.74 0.84 0.80 0.82 0.82 0.77 0.78 0.76 0.76 0.79 0.79 0.70 0.74 0.76 0.78 0.73 0.80 0.80 0.87 0.82 0.83 0.77 0.75 0.81 0.80 0.73 0.83 0.76 0.80 0.76 0.76 0.85 0.80 0.84 0.79 0.79 0.84 0.79 0.85 0.81 0.90 0.76 0.82 0.85 0.82 0.81 0.81 0.85 0.76 0.85 0.00 0.80 0.81 0.72 0.82 0.84 0.80 0.84 0.80 0.87 0.81 0.80 0.81 0.91 0.92 0.92 0.81 0.94 0.92 0.91 0.93
miR$155 0.71 0.76 0.79 0.84 0.84 0.76 0.83 0.78 0.72 0.75 0.81 0.77 0.85 0.83 0.80 0.75 0.72 0.84 0.77 0.82 0.77 0.83 0.72 0.81 0.78 0.75 0.81 0.76 0.70 0.74 0.76 0.72 0.77 0.79 0.74 0.80 0.78 0.72 0.78 0.81 0.79 0.75 0.74 0.77 0.75 0.75 0.76 0.79 0.82 0.86 0.75 0.79 0.77 0.77 0.80 0.78 0.96 0.76 0.84 0.81 0.77 0.71 0.78 0.78 0.75 0.85 0.80 0.00 0.74 0.73 0.75 0.77 0.81 0.76 0.75 0.85 0.72 0.79 0.79 0.94 0.92 0.98 0.71 0.95 1.00 0.94 0.97
miR$181abcd/4262 0.57 0.67 0.73 0.82 0.77 0.71 0.78 0.65 0.60 0.67 0.74 0.67 0.67 0.70 0.67 0.66 0.60 0.77 0.62 0.72 0.64 0.76 0.71 0.72 0.67 0.65 0.71 0.73 0.60 0.66 0.64 0.60 0.67 0.81 0.68 0.69 0.75 0.68 0.67 0.72 0.69 0.63 0.70 0.65 0.62 0.57 0.66 0.82 0.70 0.78 0.75 0.72 0.84 0.77 0.78 0.66 0.94 0.67 0.84 0.71 0.69 0.70 0.67 0.66 0.67 0.71 0.81 0.74 0.00 0.61 0.80 0.84 0.70 0.77 0.75 0.84 0.62 0.78 0.69 0.94 0.95 0.97 0.75 0.96 0.97 0.96 0.96
miR$205/205ab 0.65 0.64 0.71 0.75 0.72 0.69 0.73 0.67 0.64 0.66 0.71 0.71 0.71 0.67 0.70 0.68 0.62 0.73 0.65 0.68 0.68 0.66 0.70 0.66 0.67 0.67 0.68 0.67 0.65 0.67 0.64 0.66 0.72 0.70 0.66 0.71 0.67 0.68 0.69 0.70 0.69 0.67 0.70 0.61 0.67 0.67 0.68 0.71 0.67 0.73 0.72 0.62 0.77 0.69 0.73 0.64 0.87 0.64 0.74 0.73 0.65 0.66 0.69 0.67 0.65 0.71 0.72 0.73 0.61 0.00 0.68 0.75 0.73 0.71 0.69 0.73 0.65 0.71 0.69 0.87 0.88 0.93 0.66 0.91 0.93 0.91 0.90
miR$10abc/10a$5p 0.81 0.74 0.75 0.81 0.80 0.80 0.77 0.78 0.71 0.70 0.79 0.80 0.78 0.79 0.74 0.76 0.75 0.80 0.76 0.76 0.81 0.79 0.80 0.77 0.74 0.75 0.83 0.76 0.77 0.74 0.79 0.81 0.76 0.82 0.82 0.85 0.72 0.77 0.75 0.80 0.77 0.75 0.79 0.75 0.82 0.81 0.77 0.66 0.69 0.73 0.79 0.74 0.79 0.77 0.75 0.74 0.85 0.72 0.76 0.85 0.79 0.72 0.78 0.77 0.72 0.81 0.82 0.75 0.80 0.68 0.00 0.78 0.79 0.80 0.76 0.82 0.76 0.77 0.79 0.81 0.78 0.87 0.71 0.88 0.87 0.84 0.83
miR$21/590$5p 0.78 0.79 0.86 0.83 0.85 0.79 0.89 0.83 0.74 0.81 0.84 0.80 0.86 0.83 0.81 0.80 0.76 0.88 0.82 0.81 0.81 0.88 0.72 0.80 0.78 0.78 0.86 0.78 0.75 0.73 0.85 0.82 0.81 0.72 0.83 0.85 0.75 0.71 0.75 0.85 0.80 0.79 0.81 0.83 0.81 0.79 0.79 0.80 0.84 0.83 0.78 0.76 0.82 0.83 0.79 0.78 0.91 0.78 0.81 0.84 0.74 0.80 0.74 0.83 0.76 0.90 0.84 0.77 0.84 0.75 0.78 0.00 0.83 0.81 0.83 0.85 0.75 0.82 0.80 0.92 0.95 0.98 0.75 0.98 0.98 0.95 0.95
miR$214/761/3619$5p 0.74 0.73 0.72 0.82 0.77 0.81 0.73 0.71 0.70 0.62 0.73 0.70 0.57 0.72 0.70 0.72 0.63 0.82 0.68 0.70 0.70 0.74 0.79 0.70 0.75 0.68 0.66 0.73 0.68 0.64 0.72 0.65 0.76 0.83 0.72 0.80 0.80 0.79 0.78 0.79 0.76 0.62 0.79 0.70 0.78 0.70 0.71 0.84 0.69 0.79 0.79 0.76 0.88 0.81 0.82 0.74 0.90 0.67 0.85 0.82 0.71 0.71 0.78 0.72 0.75 0.74 0.80 0.81 0.70 0.73 0.79 0.83 0.00 0.81 0.81 0.86 0.73 0.73 0.64 0.91 0.93 0.97 0.76 0.95 0.97 0.94 0.95
miR$33a$3p/365/365$3p 0.79 0.78 0.79 0.82 0.84 0.79 0.81 0.79 0.81 0.75 0.81 0.75 0.82 0.81 0.78 0.77 0.78 0.81 0.81 0.85 0.76 0.81 0.79 0.80 0.76 0.75 0.83 0.78 0.75 0.75 0.78 0.77 0.79 0.77 0.79 0.85 0.79 0.79 0.83 0.82 0.78 0.80 0.78 0.74 0.80 0.82 0.79 0.74 0.84 0.85 0.82 0.79 0.81 0.80 0.85 0.81 0.87 0.75 0.85 0.83 0.80 0.82 0.78 0.77 0.77 0.80 0.84 0.76 0.77 0.71 0.80 0.81 0.81 0.00 0.76 0.89 0.80 0.81 0.82 0.92 0.94 0.99 0.78 0.99 0.99 0.99 0.94
miR$455$5p 0.77 0.72 0.79 0.81 0.78 0.74 0.80 0.80 0.77 0.72 0.80 0.75 0.80 0.85 0.80 0.73 0.76 0.86 0.75 0.80 0.79 0.79 0.75 0.80 0.77 0.76 0.77 0.65 0.72 0.75 0.77 0.79 0.80 0.81 0.72 0.80 0.78 0.69 0.77 0.78 0.77 0.76 0.78 0.74 0.78 0.77 0.79 0.83 0.79 0.81 0.77 0.77 0.80 0.77 0.78 0.77 0.92 0.77 0.83 0.81 0.73 0.74 0.79 0.79 0.77 0.84 0.80 0.75 0.75 0.69 0.76 0.83 0.81 0.76 0.00 0.84 0.75 0.77 0.80 0.92 0.89 0.97 0.74 0.91 0.96 0.91 0.91
miR$208ab/208ab$3p 0.78 0.84 0.83 0.83 0.80 0.17 0.90 0.76 0.86 0.80 0.88 0.83 0.89 0.88 0.79 0.84 0.78 0.85 0.83 0.86 0.84 0.84 0.75 0.86 0.82 0.83 0.87 0.75 0.75 0.81 0.77 0.88 0.82 0.88 0.83 0.86 0.82 0.73 0.79 0.83 0.85 0.75 0.86 0.82 0.82 0.80 0.82 0.80 0.86 0.84 0.84 0.83 0.81 0.85 0.86 0.87 0.94 0.82 0.81 0.86 0.79 0.87 0.80 0.85 0.81 0.89 0.87 0.85 0.84 0.73 0.82 0.85 0.86 0.89 0.84 0.00 0.83 0.83 0.84 0.95 0.93 0.95 0.79 0.95 0.95 0.96 0.96
miR$144 0.62 0.68 0.76 0.78 0.81 0.75 0.78 0.63 0.66 0.68 0.76 0.70 0.78 0.78 0.71 0.72 0.63 0.78 0.64 0.75 0.64 0.75 0.68 0.72 0.68 0.58 0.76 0.73 0.64 0.67 0.71 0.68 0.67 0.75 0.70 0.75 0.68 0.68 0.68 0.68 0.74 0.70 0.69 0.71 0.66 0.61 0.69 0.82 0.71 0.78 0.65 0.77 0.78 0.74 0.72 0.30 0.95 0.69 0.84 0.74 0.68 0.70 0.69 0.68 0.64 0.76 0.81 0.72 0.62 0.65 0.76 0.75 0.73 0.80 0.75 0.83 0.00 0.76 0.74 0.97 0.96 0.98 0.66 0.96 0.98 0.96 0.97
miR$133abc 0.72 0.72 0.72 0.78 0.76 0.79 0.81 0.78 0.73 0.72 0.81 0.67 0.76 0.82 0.75 0.72 0.72 0.78 0.71 0.82 0.79 0.74 0.76 0.71 0.75 0.72 0.76 0.66 0.70 0.72 0.78 0.71 0.73 0.88 0.75 0.78 0.75 0.74 0.72 0.78 0.75 0.64 0.77 0.74 0.78 0.71 0.75 0.81 0.75 0.78 0.80 0.75 0.81 0.78 0.76 0.76 0.92 0.75 0.84 0.79 0.77 0.76 0.70 0.73 0.74 0.74 0.80 0.79 0.78 0.71 0.77 0.82 0.73 0.81 0.77 0.83 0.76 0.00 0.75 0.91 0.88 0.93 0.75 0.92 0.93 0.92 0.94
miR$124/124ab/506 0.64 0.70 0.71 0.83 0.81 0.77 0.82 0.78 0.70 0.64 0.77 0.72 0.69 0.74 0.71 0.69 0.63 0.83 0.65 0.74 0.71 0.72 0.72 0.72 0.73 0.70 0.73 0.76 0.63 0.71 0.71 0.62 0.72 0.83 0.74 0.79 0.74 0.71 0.73 0.79 0.75 0.62 0.73 0.68 0.74 0.63 0.70 0.84 0.70 0.79 0.75 0.76 0.85 0.77 0.80 0.74 0.91 0.72 0.84 0.77 0.72 0.71 0.70 0.73 0.72 0.76 0.81 0.79 0.69 0.69 0.79 0.80 0.64 0.82 0.80 0.84 0.74 0.75 0.00 0.93 0.95 0.98 0.74 0.95 0.96 0.94 0.97
miR$184 0.95 0.95 0.89 0.99 0.92 0.91 0.94 0.96 0.95 0.87 0.95 0.91 0.94 0.98 0.93 0.96 0.92 0.93 0.94 0.91 0.96 0.93 0.91 0.95 0.94 0.92 0.94 0.68 0.94 0.90 0.91 0.92 0.93 0.98 0.96 0.97 0.90 0.86 0.93 0.92 0.89 0.89 0.95 0.93 0.93 0.95 0.94 0.95 0.92 0.92 0.96 0.90 0.90 0.95 0.90 0.97 0.90 0.87 0.91 0.94 0.94 0.92 0.91 0.96 0.97 0.95 0.91 0.94 0.94 0.87 0.81 0.92 0.91 0.92 0.92 0.95 0.97 0.91 0.93 0.00 0.90 0.86 0.91 0.86 0.87 0.90 0.87
miR$210 0.94 0.95 0.92 0.98 0.88 0.90 0.94 0.93 0.95 0.91 0.95 0.95 0.95 0.95 0.93 0.95 0.93 0.90 0.94 0.91 0.95 0.93 0.95 0.94 0.93 0.92 0.96 0.83 0.94 0.92 0.91 0.93 0.93 0.98 0.95 0.94 0.91 0.84 0.90 0.91 0.91 0.92 0.95 0.91 0.93 0.95 0.92 0.96 0.91 0.87 0.95 0.90 0.91 0.92 0.94 0.95 0.85 0.95 0.93 0.93 0.94 0.93 0.89 0.95 0.94 0.96 0.92 0.92 0.95 0.88 0.78 0.95 0.93 0.94 0.89 0.93 0.96 0.88 0.95 0.90 0.00 0.96 0.91 0.97 1.00 0.98 1.00
miR$551a 0.99 0.99 0.98 1.00 0.95 0.94 0.97 0.97 0.97 0.96 0.99 0.98 0.98 0.99 0.97 0.99 0.95 0.98 0.99 0.99 0.98 0.97 1.00 0.98 0.96 0.99 0.98 1.00 0.97 0.95 0.95 1.00 0.99 1.00 0.97 1.00 0.97 0.99 0.96 0.96 0.95 0.97 1.00 0.98 0.94 0.97 0.99 1.00 1.00 0.94 1.00 0.98 0.98 1.00 0.97 0.99 0.87 0.96 1.00 0.97 0.97 0.96 0.95 1.00 0.97 0.99 0.92 0.98 0.97 0.93 0.87 0.98 0.97 0.99 0.97 0.95 0.98 0.93 0.98 0.86 0.96 0.00 0.98 1.00 1.00 1.00 1.00
miR$375 0.70 0.74 0.80 0.82 0.77 0.71 0.82 0.68 0.67 0.72 0.76 0.73 0.78 0.76 0.70 0.73 0.69 0.76 0.69 0.75 0.71 0.68 0.65 0.73 0.72 0.70 0.76 0.69 0.67 0.69 0.75 0.73 0.77 0.78 0.76 0.80 0.71 0.69 0.70 0.72 0.77 0.72 0.68 0.68 0.71 0.71 0.69 0.77 0.70 0.75 0.71 0.77 0.74 0.76 0.77 0.71 0.93 0.75 0.78 0.75 0.68 0.68 0.66 0.70 0.69 0.79 0.81 0.71 0.75 0.66 0.71 0.75 0.76 0.78 0.74 0.79 0.66 0.75 0.74 0.91 0.91 0.98 0.00 0.95 0.98 0.93 0.97
miR$451 0.96 1.00 0.92 1.00 0.93 0.94 0.97 0.96 0.96 0.91 0.97 0.95 0.98 1.00 0.95 0.96 0.94 0.97 0.97 0.97 0.97 0.96 0.92 0.98 0.94 0.93 0.98 1.00 0.95 0.92 0.92 0.94 0.96 0.99 0.96 0.98 0.90 0.91 0.95 0.98 0.95 0.94 0.97 0.94 0.94 0.96 0.97 0.97 0.93 0.94 0.96 0.98 0.93 0.97 0.90 0.97 0.88 0.95 0.95 0.97 0.95 0.93 0.92 0.96 0.97 0.98 0.94 0.95 0.96 0.91 0.88 0.98 0.95 0.99 0.91 0.95 0.96 0.92 0.95 0.86 0.97 1.00 0.95 0.00 1.00 1.00 0.84
miR$99ab/100 0.98 0.98 0.96 1.00 0.95 0.94 0.97 0.97 0.97 0.97 0.99 0.98 0.98 0.99 0.97 0.97 0.95 0.99 0.97 0.96 0.98 0.97 1.00 0.98 0.96 0.97 0.97 1.00 0.96 0.94 0.99 0.97 0.98 1.00 0.96 1.00 0.96 0.94 0.93 0.96 0.95 0.97 0.97 0.99 0.94 0.97 0.97 0.97 1.00 0.94 1.00 0.98 0.92 0.97 0.96 0.99 0.88 0.98 0.98 0.97 0.97 0.96 0.94 0.96 0.97 0.99 0.92 1.00 0.97 0.93 0.87 0.98 0.97 0.99 0.96 0.95 0.98 0.93 0.96 0.87 1.00 1.00 0.98 1.00 0.00 1.00 0.80
miR$191 0.92 0.97 0.98 0.98 0.91 0.91 0.97 0.96 0.96 0.94 0.97 0.94 0.98 0.99 0.92 0.96 0.93 0.93 0.95 0.99 0.97 0.91 0.95 0.94 0.92 0.91 0.96 0.87 0.94 0.91 0.91 0.96 0.95 1.00 0.95 0.99 0.86 0.79 0.89 0.93 0.92 0.91 0.95 0.93 0.92 0.93 0.93 1.00 0.92 0.89 0.96 0.92 0.94 0.98 0.96 0.96 0.91 0.94 0.95 0.97 0.95 0.94 0.91 0.96 0.95 0.97 0.91 0.94 0.96 0.91 0.84 0.95 0.94 0.99 0.91 0.96 0.96 0.92 0.94 0.90 0.98 1.00 0.93 1.00 1.00 0.00 0.90
miR$126$3p 0.95 0.98 0.91 0.98 0.94 0.90 0.93 0.99 0.96 0.96 0.95 0.98 0.97 0.98 0.96 0.99 0.95 0.96 0.98 0.99 0.97 0.96 0.95 0.98 0.95 0.97 0.96 0.59 0.96 0.94 0.99 0.96 0.98 0.98 0.95 0.99 0.89 0.92 0.91 0.97 0.95 0.95 0.97 0.97 0.96 0.97 0.96 1.00 0.96 0.89 0.96 0.97 0.92 0.95 0.96 0.98 0.90 0.97 0.96 0.93 0.92 0.97 0.90 0.99 0.95 0.97 0.93 0.97 0.96 0.90 0.83 0.95 0.95 0.94 0.91 0.96 0.97 0.94 0.97 0.87 1.00 1.00 0.97 0.84 0.80 0.90 0.00
Jaccard distance 
matrix
Repeat the process 
for all the miR pairs?
No
Yes
Hierarchical Clustering 
Analysis on Jaccard distance 
matrix using Ward’s linkage
miRNA clusters 
and heat map 
based on miRNA 
clustering result
m
iR−23abc/23b−3p
m
iR−218/218a
m
iR−338/338−3p
m
iR−219−5p/508/508−3p/4782−3p
m
iR−490−3p
m
iR−499−5p
m
iR−503
m
iR−25/32/92abc/363/363−3p/367
m
iR−26ab/1297/4465
m
iR−24/24ab/24−3p
m
iR−22/22−3p
m
iR−9/9ab
m
iR−15abc/16/16abc/195**
let−7/98/4458/4500
m
iR−7/7ab
m
iR−1ab/206/613
m
iR−17/17−5p/20ab/20b−5p/93/106ab**
m
iR−18ab/4735−3p
m
iR−27abc/27a−3p
m
iR−29abcd
m
iR−30abcdef/30abe−5p/384−5p
m
iR−31
m
iR−33ab/33−5p
m
iR−34ac/34bc−5p/449abc/449c−5p
m
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 and clusters by hybrid tree algorithm
Height
overlapped predicted 
target genes between 
two miRNA families in 
a cluster 
KEGG pathway enrichment analysis 
on overlapped of predicted target 
genes between two miRNA families 
(288 human pathways)
Enriched KEGG 
pathways for each 
miRNA pair 
Repeat the process 
for all the miR pairs in 
the cluster?
Numbers and p-values of 
enriched KEGG pathways 
for every miRNA pair in 
the cluster
Over-representation analysis on 
the number of occurrences of 
the pathways in the cluster
No
Yes
Pathway' number'of'
occurrences
p3value FDR3adjusted'p3value
Type'II'diabetes'mellitus 161 1.56E316 3.22E314
Butanoate'metabolism 144 6.41E315 6.60E313
Insulin'signaling'pathway 145 2.91E312 2.00E310
RegulaJon'of'acJn'cytoskeleton 120 5.74E312 2.96E310
ProlacJn'signaling'pathway 105 1.93E311 7.94E310
Bacterial'invasion'of'epithelial'cells 94 1.37E310 4.71E309
Chronic'myeloid'leukemia 94 1.98E310 5.10E309
Acute'myeloid'leukemia 96 1.89E310 5.10E309
Colorectal'cancer 95 2.53E310 5.80E309
B'cell'receptor'signaling'pathway 100 5.59E310 1.07E308
Vitamin'digesJon'and'absorpJon 109 5.70E310 1.07E308
Renal'cell'carcinoma 105 1.37E308 2.34E307
Glycine,'serine'and'threonine'metabolism 86 4.12E308 6.53E307
Non3small'cell'lung'cancer 106 1.16E307 1.70E306
Tyrosine'metabolism 82 1.98E307 2.72E306
Apoptosis 80 2.20E307 2.84E306
Vitamin'B6'metabolism 86 3.23E307 3.91E306
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Table 3.2 Summary of number of predicted target genes in each miRNA family. 
miRNA family All genes 
Metabolic 
genes only 
% of 
metabolic 
genes 
let-7/98/4458/4500 2353 191 8.12 
miR-101/101ab 3013 217 7.20 
miR-103a/107/107ab 3366 246 7.31 
miR-10abc/10a-5p 2475 179 7.23 
miR-122/122a/1352 3161 244 7.72 
miR-124/124ab/506 3482 277 7.96 
miR-125a-5p/125b-5p* 3428 278 8.11 
miR-126-3p 154 17 11.04 
miR-128/128ab 4247 341 8.03 
miR-129-5p/129ab-5p 5077 361 7.11 
miR-130ac/301ab** 2633 195 7.41 
miR-132/212/212-3p 2878 224 7.78 
miR-133abc 2216 183 8.26 
miR-135ab/135a-5p 2708 212 7.83 
miR-137/137ab 2743 195 7.11 
miR-138/138ab 2995 208 6.94 
miR-139-5p 2535 189 7.46 
miR-140/140-5p*** 2106 158 7.50 
miR-141/200a 3634 286 7.87 
miR-142-3p 1601 113 7.06 
miR-143/1721/4770 3288 245 7.45 
miR-144 3332 245 7.35 
miR-145 3247 243 7.48 
miR-146ac/146b-5p 2773 210 7.57 
miR-148ab-3p/152 2989 218 7.29 
miR-150/5127 4538 376 8.29 
miR-153 2430 176 7.24 
miR-155 2390 177 7.41 
miR-15abc/16**** 3903 305 7.81 
miR-17/17-5p# 4255 334 7.85 
miR-181abcd/4262 3867 286 7.40 
miR-182 3329 265 7.96 
miR-183 2512 192 7.64 
miR-184 731 54 7.39 
miR-187 582 48 8.25 
miR-18ab/4735-3p 2150 163 7.58 
miR-190/190ab 1800 130 7.22 
miR-191 568 39 6.87 
miR-192/215 1759 132 7.50 
miR-193/193b/193a-3p 2186 168 7.69 
miR-194 2731 193 7.07 
miR-196abc 1620 120 7.41 
miR-199ab-5p 3071 245 7.98 
miR-19ab 3025 214 7.07 
miR-1ab/206/613 3117 266 8.53 
miR-200bc/429/548a 3414 250 7.32 
miR-203 4586 380 8.29 
miR-204/204b/211 3985 285 7.15 
miR-205/205ab 3175 246 7.75 
miR-208ab/208ab-3p 1787 109 6.10 
miR-21/590-5p 1920 142 7.40 
miR-210 586 43 7.34 
miR-214/761/3619-5p 4602 370 8.04 
miR-216a 2849 210 7.37 
miR-216b/216b-5p 2696 216 8.01 
miRNA family All genes 
Metabolic 
genes only 
% of 
metabolic 
genes 
miR-217 2853 208 7.29 
miR-218/218a 2940 226 7.69 
miR-219-5p/508## 1622 122 7.52 
miR-22/22-3p 2770 215 7.76 
miR-221/222/222ab### 2275 165 7.25 
miR-223 2332 162 6.95 
miR-23abc/23b-3p 4206 322 7.66 
miR-24/24ab/24-3p 4321 328 7.59 
miR-25/32/92abc#### 2779 213 7.66 
miR-26ab/1297/4465 3419 265 7.75 
miR-27abc/27a-3p 4075 315 7.73 
miR-29abcd 2627 193 7.35 
miR-30abcdef+ 3261 237 7.27 
miR-31 2901 224 7.72 
miR-338/338-3p 3410 256 7.51 
miR-33a-3p/365++ 2099 157 7.48 
miR-33ab/33-5p 2900 215 7.41 
miR-34ac/34bc-5p+++ 3372 244 7.24 
miR-375 2267 182 8.03 
miR-383 1978 160 8.09 
miR-425/425-5p/489 2550 217 8.51 
miR-451 397 36 9.07 
miR-455-5p 2077 159 7.66 
miR-490-3p 2539 177 6.97 
miR-499-5p 2413 167 6.92 
miR-503 1905 155 8.14 
miR-551a 323 23 7.12 
miR-7/7ab 3576 282 7.89 
miR-9/9ab 3347 268 8.01 
miR-93/93a/105++++ 3668 286 7.80 
miR-96/507/1271 3079 231 7.50 
miR-99ab/100 258 25 9.69 
Full name of miRNA families marked with symbols are:  
* miR-125a-5p/125b-5p/351/670/4319 
** miR-130ac/301ab/301b/301b-3p/454/721/4295/3666 
*** miR-140/140-5p/876-3p/1244 
**** miR-15abc/16/16abc/195/322/424/497/1907 
# miR-17/17-5p/20ab/20b-5p/93/106ab/427/518a-3p/519d 
## miR-219-5p/508/508-3p/4782-3p 
### miR-221/222/222ab/1928 
#### miR-25/32/92abc/363/363-3p/367 
+ miR-30abcdef/30abe-5p/384-5p 
++ miR-33a-3p/365/365-3p 
+++ miR-34ac/34bc-5p/449abc/449c-5p 
++++ miR-93/93a/105/106a/291a-3p/294/295/302abcde
 
On average, the number of predicted target genes of a miRNA family is around 2700 
genes, the number of predicted target genes that are also metabolic genes is around 
200 genes, and the percentage of metabolic genes of the predicted targets of a miRNA 
family is 7.64%.   
  
Chapter 3 
 
92 
Table 3.3 Basic statistics of each miRNA cluster. 
Cluster 
number  
Number of 
miRNA families 
in the cluster 
Number of predicted target 
genes in the cluster 
(% of all predicted targets) 
Number of predicted metabolic 
genes in the cluster 
(% of present metabolic target) 
Average Jaccard 
distance in the 
cluster  
Cluster 1 4 1,724 (10.09%) 125 (9.20%) 0.92 
Cluster 2 5 4,213 (24.65%) 317 (23.34%) 0.85 
Cluster 3 22 12,716 (74.41%) 982 (72.31%) 0.78 
Cluster 4 14 12,510 (73.21%) 962 (70.84%) 0.67 
Cluster 5 16 12,707 (74.36%) 981 (72.24%) 0.73 
Cluster 6 26 15,396 (90.10%) 1205 (88.73%) 0.69 
These are number of miRNA families, number of all the predicted target genes present, number of 
predicted metabolic genes, and average Jaccard distance between the miRNA family pair in each 
cluster. The numbers in parentheses are percentages of genes in the cluster compared to all predicted 
targets and percentages of metabolic target genes compared to present metabolic targets.  
3.3.2 Hierarchical clustering of miRNA families based on predicted metabolic target 
genes 
After the predicted target genes of all miRNA families were retrieved, a weighted 
Jaccard distance matrix of all miRNA family pairs was then calculated. The squared 
Jaccard distance matrix was then subjected to hierarchical clustering by using Ward’s 
minimal variance criterion or Ward’s linkage, in order to group the miRNA family 
that have minimal distance between them. The clustering tree was further processed 
by a Dynamic Hybrid tree cut algorithm to identify the clusters from the hierarchical 
clustering results. The resulting clusters are shown in Figure 3.2. A heatmap that 
illustrates the distances between all miRNA family pairs is shown in Figure 3.3, with 
the clusters defined by the Dynamic Hybrid cut tree algorithm as multicolour-shading 
on top of the heatmap. Table 3.3 summaries the number of miRNA families in each 
cluster. Appendix A1 Table A1.1 – A1.6 list the miRNA familes in clusters 1 
through 6. From the Figure 3.3, miRNA families in clusters 1 and 2 have very distinct 
sets of predicted target genes compared to other miRNA families, while miRNA 
families in clusters 4 and 6 have high proportions of similar predicted target genes 
within the clusters. According to Table 3.3, miRNA families in clusters 3, 4, 5, and 6 
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have good coverage of metabolic genes, which are around 76% of all metabolic genes 
present in the database. Despite the high coverage of predicted target genes, some of 
the genes might not be taking into account in the calculation of the hierarchical 
clustering because some genes have PCT score of 0, which means that the number of 
binding sites in the 3’UTR of the genes do not exceed the background number of 
overall miRNA binding sites of that particular 3’UTR (Friedman et al. 2009). Clusters 
1 and 2 cover less than 25% of the metabolic genes present in the database.  
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Figure 3.2 Hierarchical clustering of miRNA families based on predicted 
metabolic target genes results from Jaccard distance matrix using Ward's 
linkage.  The six clusters are identified using the Dynamic Hybrid tree cut algorithm.  
** Full miRNA family names are as follow: miR-130ac/301ab/301b/301b-3p/454/721/4295/3666, miR-15abc/16/16abc/195/322/424/497/1907, 
miR-17/17-5p/20ab/20b-5p/93/106ab/427/518a-3p/519d, and miR-93/93a/105/106a/291a-3p/294/295/302abcde
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Figure 3.3 The heatmap illustrating squared Jaccard distance between all miRNA family pairs. 
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Figure 3.3 Dark red box signifies low distance between two miRNA families, i.e. 
high proportion of overlapped set of predicted target genes. Blue box signifies high 
distance between two miRNAs families, i.e. low proportion of overlapped set of 
predicted target genes. miRNA families in clusters 1 and 2 have very distinct sets of 
predicted target genes compared to other miRNA families in the database. In contrast, 
miRNA families in clusters 4 and 6 have higher proportions of overlapped predicted 
target genes within their clusters according to the average Jaccard distance of these 
two clusters.  
3.3.3 KEGG pathway enrichment analysis on the overlapped predicted target genes in 
each cluster 
After the clusters of miRNA families have been defined by hierarchical clustering and 
Dynamic Hybrid tree cut algorithm, the list of overlapped predicted target genes of 
each miRNA family pair was subjected to KEGG pathway enrichment analysis using 
over-representation analysis (ORA). The predicted gene list was tested against all 288 
KEGG human pathways, resulting in a list of 288 p-values for each overlapped 
predicted target genes list between each miRNA family pair. The ORA uses the 
hypergeometric distribution to calculate probability of obtaining over-represented 
number of elements. The hypergeometric p-value is calculated using the following 
equation:  
! ! ≥ ! = !1− !! !!!!!!!!!!!!  (4) 
where p(i ≥ x) is the cumulative probability of having the number of predicted target 
genes equal or more than x genes , !! = ! !!!! !!! ! is a binomial coefficient, m is the 
number of genes in a testing pathway, K is the number of predicted target genes 
between the two miRNA families, x is the number of overlapped between sets m and 
K, and N is the number of all the genes presented in the KEGG database. Figure 3.4 
summarises the formulation of ORA on KEGG pathways. The matrix of p-value lists 
of all miRNA family pairs is stored in an R object, which can be found in the 
Supplementary file S1. The p-value list on each miRNA family pairs was subjected to 
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multiple hypothesis testing using the Benjamini-Hochberg false discovery rate (FDR) 
procedure. The FDR-adjusted p-values of the pathways less then 0.05 cutoff were 
retained for final analysis.  
 
Figure 3.4 Venn diagram illustrating KEGG pathway enrichment formulation. 
For the final analysis, the pathways that passed the FDR-adjusted p-values of 0.05 
were counted in each cluster separately. The list of pathways that passed the FDR-
adjusted p-value cutoff of 0.05 of each cluster with the number of occurrences was 
produced. The numbers of occurrences of over-represented pathways in were then 
subjected to another ORA. Again, the hypergeometric p-value of each over-
represented pathway can be calculated with the equation 4:  
! ! ≥ ! = !1− !! !!!!!!!!!!!!  (4) 
where p(i ≥ x) is the cumulative probability of having the number of occurrences of a 
pathway equal or more than x times , m is the number of occurrences of the pathway 
in all of the miRNA family pairs, K is the number of occurrences of all the pathways 
in the cluster of interest, x is the number of overlapped between sets m and K, and N is 
the number of all occurrences of all the over-represented pathways in all of miRNA 
family pairs. Figure 3.5 summarises the formulation of ORA on over-represented 
KEGG pathways in each cluster. 
m
K
N
Number of genes 
in a testing pathway
Number of predicted target genes
between the two miRNA families
x
Number of overlapped genes 
between sets m and K
Number of all genes 
present in KEGG database 
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Figure 3.5 Venn diagram illustrating ORA formulation of over-represented 
KEGG pathway in each cluster. 
After the ORA of pathways of all the clusters, the hypergeometric p-values of those 
pathways in each cluster were again subjected to the multiple hypothesis testing using 
Benjamini-Hochberg FDR procedure. The full table results of the ORA of all clusters 
are shown in Appendix A1 table A1.7-A1.12. Using the FDR-adjusted p-value cutoff 
of 0.05, clusters 1, 2, and 5 did not yield any over-represented pathways that occurred 
more than expected by chance. The ORA of over-represented pathways in clusters 3, 
4, and 6 yielded several pathways that are occurred more than expected by chance, 
which are shown in Table 3.4, 3.5, and 3.6, respectively.  
Table 3.4 Over-represented pathways within miRNA family cluster 3. 
KEGG Pathway Number of occurrences p-value 
FDR-adjusted 
p-value 
Purine metabolism 199 2.48E-12 4.76E-10 
Phosphatidylinositol signaling system 141 0.0015 0.0244 
Morphine addiction 132 6.60E-06 4.22E-04 
Salivary secretion 127 0.0006 0.0112 
Pancreatic secretion 120 0.0002 0.0058 
cAMP signaling pathway 120 0.0006 0.0112 
Glycosphingolipid biosynthesis - lacto and neolacto series 104 9.36E-07 8.99E-05 
GABAergic synapse 104 0.0004 0.0103 
Valine, leucine and isoleucine degradation 102 0.0019 0.0257 
Glycosphingolipid biosynthesis - globo series 92 0.0002 0.0056 
Pantothenate and CoA biosynthesis 70 0.0001 0.0049 
Lysine degradation 68 0.0007 0.0124 
Valine, leucine and isoleucine biosynthesis 61 3.68E-05 0.0018 
Retinol metabolism 37 0.0034 0.043 
alpha-Linolenic acid metabolism 31 0.0018 0.0257 
m
K
N
Number of occurrences 
of a specific pathway
Number of occurrences of 
all pathways in the cluster of interest
x
Number of overlapped occurrences 
between sets m and K
Number of all occurrences 
of all over-represented pathways 
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According to Table 3.4, over-represented pathways in cluster 3 are involved in 
essential metabolite biosynthesis and metabolism within the cells. The metabolites 
that might be associated with the miRNA families in cluster 3 are purine (for DNA 
synthesis), glycans, amino acids, a fatty acid and vitamin A precursor retinol. This 
suggests that miRNA families in cluster 3 might have important roles in the regulation 
of these metabolites production/degradation. 
Table 3.5 Over-represented pathways within miRNA family cluster 4. 
KEGG Pathway Number of occurrences p-value 
FDR-adjusted 
p-value 
Peroxisome 58 3.02E-05 0.0007 
Vibrio cholerae infection 57 1.50E-07 1.02E-05 
Valine, leucine and isoleucine biosynthesis 51 0.0031 0.0248 
Glycolysis / Gluconeogenesis# 51 0.0052 0.0319 
Pyruvate metabolism# 48 1.55E-07 1.02E-05 
Protein digestion and absorption 48 6.53E-05 0.0011 
Synaptic vesicle cycle 47 1.59E-05 0.0004 
Glycosylphosphatidylinositol(GPI)-anchor biosynthesis 46 6.31E-05 0.0011 
Endometrial cancer* 44 3.21E-06 0.0001 
Proximal tubule bicarbonate reclamation 42 0.0042 0.0299 
Oxidative phosphorylation# 42 0.0049 0.031 
mTOR signaling pathway# 40 4.95E-05 0.0011 
Glioma* 39 0.0014 0.013 
Melanoma* 37 0.0002 0.003 
Collecting duct acid secretion 36 5.45E-05 0.0011 
Starch and sucrose metabolism 36 0.001 0.0112 
Small cell lung cancer* 34 0.001 0.0112 
Fat digestion and absorption 34 0.0045 0.0301 
Adipocytokine signaling pathway 33 0.002 0.0178 
FoxO signaling pathway# 30 0.0061 0.0366 
MicroRNAs in cancer* 28 2.91E-11 5.74E-09 
Vitamin digestion and absorption 28 0.0013 0.013 
Citrate cycle (TCA cycle)# 25 3.41E-07 1.68E-05 
Tyrosine metabolism 25 0.0003 0.0038 
Phagosome 25 0.0041 0.0296 
Histidine metabolism 22 0.009 0.0491 
Chemical carcinogenesis* 20 0.0014 0.013 
Serotonergic synapse 20 0.0067 0.0389 
Focal adhesion 15 0.0003 0.0043 
Glutathione metabolism 14 0.0006 0.007 
Pathways in cancer* 13 0.0023 0.0194 
Phenylalanine metabolism 12 0.007 0.0391 
Primary bile acid biosynthesis 11 0.0046 0.0301 
Protein export 10 5.14E-06 0.0002 
PI3K-Akt signaling pathway# 9 0.003 0.0248 
Other glycan degradation 5 0.0035 0.0266 
Asterisks (*) marked the cancer-specific pathways. Hashes (#) marked cancer-related pathways. 
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Table 3.6 Over-represented pathways within miRNA family cluster 6. 
KEGG Pathway Number of occurrences p-value 
FDR-adjusted 
p-value 
Carbohydrate digestion and absorption 222 0.0024 0.0099 
Sphingolipid metabolism 220 8.43E-05 0.0005 
Lysine degradation 210 0.0055 0.0191 
AMPK signaling pathway 205 1.02E-06 1.16E-05 
Mineral absorption 203 0.0013 0.0058 
Chemokine signaling pathway 185 0.0064 0.0215 
Aldosterone-regulated sodium reabsorption 168 8.64E-06 6.59E-05 
Type II diabetes mellitus 161 1.56E-16 3.22E-14 
HIF-1 signaling pathway# 148 9.99E-05 0.0005 
HTLV-I infection 146 0.0011 0.0052 
Insulin signaling pathway 145 2.91E-12 2.00E-10 
Glycosaminoglycan biosynthesis - keratan sulfate 145 1.28E-06 1.32E-05 
Butanoate metabolism 144 6.41E-15 6.60E-13 
beta-Alanine metabolism 140 7.92E-06 6.27E-05 
Tryptophan metabolism 137 4.03E-05 0.0002 
Drug metabolism - other enzymes 134 0.0096 0.0309 
Regulation of actin cytoskeleton 120 5.74E-12 2.96E-10 
Fructose and mannose metabolism 119 0.0015 0.0063 
VEGF signaling pathway# 116 0.0013 0.0055 
Glioma* 116 0.0129 0.0385 
Fc gamma R-mediated phagocytosis 115 0.0112 0.0343 
Endometrial cancer* 110 0.0022 0.0092 
Vitamin digestion and absorption 109 5.70E-10 1.07E-08 
Fc epsilon RI signaling pathway 107 1.53E-06 1.43E-05 
Non-alcoholic fatty liver disease (NAFLD) 107 8.69E-05 0.0005 
mTOR signaling pathway# 107 0.0034 0.0133 
Non-small cell lung cancer* 106 1.16E-07 1.70E-06 
Prolactin signaling pathway 105 1.93E-11 7.94E-10 
Renal cell carcinoma* 105 1.37E-08 2.34E-07 
Pancreatic cancer* 105 1.13E-06 1.23E-05 
Propanoate metabolism 105 2.48E-05 0.0002 
Melanoma* 103 0.0038 0.0141 
B cell receptor signaling pathway 100 5.59E-10 1.07E-08 
Pentose phosphate pathway 100 2.91E-05 0.0002 
Acute myeloid leukemia* 96 1.89E-10 5.10E-09 
Colorectal cancer* 95 2.53E-10 5.80E-09 
Bacterial invasion of epithelial cells 94 1.37E-10 4.71E-09 
Chronic myeloid leukemia* 94 1.98E-10 5.10E-09 
Glycine, serine and threonine metabolism 86 4.12E-08 6.53E-07 
Vitamin B6 metabolism 86 3.23E-07 3.91E-06 
ErbB signaling pathway# 84 4.18E-05 0.0002 
Prostate cancer* 84 0.0119 0.0361 
Lysine biosynthesis 83 4.44E-06 3.81E-05 
Tyrosine metabolism 82 1.98E-07 2.72E-06 
Epstein-Barr virus infection 82 3.96E-06 3.54E-05 
Lysosome 81 0.0028 0.011 
Apoptosis# 80 2.20E-07 2.84E-06 
Fatty acid biosynthesis 75 1.84E-05 0.0001 
Histidine metabolism 73 0.0012 0.0055 
Galactose metabolism 70 0.0096 0.0309 
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KEGG Pathway Number of occurrences p-value 
FDR-adjusted 
p-value 
Ras signaling pathway# 66 0.0005 0.0024 
ABC transporters 58 0.0075 0.0251 
T cell receptor signaling pathway 58 0.0102 0.0322 
TNF signaling pathway# 57 0.0049 0.0174 
Caffeine metabolism 56 4.63E-06 3.82E-05 
Toll-like receptor signaling pathway 55 0.0007 0.0031 
Phenylalanine, tyrosine and tryptophan biosynthesis 47 5.21E-05 0.0003 
Butirosin and neomycin biosynthesis 44 0.0035 0.0134 
Phenylalanine metabolism 36 0.0011 0.0052 
Ascorbate and aldarate metabolism 33 0.0037 0.014 
Focal adhesion# 32 0.0161 0.0473 
Proteoglycans in cancer* 28 1.44E-06 1.42E-05 
Jak-STAT signaling pathway# 27 0.0006 0.0028 
Influenza A 20 0.0003 0.0016 
Viral carcinogenesis* 19 4.10E-05 0.0002 
Terpenoid backbone biosynthesis 17 3.50E-05 0.0002 
Folate biosynthesis 14 0.0108 0.0338 
Phototransduction 11 0.0046 0.0168 
Nicotine addiction 8 3.22E-05 0.0002 
Ubiquinone and other terpenoid-quinone 
biosynthesis 7 0.0063 0.0215 
Asterisks (*) marked the cancer-specific pathways. Hashes (#) marked cancer-related pathways. 
Table 3.5 and Table 3.6 showed that over-represented pathways in miRNA family 
clusters 4 and 6 have several pathways that are cancer-specific, such as glioma, 
melanoma, lung cancer etc., suggesting that the miRNA families in these two clusters 
are having important roles in regulating the genes involving in these cancers. Over-
represented pathways in clusters 4 and 6 also have several pathways that are cancer-
related, i.e. pathways that are deregulated in cancer cells, such as mTOR signaling 
pathway, PI3K-Akt signaling pathway, Citrate cycle (TCA cycle), VEGF signaling 
pathway etc. Figure 3.6 shows over-represented pathways from clusters 4 and 6 that 
are cancer-specific and cancer-related based on KEGG pathway diagram.  
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Figure 3.6 Over-represented pathways from clusters 4 and 6 that are cancer-specific and cancer-related based on KEGG pathways in 
cancer diagram (figure legend continues on the next page). 
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Figure 3.6 Over-represented pathway names from clusters 4 and 6 are in yellow and green boxes, 
respectively. Pathways that are presented in both clusters are in boxes with green outer-layer and 
yellow inner-layer. Ras and HIF-1α are also present in the pathways in cancer but do not clearly 
labeled as separate pathways. Ras is downstream of ErbB signaling pathway, whereas HIF-1α is 
upstream of VEGF signaling pathway. Note that microRNAs in cancer, viral carcinogenesis, TNF 
signaling pathway, and chemical carcinogenesis do not present in the figure. The figure was retrieved 
from www.kegg.jp on 24 August 2014.  
3.3.4 Experimentally validated miRNAs in the three cancer types identified in each 
miRNA cluster   
Experimentally validated miRNAs associated with the three cancer types highlighted 
in the over-represented pathways were identified and marked in the tables with 
miRNAs in clusters 4 and 6. Three cancer types were identified to be regulated by 
both miRNA in clusters 4 and 6, i.e. lung cancer (small-cell in cluster 4 and non 
small-cell in cluster 6), melanoma, and glioma. At least five review articles with the 
sets of miRNAs that are involved in these cancer types were examined to identify 
which miRNAs in the clusters 4 and 6 are implicated in these cancer types. Lists of 
miRNA families in clusters 4 and 6 that are implicated in the three types of cancer are 
shown in Table 3.7 and Table 3.8. These results show that the approach in this study 
can correctly identify groups of miRNAs that are implicated in these diseases. 
However, there are miRNAs that are involved in these three cancer types but not 
presented in these two clusters, which are let-7 family, miR-10a/10b, miR-34a, miR-
21, miR-210 and miR-221/222. It is possible that these miRNAs regulate different 
types of target genes compared to the miRNAs in clusters 4 and 6.  
3.4 Discussion 
The analysis presented here can help narrow down the scope of the miRNA network 
that work together as the same units of transcriptional regulation. It is widely known 
that multiple miRNAs, especially miRNAs in the same cluster, can target mRNAs 
that are functionally related [see review by Peter (2010) and Hausser & Zavolan 
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(2014)], therefore this analysis built up from the sets of common predicted target 
genes between miRNA family pairs, and then used that information to classify 
miRNA families into clusters based on the distances between them.  
Table 3.7 miRNA families of cluster 4 that are found in three cancer types. 
miRNA family 
in cluster 4 
Lung cancer Melanoma Glioma 
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miR-23abc/23b-3p x   x x       x x   x 
miR-25/32/92abc/363/363-3p/367         x x  x  x x x 
miR-26ab/1297/4465 x  x   x   x       x 
miR-30abcdef/30abe-5p/384-5p     x x  x  x x   x x x 
miR-101/101ab  x x x    x    x  x  x 
miR-132/212/212-3p            x    x 
miR-137/137ab  x    x x x x x x x x    
miR-141/200a  x  x  x  x  x x      
miR-144                 
miR-181abcd/4262   x         x  x  x 
miR-194  x               
miR-200bc/429/548a  x x  x x x x  x x     x 
miR-203      x x x x x       
miR-217                 
 
Some of the findings in this chapter also support the results of the previous chapter on 
miR-22. Two pathways, which are glycine, serine and threonine metabolism and fatty 
acid biosynthesis pathways, were identified by KEGG pathway enrichment analysis 
(Table 3.6). These two pathways have two metabolic genes, i.e. MTHFD2 and 
ELVOL6, which are under the regulation of miR-22, a member in cluster 6. Another 
miRNA that targets MTHFD2 is miR-9 (Selcuklu et al. 2012), which was also 
classified to be a member in miRNA cluster 6.  
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Table 3.8 miRNA families of cluster 6 that are found in three cancer types. 
miRNA families  
in cluster 6 
Lung cancer Melanoma Glioma 
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miR-1ab/206/613 x    x            
miR-7/7ab   x      x   x    x 
miR-9/9ab   x   x x  x x x x x  x x 
miR-15abc/16/16abc/195* x x    x x x x  x x  x  x 
miR-17/17-5p/20ab/20b-5p** x   x x    x   x x x x x 
miR-22/22-3p         x       x 
miR-24/24ab/24-3p                 
miR-27abc/27a-3p              x   
miR-29abcd      x x x  x x x    x 
miR-93/93a/105/106a/291a-3p# x   x x    x   x x x x x 
miR-124/124ab/506        x    x x  x x 
miR-125a-5p/125b-
5p/351/670/4319    x x   x x   x x x x x 
miR-128/128ab     x       x x  x x 
miR-129-5p/129ab-5p  x              x 
miR-133abc     x       x     
miR-135ab/135a-5p            x  x x x 
miR-138/138ab            x    x 
miR-143/1721/4770     x        x    
miR-145      x x    x x x x   
miR-150/5127  x   x    x        
miR-199ab-5p      x   x x x   x x  
miR-204/204b/211      x x x x x x  x x  x 
miR-214/761/3619-5p      x  x x x x     x 
miR-218/218a            x x x  x 
miR-338/338-3p                x 
miR-503                 
Full family names  
* miR-15abc/16/16abc/195/322/424/497/1907 
** miR-17/17-5p/20ab/20b-5p/93/106ab/427/518a-3p/519d 
# miR-93/93a/105/106a/291a-3p/294/295/302abcde/372/373/428/519a/520be/520acd-3p/1378/1420ac 
 
Cluster 6 also has very high within-cluster similarity, and also has the highest number 
of predicted metabolic target genes of miRNAs (Table 3.3 and Table 3.6). This 
cluster also contains two polycistronic miRNA clusters, which are miR-24-27a cluster 
and miR-17-92 cluster. It is widely known that miR-17-92 cluster has the same seed 
sequence. Hence, the predicted target gene pool of this miRNA cluster would be very 
similar. On the other hand, miR-24 and miR-27 families have very different seed 
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sequences (miR-24 family: GGCUCAG, miR-27 family: UCACAGU), and it is 
interesting that these two miRNA families would have similar pool of predicted 
metabolic target genes and be clustered together. These two polycistronic miRNA 
clusters were also known to regulate several metabolic pathways (Dumortier et al. 
2013).  
One drawback of this analysis is that the list of metabolic genes used in this study 
might not be a complete one. Therefore, pathways that contain the missing metabolic 
genes from the list would not be identified by this approach. This problem will be 
resolved once more data, i.e. metabolic genes list, are discovered. Another drawback 
is that the analysis did not have any experimental validation to back up the findings. 
A simple correlation calculation might be useful to a certain extent, but might be 
misleading as well since not all the target genes of miRNAs have high anti-correlation 
between them. As for the cancer-specific pathways such as melanoma or glioma, etc., 
miRNAs and mRNA profiles from large-scale studies can be a good starting point for 
validating the findings. Resources such as The Cancer Genome Atlas (TCGA) 
database, which has miRNA and mRNA profiling data on these cancer, or Cancer 
Cell Line Encyclopedia (CCLE) database, which has mRNA expression where some 
of those mRNAs can be used as miRNA surrogate measurement, can be used to 
screen for the possibilities of associations.  
The conditions under which the hypergeometric test was applied in the last two steps 
is violating the assumption of variable independence and might exaggerate the 
hypergeometric p-values. Although a p-value adjustment procedure was carried out, 
the effect of p-value over- or underestimation might still persist. One remedy for this 
is to set more stringent p-value cutoff, such as from 0.05 to 0.01 or to 0.001, or 
implanting more stringent multiple hypothesis testing procedure, such as the 
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Bonferroni adjustment. Another way to address the p-value inaccuracy is to perform 
permutation test, by reshuffle the names of the target genes in each miRNA family 
and then repeat the analysis until the desired statistically significant level is reached.  
There is another study on miRNA clustering, called miRConnect, which uses sums of 
Pearson’s correlation coefficients between miRNA and mRNA expression profiles as 
the criteria for miRNA clustering (Hua et al. 2011). Although the clusters in 
miRConnect study are correctly identified (according to the next chapter of this 
thesis), the way they classified the miRNA clusters are biased by using the correlation 
coefficients between the miRNA and mRNA, as it was shown in the previous chapter 
that the correlation between miRNA and its target genes might not always be high 
(i.e. miR-22 and ACLY). Therefore, some of the members in their clusters will be 
wrongly classified into the clusters (as will be shown later in the next chapter). Also, 
some of the miRNAs in the miRConnect study can be grouped by their seed 
sequences, which made some of the miRNAs in the same clusters redundant in terms 
of the target genes. The approach in this study does not suffer from the problem 
previously mentioned because the miRNAs were already grouped in terms of their 
seed sequences. The use of probability of conserved targeting (or PCT score) for the 
calculation of the clusters in this study is less biased than correlation coefficients 
between miRNA and mRNA, which sometimes proved to be misleading. However, 
the PCT score in itself does not include all the information that are necessary for the 
miRNA-mRNA regulation, such as minimum free energy of secondary structure of 
miRNA-mRNA duplex (Rehmsmeier et al. 2004; Kertesz et al. 2007), or a 
combination between the seed sequence complementarity and free energy of the 
miRNA-mRNA duplex (Krek et al. 2005). Integration of these metrics into the 
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Jaccard distance calculation might improve the accuracy of the miRNA family cluster 
classification.  
One important limitation was that this study used only highly conserved predicted 
target genes in the TargetScan database. The latest TargetScan database disregards 
three features that might be important in targeting of genes by miRNAs, which are 
site accessibility, minimum free energy of miRNA:mRNA duplex, and target site 
abundance. By including these features into the algorithm, predicted target genes in 
the TargetScan database might be more sensitive and yield more true positive 
predicted target genes (while sacrificing the precision of the prediction in the 
process). Increasing sensitivity of the database used can be achieved through union 
between different databases, which would in a way take into account the features that 
different algorithms did not use in the individual algorithms. However, a review of 
several miRNA prediction software found that the benefit of union or intersect the 
databases for sensitivity did not yield good return of the precision (Alexiou et al. 
2009). Therefore, a novel approach that intrinsically combines probability of 
conserved targeting of TargetScan database and other features from other miRNA 
prediction algorithms could be immensely beneficial to this analysis in the future.   
One improvement that can be implemented in this study is to include more pathways 
or gene sets information from different sources or databases in order to expand the 
pathways or gene sets that might be over-represented by the metabolic gene sets used 
in this study. Another possible tweak is the list of genes used as the constraints for 
clustering. This study used metabolic gene list as the constraints for the clustering 
process. If different sets of genes are applied as the constraints, along with pathways 
that are linked with the gene list, for example list of genes and pathways involved in 
cholesterol metabolism, this approach could be used to identify groups of miRNAs 
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that linked to the cholesterol metabolism and the diseases linked to these processes. 
The scientific community is also constantly updating validated target genes of 
miRNAs. Therefore, manually curating the validated metabolic target genes in the 
analysis might add more accuracy of cluster identification and the enriched pathway 
in each cluster.   
 
  
 
 
 
 
 
 
Chapter 4 : Over-Representation of Correlation 
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4.1 Introduction 
High-throughput, high-dimensional biological data analysis is becoming a routine 
task for most biological and biomedical researchers. Several layers of measurements, 
comprising gene (either non-coding or protein-coding) expression, protein profiles, 
and metabolite concentrations are overwhelmingly generated in massive quantity, 
sometimes simultaneously. The rationale behind the taking of these measurements 
together is to better understanding complex diseases, such as cancer or metabolic 
disorders like diabetes, where these biomolecules are often altered in concert. In the 
past, two conventional analyses, correlation analysis and pathway analysis, were 
considered the standard steps in analysing coordinated responses in the biomolecular 
profiles of those complex diseases. Correlation analysis (and its multivariate 
extensions such as principal component analysis, or PCA, and canonical correlation 
analysis) focuses on the estimation of quantitative explanatory power of one variable, 
which could be any gene, miRNA, or protein measurement, over another variable to 
infer an association between those two variables quantitatively. By contrast, pathway 
analysis has the objective of exploiting prior knowledge on the interactions or related 
sets of biomolecules previously identified and then test specific hypotheses whether 
or not the relationship between a particular set of biomolecules (either a specific 
pathway or a gene set) and a given experimental condition exists. Conventional 
pathway analysis uses the over-representation analysis (ORA) to determine that a 
relationship between the sets in a specific group of variables exists. The first 
implementation of ORA in biological data analysis was by Tavazoie et al. (1999), 
where transcriptional regulatory sub-networks in yeast were identified using data 
from gene expression microarray profiling. Since the first biological implementation, 
ORA has been used to perform pathway analysis based on pathway information such 
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as those from Kyoto Encyclopedia of Genes and Genomes (KEGG) (Kanehisa & 
Goto 2000) or from consolidated pathway database (Cavill et al. 2011), or to infer 
biological categories (molecular functions, cellular compartments, etc.) that were 
deemed important from two different experimental conditions in Gene Ontology (GO) 
(Zeeberg et al. 2003; Beissbarth & Speed 2004).   
One problem with pathway analysis using the ORA is that after the variables have 
been determined as differentially expressed between different conditions the 
measurements of those variables will be disregarded. A novel method introduced here 
called Over-Representation of Correlation Analysis (ORCA) provides a new way to 
test for a high prevalence of informative associations between two sets of variables, 
whether the variables are mRNAs, miRNAs, proteins, or metabolites. The set of 
variables could be pathways, gene sets, or any groupings that are deemed biologically 
important. This study also provides a means to determine the threshold of correlation 
coefficient for each data set based on Shannon’s information entropy principle. The 
work in this chapter has recently been published (Pomyen et al. 2014) and the 
manuscript is included as an appendix to this thesis (Appendix A2).  
4.2 Materials and methods 
4.2.1 Over-representation of Correlation analysis method outline 
ORCA combines two conventional statistical analyses together, which are correlation 
analysis and ORA. For this method development, the correlation metric used was 
Spearman’s rank correlation. The reason for using Spearman’s rank correlation is to 
avoid the assumption of a normal distribution in the data set. The ORA is performed 
after the correlation coefficient calculation by using the hypergeometric test to 
calculate the probability of getting the number of correlation coefficients that are 
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higher than expected by chance in a certain group. There are two prerequisites for the 
data sets in order to apply ORCA: 1) the variables must be divided into sets according 
to relevant criteria, such as KEGG pathways or GO annotations where the variables 
are mRNA genes, or groups resulting from unsupervised classification techniques 
such as hierarchical clustering; and 2) the number of data points in each variable must 
be adequate in order to accurately calculate the correlation coefficient. The 
schematics of the method is shown in Figure 4.1. The method starts by calculating 
the correlation matrix of all n variables, resulting in an n x n matrix of correlation 
coefficients between every possible pair of variables. The variables in the correlation 
matrix are then sorted into groups or sets according to relevant criteria, such as 
pathway information or GO annotation. There are two types of correlation 
coefficients in the correlation matrix: the first type is the within-group correlation, 
which is the correlation coefficients between variables within the same group or set; 
and the second type is the between-group correlation, which is the correlation 
coefficients between variables from different groups. The correlation coefficients are 
labels as above or below a certain correlation coefficient threshold, which can be 
empirically chosen or calculated by the threshold selection method, which will be 
explained in detail in section 4.2.2. Table 4.1 illustrates four categories of the 
correlation coefficients in the ORCA. Finally, to determine if the association between 
groups is statistically significant, ORCA is applied. The p-value of obtaining a certain 
number of correlation coefficients that passes the threshold and also presents in the 
between-group correlations can be calculated by a cumulative hypergeometric 
distribution: 
! ! > ! = 1− ! !! !! !!!!!!!!!!  (1) 
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where !! = ! !!!! !!! ! is the binomial coefficient, M is the number of between-group 
correlation coefficients, N is the number of all correlation coefficients in the 
correlation matrix (excluding all the within-group correlation), X is the number of all 
between-group correlation coefficients that pass the threshold, and k is the number of 
correlation coefficients in the between-group pair of interest that pass the threshold. 
The within-group correlation is excluded because the correlation coefficients between 
the variables in the same group are usually very high compared to the between-group 
correlation. This high correlation will lead to an underestimation of the p-values of 
the between-group correlations. The p-values of the within-group correlation, 
therefore, are separately calculated using the same equation, with the inclusion of the 
within-group correlations in the variables N, M, and X.  
4.2.2 Threshold selection 
A correlation threshold selection method was developed in order to objectively select 
a correlation coefficient threshold that provides the highest amount of information 
from a given data set. This threshold selection method is based on Shannon’s entropy 
(Shannon 1948), where the correlation coefficient threshold that provides the most 
contrast in a data set yields the highest amount of information. In order to calculate an 
entropy-based score for correlation coefficient threshold, ORCA is performed on 
every group-pairs in a given data set on every correlation threshold from 0.01 to 1.00 
with an increment of 0.01. Therefore, there are 100 p-value lists for a given data set. 
Each p-value list is then subjected to the following equation:  
! ! = !− ! !(!!)!!!! ln!(!!) (2) 
 where H(X) is a Shannon’s entropy-like score, p(xi) is a p-value of a within- or 
between group association between a group-pair i calculated by hypergeometric 
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distribution, J is the number of all within- and between-group pairs (where the 
number of groups of the data set is n then J = n(n-1)/2 + n), and ln is the natural 
logarithm (i.e. loge). The correlation coefficient threshold that yields the highest 
Shannon’s entropy-like score is used as the threshold for ORCA.  
 
Figure 4.1 Concept of Over-Representation of Correlation Analysis. A lower half 
of an example correlation matrix is shown here with two types of correlation 
coefficients, labeled with different colours in the figure. The white, turquoise and pink 
boxes represent correlation coefficients between variables in the data set. The 
boundaries between groups are bold black lines. The Venn diagram labeled with 
variable names is corresponding to the equation 1. The colours in the Venn diagram 
are also corresponding to the types of correlation coefficients in the example 
correlation matrix. The variables are further explained in the Table 4.1.
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Table 4.1 Contingency table with variables correspond to the equation 1 and 
figure 4.1. 
C
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Correlation Coefficients  
in sets 1 & 7 
 Yes No Total 
Yes k X – k  X 
No M – k  N – (M + X – k)  N – k  
Total M N – M  N 
The variables in rows represent the number of correlation coefficients that are pass/not pass a certain 
correlation coefficient threshold. The variables in columns represent the number of correlation 
coefficients that are in/out of the set-pair 1 & 7. According to equation 1, M is the number of 
correlation coefficients in the between set-pair 1 & 7, X is the number of all correlation coefficients 
between every set-pairs that pass the certain threshold, k is the number of correlation coefficients in the 
between set-pair 1 & 7 that also pass the certain threshold, and N is the number of all correlation 
coefficients of all between set-pairs (excluding the correlation coefficients between variables within the 
same sets). The calculation of hypergeometric p-values in the within set, the number of all correlation 
coefficients, including all the correlation coefficients between variables within the same sets, are added 
into X and N.  
4.2.3 Permutation analysis 
Because the variables in the correlation matrix of a given data set are not usually 
independent, permutation analysis was used to calculate the null distribution of the p-
values obtained by the hypergeometric distribution for a given data set. To achieve 
this, the exclusive group membership for each variable was permuted, however, the 
group structure, i.e. the number of groups and the number of members in the groups, 
along with the correlation coefficients between the variables was retained. One 
million permutations were performed for each data set. The empirical p-values for 
each within- and between-groups were calculated by using this equation (Davison & 
Hinkley 1997): 
! = ! (! + 1)(! + 1) (3) 
where p is the empirical p-value of each within- or between-group, r is the number of 
times in which the hypergeometric p-values from permutation test are equal or less 
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than the actual p-values from ORCA on the original data matrix, and n is the number 
of permutation used in the test (which is one million permutations).  
4.2.4 Data sets 
4.2.4.1 Drug sensitivity data set  
The drug sensitivity profiles of 58 cell lines from National Cancer Institute cell line 
panel (the NCI-60 panel) were used (Scherf et al. 2000). The values represent the 
sensitivity to each drug in each cell line is called the GI50, which is the concentration 
of a drug that can inhibit the growth of a cell line to 50% of the original growth rate of 
the cell line without the drug. Therefore, each drug has 58 GI50 values for every cell 
lines in the panel. The drugs can be grouped by using their mechanisms of actions, i.e. 
the molecular targets of the drugs. In total, 116 chemotherapeutic drugs with nine 
different mechanisms of actions were chosen from the Developmental Therapeutics 
Program (DTP) database. The compound names, NSC (National Service center) 
numbers and their mechanisms of actions, were shown in Table 4.2. Overall of the 
drug sensitivity data in the form of summed of GI50 for each compound is shown in 
Figure 4.2. 
4.2.4.2 miRNA data sets 
Two independent miRNA data sets were used in this study. The data sets are the 
baseline miRNA profiles of the cell lines from NCI-60 cell panel. The two data sets 
were from Liu et al. (2010), which used G4470B design ID 019118 miRNA 
microarray chips from Agilent Technologies and Søkilde et al. (2011), which used 
LNA (Locked Nucleic Acid)-enhanced miRCURY Dx 9.2 microarray platform from 
Exiqon. The overlapped number of miRNAs between the two data sets is 124 
miRNAs, and the list is shown in Table 4.3. The groupings of the miRNAs used in 
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this study were the miRNA clusters from miRConnect (Hua et al. 2011), which 
divided the miRNAs into 13 clusters according to the correlation between mRNA and 
miRNA profiles. Briefly, the summed correlation coefficients between mRNAs and 
each miRNA were ranked and the top 2000 genes on each direction (i.e. positive and 
negative) were selected to create a gene list for each miRNA. The number of 
overlapped genes of every miRNA pair was calculated, resulting in a 136 x 136 
matrix. Finally, the overlapped gene list matrix was used for hierarchical clustering. 
Overall of the two miRNA data sets in the form of summed expression for each 
miRNA are shown in Figure 4.3 and Figure 4.4 for Liu et al. (2010) and Søkilde et 
al. (2011), respectively. 
  
Chapter 4 
 
119 
Table 4.2 NSC numbers and compound names of 116 chemotherapeutic drugs by 
their mechanisms of actions. 
NSC Chemical Name  Mechanisms of actions 
56410 Porfiromycin 
1) Alkylating agents 
26980 Mytomycin C 
132313 Dianhydrogalactitol 
363812 Tetraplatin 
73754 Fluorodopan 
6396 Tris(aziridinyl)phosphine sulfide 
329680 Hepsulfam 
344007 Piperazine mustard 
135758 Piperazinedione 
241240 Carboplatin 
762 Nitrogen mustard hydrochloride 
119875 cis-Diamminedichloroplatinum(II) (cisplatin) 
34462 Uracil mustard 
8806 Melphalan 
271674 Diaminocyclohexyl-Pt-II 
25154 Pipobroman 
182986 Diaziridinylbenzoquinone 
296934 Teroxirone 
3088 Chlorambucil 
167780 Asaley 
9706 Triethylenemelamine 
172112 Spiromustine 
750 Busulfan 
348948 Cyclodisone 
102627 Yoshi-864 
256927 Iproplatin 
95441 Semustine (MeCCNU) 
353451 Mitozolamide 
338947 Clomesone 
409962 Carmustine (BCNU) 
79037 Lomustine (CCNU) 
178248 Chlorozotocin 
95466 PCNU 
139105 Baker's-soluble-antifolate 
2) Antifols 
184692 Aminopterin-derivative 
740 Methotrexate 
132483 Aminopterin 
623017 an-antifol 
633713 an-antifol 
134033 Aminopterin-derivative 
174121 Methotrexate-derivative 
352122 Trimetrexate 
366140 Pyrazoloacridine 
3) DNA binder 
354646 Morpholino-adriamycin 
142982 Hycanthone methanesulfonate 
268242 N-N-Dibenzyl-daunomycin 
357704 Cyanomorpholinodoxorubicin 
102816 Azacytidine 
4) DNA incorporation 
71851 alpha-2'-Deoxythioguanosine 
264880 5-6-Dihydro-5-azacytidine 
752 Thioguanine 
71261 beta-2'-Deoxythioguanosine 
145668 Cyclocytidine 
5) DNA synthesis 
inhibitors 
303812 Aphidicolin-glycinate 
63878 Cytarabine hydrochloride 
27640 5-fluorodeoxyuridine 
755 Thiopurine (6MP) 
19893 5-fluorouracil 
148958 Ftorafur 
32065 Hydroxyurea 6) Ribonucleotide 
reductase inhibitors 1895 Guanazole 51143 Pyrazoloimidazole 
143095 Pyrazofurin 
7) RNA synthesis 
inhibitors 
153353 L-Alanosine 
163501 Acivicin 
224131 N-phosphonoacetyl-L-aspartic-acid 
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126771 Dichloroallyl-lawsone 
368390 DUP785 (brequinar) 
 629971 Camptothecin,9-NH2 (RS) 
8) Topoisomerase 
Inhibitors 
176323 Camptothecin,9-MeO 
94600 Camptothecin 
603071 Camptothecin,9-NH2 (S) 
606172 Camptothecin,11-formyl (RS) 
606497 Camptothecin,20-ester (S) 
606985 Camptothecin,20-ester (S) 
618939 Camptothecin,20-ester (S) 
249910 Camptothecin,7-Cl 
610456 Camptothecin,20-ester (S) 
606173 Camptothecin,11-HOMe (RS) 
107124 Camptothecin,10-OH 
337766 Bisantrene 
123127 Doxorubicin 
301739 Mitoxantrone 
269148 Menogaril 
267469 Deoxydoxorubicin 
249992 Amsacrine 
355644 Anthrapyrazole-derivative 
122819 Teniposide 
82151 Daunorubicin hydrochloride 
141540 Etoposide 
349174 Oxanthrazole (piroxantrone) 
308847 Amonafide 
164011 Zorubicin (Rubidazone) 
95678 3-Hydropicolinaldehyde-thiosemicarbazone 
9) Unknown 
49842 Vinblastine-sulfate 
658831 Taxol analog 
107392 5-Hydroxypicolinaldehyde-thiosemicarbazone 
153858 Maytansine 
757 Colchicine 
673188 Taxol analog 
671867 Taxol analog 
664402 Taxol analog 
661746 Taxol analog 
33410 Colchicine-derivative 
376128 Dolastatin-10 
673187 Taxol analog 
664404 Taxol analog 
671870 Taxol analog 
67574 Vincristine-sulfate 
83265 Trityl-cysteine 
666608 Taxol analog 
600222 Taxol analog 
609395 Halichondrin B 
125973 Taxol 
118994 Inosine-glycodialdehyde 
656178 Taxol analog 
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Table 4.3 miRNA cluster assignment from miRConnect study on 124 miRNAs. 
microRNA microRNA Cluster 
hsa-miR-135a 
Cluster I 
hsa-miR-135b 
hsa-miR-7 
hsa-miR-192 
hsa-miR-194 
hsa-miR-429 
hsa-miR-200a 
hsa-miR-200b 
hsa-miR-141 
hsa-miR-200c 
hsa-miR-203 
hsa-miR-375 
hsa-miR-335 
Cluster II 
hsa-miR-328 
hsa-miR-95 
hsa-miR-425* 
hsa-miR-374a 
hsa-miR-98 
hsa-miR-340 
hsa-miR-330-3p 
hsa-miR-33a 
hsa-miR-96 
hsa-miR-15b 
Cluster III 
hsa-miR-339-5p 
hsa-miR-26a 
hsa-miR-148b 
hsa-miR-196a 
hsa-miR-331-3p 
Cluster IV 
hsa-miR-182 
hsa-miR-183 
hsa-let-7d 
hsa-miR-345 
hsa-miR-107 
hsa-miR-103 
hsa-miR-301a 
hsa-miR-423-3p 
Cluster V 
hsa-miR-142-3p 
hsa-miR-17* 
hsa-miR-18a 
hsa-miR-106a 
hsa-miR-17 
hsa-miR-19a 
hsa-miR-19b 
hsa-miR-20a 
hsa-miR-92a 
hsa-miR-32 
hsa-miR-191 
hsa-miR-93 
hsa-miR-106b 
hsa-miR-25 
hsa-miR-126 
hsa-miR-130b 
hsa-miR-186 
hsa-miR-378 
hsa-miR-378* 
hsa-miR-197 
hsa-let-7f 
hsa-miR-361-5p 
hsa-miR-342-3p 
hsa-miR-181c 
hsa-miR-181a 
hsa-miR-181b 
hsa-miR-15a 
hsa-miR-16 
hsa-miR-30e 
Cluster VI hsa-let-7g 
hsa-miR-29c 
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hsa-miR-101 
hsa-miR-148a 
hsa-miR-195 
hsa-miR-296-5p 
Cluster VII 
hsa-miR-188-5p 
hsa-miR-34a 
hsa-miR-30d 
hsa-miR-29a 
hsa-miR-29b 
hsa-miR-204 
hsa-miR-105 
hsa-miR-146a 
hsa-miR-324-5p 
hsa-miR-140-5p 
Cluster VIII hsa-miR-145 hsa-miR-152 
hsa-miR-28-5p 
hsa-miR-132 Cluster IX hsa-miR-9 
hsa-let-7i 
Cluster X 
hsa-miR-99b 
hsa-let-7e 
hsa-miR-125a-5p 
hsa-miR-21 
hsa-miR-23b 
hsa-miR-27b 
hsa-miR-196b 
Cluster XI 
hsa-miR-212 
hsa-miR-10b 
hsa-miR-30a 
hsa-miR-30b 
hsa-miR-30e* 
hsa-miR-30a* 
hsa-miR-30c 
hsa-miR-221 
Cluster XII 
hsa-miR-222 
hsa-miR-130a 
hsa-miR-149 
hsa-miR-10a 
hsa-miR-151-3p 
hsa-miR-31 
hsa-miR-125b 
Cluster XIII 
hsa-miR-100 
hsa-miR-99a 
hsa-miR-22 
hsa-miR-24 
hsa-let-7c 
hsa-miR-137 
hsa-miR-23a 
hsa-miR-27a 
hsa-miR-218 
hsa-let-7a 
hsa-let-7b 
hsa-miR-155 
hsa-miR-210 
hsa-miR-193a-3p 
hsa-miR-424 
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Figure 4.2 Summed GI50 of each drug compound. The drugs are divided into 
groups according to their mechanisms of actions. The labels of drugs are the NSC 
numbers, which can be traced back to the names of compounds in Table 4.2. 
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Figure 4.3 Summed log2 normlised expression of each miRNA in Lie et al. (2010) 
data set. The miRNAs are divided into groups according to miRNA clusters from 
miRConnect study. As the expression data was log scaled, some miRNAs that have 
very low expression (i.e. less than 1) might have negative values. 
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Figure 4.4 Summed normalised expression of each miRNA in Søkilde et al. 
(2011) data set. The miRNAs are divided into groups according to miRNA clusters 
from miRConnect study. 
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4.3 Results 
4.3.1 ORCA identifies an association between the sensitivity in cancer cell lines to 
two chemotherapeutic drug groups: alkylating agents and topoisomerase 
inhibitors  
To evaluate ORCA, the method was tested on varied data sets, including drug 
sensitivity data and miRNA profiles for the NCI-60 cell line panel. The objective of 
ORCA on the drug sensitivity data set was to determine if there are similarity of 
sensitivity pattern across the cell line panel between any pair of drug groups. From the 
correlation matrix between all 116 chemotherapeutic drugs, there are drug groups that 
have high similarity pattern between them. ORCA was used to determine if any two 
drug-groups pair has correlation coefficients that are above a correlation threshold 
more than expected by chance. Applying the threshold selection method in section 
4.2.2 identified the correlation coefficient threshold of the drug sensitivity data set to 
be 0.79, i.e. a correlation coefficient threshold of 0.79 yields the highest information 
content according to the Shannon’s entropy-like score. Figure 4.5 illustrates 
Shannon’s entropy-like score from different correlation coefficient cutoffs. Figure 4.6 
illustrates the correlation matrix between every drug from drug sensitivity data set. 
Correlation coefficients that passed the 0.79 correlation cutoff highlighted in red 
circles with the boundaries of the drug groups in yellow lines. After ORCA was 
applied at the correlation coefficient threshold of 0.79, a p-value table for obtaining 
the number of correlation coefficients above the threshold by chance between every 
possible group pairs was generated. Table 4.4, shows the hypergeometric p-values 
and FDR-adjusted p-values between all the group pairs. 
From a closer inspection, the sensitivity pattern across NCI-60 cell panel between 
alkylating agents and topoisomerase inhibitors (drug group 1 and 8 according to 
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Table 4.2 and Figure 4.6, respectively) was very similar, judging by the number of 
correlation coefficients that passed the threshold of 0.79 between the two drug groups. 
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Figure 4.5 Shannon's entropy-like scores from different correlation coefficient thresholds of the drug sensitivity data. Shannon’s entropy-
like score was calculated for each correlation coefficient cutoff (from 0 to 1 with an increment of 0.01). The red vertical line marks the 
correlation coefficient threshold that yields the highest Shannon’s entropy-like score, which was 0.79 for the drug sensitivity data set. 
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Figure 4.6 Correlation matrix between all drugs in the drug sensitivity data set. 
Each circle represents a correlation coefficient between two drugs. The sizes of the 
circles reflect the strength of the correlation coefficients. Blue circles represent 
positive correlation coefficients, whereas pink circles represent negative correlation 
coefficients. The circles marked in red are the correlation coefficients that pass the 
correlation coefficient threshold of 0.79. Each drug is labeled using its NSC number 
according to Table 4.2 . The drug group names are as follow: 1) Alkylating agents; 2) 
Antifols; 3) DNA binders; 4) DNA incorporation; 5) DNA synthesis inhibitors; 6) 
Ribonucleotide reductase inhibitors; 7) RNA synthesis inhibitors; 8) Topoisomerase 
inhibitors; 9) Unknown. 
From Table 4.4A, the FDR-adjusted hypergeometric p-value for obtaining the 
number of correlation coefficients of the drugs between alkylating agents and 
topoisomerase inhibitors was 1 × 10-57, and the empirical p-value from the one-
million permutation test was 1 × 10-6, which suggests that it is highly unlikely that 
this amount of correlation coefficients that passed the threshold of 0.79 was by 
1
2
3
4
5
6
7
8
9
1 2 3 4 5 6 7 8 9
Chapter 4 
 
130 
chance. The high correlation between these two drug groups may results from the fact 
that the compounds in these two drug groups can cause single- and double-stranded 
DNA breaks in rapidly dividing cells, in which the cells have to rely on a common set 
of DNA repair pathways for cell survival (Bargonetti et al. 2010; Rudolf et al. 2011). 
Another drug group pair that shows the association that is higher than expected is the 
group pair between DNA synthesis inhibitors (group 5) and ribonucleotide reductase 
inhibitors (group 6), although with a lesser degree of statistical significance than the 
group pair between alkylating agents and topoisomerase inhibitors (see Table 4.4A). 
Table 4.4 P-value table after ORCA was applied to the drug sensitivity data set. 
A) 
Drug 
Group 1 2 3 4 5 6 7 8 9 
Drug 
Group 
1  0.94 0.82 0.82 0.29 0.70 0.87 1E-6 0.99 1 
2 1.00  0.59 0.59 0.66 0.58 0.60 0.92 0.91 2 
3 1.00 1.00  0.58 0.68 0.42 0.64 0.78 0.79 3 
4 1.00 1.00 1.00  0.11 0.42 0.64 0.78 0.79 4 
5 1.00 1.00 1.00 0.33  0.01 0.62 0.24 0.86 5 
6 1.00 1.00 1.00 1.00 0.01  0.47 0.64 0.62 6 
7 1.00 1.00 1.00 1.00 1.00 1.00  0.81 0.81 7 
8 1E-57 1.00 1.00 1.00 1.00 1.00 1.00  0.99 8 
9 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00  9 
Drug 
Group 1 2 3 4 5 6 7 8 9 
Drug 
Group 
  
Drug 
Group 1 2 3 4 5 6 7 8 9 
Empirical 
p-value 5E-5 0.03 0.31 0.007 0.21 1E-6 0.11 1E-6 0.01 
FDR-adjusted 
p-value 9E-21 0.01 0.41 0.001 0.31 0 0.56 2E-37 0.26 
A) Benjamini-Hochberg FDR adjusted hypergeometric p-values (lower half) and empirical p-values 
from permutation test (upper half). B) P-values from within-group correlation coefficients (from 
diagonal of the matrix). The p-values in grey-shaded boxes are the group pairs that have the p-values 
less than 0.05.  
Empirical p-value  
FDR-adjusted p-value B) 
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4.3.2 Using ORCA to verify miRNA clusters defined by the miRConnect study 
In this part, the baseline expression of 124 miRNAs from the two data sets, i.e. Liu et 
al. (2010) and Søkilde et al. (2011), were divided into 13 clusters according to the 
miRConnect study (Hua et al. 2011). The two data sets have the same basic data 
structure, i.e. equal number of variables (miRNAs) and number of data points in each 
variable from the same number of cell lines used in the experiments. However, the 
information content might be different between the two data sets, due to systematic 
variations, for example, from different types of microarrays used in the measurement 
of miRNA expression. If a single correlation coefficients threshold is used in ORCA 
for both of the data sets, where the amount of information between the two data sets 
are different, the results would not be comparable. The threshold selection method 
based on Shannon’s entropy in the section 4.2.2 is an objective means to select the 
correlation coefficient cutoff that is suitable for individual data sets. Therefore, after 
applied ORCA to the two miRNA data sets, the correlation coefficient thresholds for 
the two data sets were determined to be 0.29 and 0.61 for Liu et al. (2010) and 
Søkilde et al. (2011) data sets, respectively. Figure 4.7 shows the Shannon’s entropy-
like scores from different correlation coefficient cutoffs of the Liu et al. (2010) and 
Søkilde et al. (2011) miRNA data sets. Figure 4.8 shows the correlation matrices 
from the two miRNA data sets with cluster boundaries. Table 4.5 and Table 4.6 show 
the p-values after ORCA were applied on the two miRNA data sets.  
From the Table 4.5 and Table 4.6, several clusters proposed by Hua et al. (2011) 
contained significant within-cluster overrepresentation of correlations identified by 
ORCA at FDR-adjusted p-value of 0.05 in both data sets, which were clusters I, IV, 
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V, X and XIII. As for association between any two clusters, ORCA identified one 
cluster pair that had overrepresentation of correlations, which was cluster pair X/XIII. 
The miRNAs within the clusters I, IV, V, X and XIII contain overrepresentation of 
correlations as determined by ORCA support the hypothesis that the miRNAs in these 
clusters might be controlled by the same transcription factors, located at the same 
chromosomal regions, or involved in the same processes or pathways. The association 
between cluster pair X/XIII, which was determined to be statistically significant by 
ORCA, could be explained by the fact that several of the miRNAs in these two 
clusters have the same seed sequences from the same miRNA families. According to 
miRBase database release 21 in June 2014 (Kozomara & Griffiths-Jones 2014), the 
miRNA families presented in these two miRNA clusters are let-7 family (let-7e, and 
let-7i in cluster X and let-7a, let-7b, let-7c in cluster XIII), miR-23 family (miR-23b 
in cluster X and miR-23a in cluster XIII), miR-27 family (mir-27b in cluster X and 
miR-27a in cluster XIII), miR-125 family (miR-125a-5p in cluster X and miR-125b in 
cluster XIII), and miR-99/100 family (miR-99b in cluster X, and miR-99a, miR-100 
in cluster XIII). This observation has not been reported in the original miRConnect 
study. The result suggests that this cluster pair X/XIII might be considered as a single 
superfamily of miRNAs, or a single cluster. Other miRNA cluster pairs identified by 
ORCA as statistically significant, miRNA cluster pairs II/IV and V/VI, were difficult 
to rationalised than cluster pair X/XIII because within-cluster overrepresentation of 
correlation in clusters II and VI were not statistically significant. This result suggests 
that there might be possible misclassification in the original clustering of these 
miRNAs.
Chapter 4 
 133 
 
Figure 4.7 Shannon's entropy-like scores from different correlation coefficient thresholds of the two miRNA data sets. Shannon’s 
entropy-like score was calculated for each correlation coefficient cutoff (from 0 to 1 with an increment of 0.01). The red vertical lines mark the 
correlation coefficient threshold that yields the highest Shannon’s entropy-like scores, which were 0.29 (left) and 0.61 (right) for Liu et al. 
(2010) and Søkilde et al. (2011), respectively. These results demonstrate that different sources of data have different amount of information, in 
which a single correlation coefficient threshold will not be able to yield the highest amount of data from different sets of data. 
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Figure 4.8 Correlation matrices from the two miRNA data sets. The circles represent correlation coefficients between two miRNAs. Blue 
and pink circles are positive and negative correlation coefficients, respectively. The size and the colour shade of the circle signify the strength of 
the correlation. The clusters are divided by yellow lines, and the red boxes indicate the cluster pairs that have FDR-adjusted hypergeometric p-
values and empirical p-values less than 0.05 in both data sets. 
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Table 4.5 P-value table after ORCA was applied to the Liu et al. 
(2010) miRNA data set. 
A) 
Cluster I II III IV V VI VII VIII IX X XI XII XIII Cluster 
I  0.17 0.94 0.005 0.003 0.74 0.94 0.20 0.95 0.99 0.94 0.35 0.007 I 
II 0.33  0.80 0.04 0.02 0.71 0.54 0.75 0.67 0.86 0.99 0.94 0.99 II 
III 1.00 1.00  0.18 0.06 0.55 0.61 0.20 0.68 0.99 0.48 0.90 0.88 III 
IV 4E-4 0.027 0.44  0.01 0.35 0.77 0.85 0.87 0.88 0.96 0.64 0.99 IV 
V 7E-6 8E-4 0.025 4E-4  0.04 0.96 0.65 0.99 0.008 0.46 0.97 0.08 V 
VI 1.00 1.00 1.00 0.85 6E-3  0.98 0.97 0.93 0.66 0.26 0.67 0.48 VI 
VII 1.00 1.00 1.00 1.00 1.00 1.00  0.26 0.82 0.91 0.99 0.54 0.99 VII 
VIII 0.44 1.00 0.44 1.00 1.00 1.00 0.69  0.85 0.63 0.97 0.99 0.61 VIII 
IX 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00  0.83 0.71 0.83 0.99 IX 
X 1.00 1.00 1.00 1.00 1E-4 1.00 1.00 1.00 1.00  0.73 0.28 3E-6 X 
XI 1.00 1.00 1.00 1.00 1.00 0.67 1.00 1.00 1.00 1.00  0.02 0.46 XI 
XII 0.85 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.7 8E-3  0.11 XII 
XIII 3E-4 1.00 1.00 1.00 0.031 1.00 1.00 1.00 1.00 9E-14 1.00 0.16  XIII 
Cluster I II III IV V VI VII VIII IX X XI XII XIII Cluster 
 
B) 
Cluster I II III IV V VI VII VIII IX X XI XII XIII 
Empirical  
p-value 3E-6 0.15 0.21 0.006 1E-5 0.45 0.57 0.05 0.24 1E-4 0.33 0.23 4E-5 
FDR-adjusted 
p-value 4E-15 0.67 0.83 4E-3 4E-15 1.00 1.00 0.22 0.83 4E-7 1.00 0.87 3E-11 
A) Benjamini-Hochberg FDR adjusted hypergeometric p-values (lower half) and 
empirical p-values from permutation test (upper half). B) P-values from within-
cluster correlation coefficients (from diagonal of the matrix). The p-values in 
grey-shaded boxes are the clusters and cluster pairs that have the FDR-adjusted 
and empirical p-values less than 0.05. P-values in red are the clusters and cluster 
pair that passed the threshold of in both miRNA data sets (also correspond to red 
boxes on the left panel in the figure 4.8). P-values in blue correspond to the figure 
4.9. 
Table 4.6 P-value table after ORCA was applied to the Søkilde 
et al. (2011) miRNA data set. 
A) 
Cluster I II III IV V VI VII VIII IX X XI XII XIII Cluster 
I  0.02 0.51 0.55 0.84 0.23 0.91 0.72 0.47 0.87 0.92 0.89 0.96 I 
II 0.016  0.12 0.003 0.15 0.005 0.38 0.66 0.42 0.11 0.27 0.48 0.28 II 
III 0.61 0.32  0.024 0.37 0.25 0.74 0.44 0.26 0.31 0.67 0.63 0.86 III 
IV 0.79 1E-3 0.049  0.27 0.12 0.88 0.59 0.37 0.50 0.82 0.78 0.17 IV 
V 0.95 0.28 0.61 0.52  1E-6 0.64 0.88 0.70 0.87 0.88 0.95 0.99 V 
VI 0.52 1E-3 0.43 0.32 6E-3  0.16 0.50 0.30 0.69 0.73 0.69 0.91 VI 
VII 0.95 0.61 0.83 0.92 5E-14 0.43  0.66 0.43 0.48 0.15 0.85 0.82 VII 
VIII 0.83 0.79 0.61 0.75 0.85 0.68 0.79  0.22 0.55 0.59 0.23 0.79 VIII 
IX 0.68 0.61 0.54 0.61 0.95 0.56 0.61 0.51  0.33 0.37 0.33 0.55 IX 
X 0.92 0.26 0.51 0.61 0.86 0.79 0.68 0.72 0.59  0.50 0.74 6E-5 X 
XI 0.93 0.55 0.79 0.86 0.95 0.83 0.32 0.75 0.61 0.61  0.78 0.71 XI 
XII 0.92 0.68 0.77 0.85 0.97 0.79 0.89 0.41 0.59 0.83 0.85  0.07 XII 
XIII 0.99 0.55 0.92 0.41 0.99 0.93 0.92 0.86 0.75 6E-8 0.86 0.13  XIII 
Cluster I II III IV V VI VII VIII IX X XI XII XIII Cluster 
 
B) 
Cluster I II III IV V VI VII VIII IX X XI XII XIII 
Empirical  
p-value 2E-5 0.19 0.26 1E-4 3E-6 0.006 0.38 0.17 0.03 6E-4 0.001 0.14 0.003 
FDR-adjusted 
p-value 2E-10 0.57 0.61 4E-7 2E-17 0.013 0.77 0.55 0.22 8E-5 0.54 3E-4 3E-11 
A) Benjamini-Hochberg FDR adjusted hypergeometric p-values (lower half) and 
empirical p-values from permutation test (upper half). B) P-values from within-
cluster correlation coefficients (from diagonal of the matrix). The p-values in 
grey-shaded boxes are the clusters and cluster pairs that have the FDR-adjusted 
and empirical p-values less than 0.05. P-values in red are the clusters and cluster 
pair that passed the threshold and in both miRNA data sets (also correspond to red 
boxes on the right panel in the figure 4.8). 
FDR-adjusted p-value FDR-adjusted p-value 
Empirical p-value 
Empirical p-value 
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In a follow-up study by the authors of the miRConnect study, clusters I and V was 
found to be functionally antagonistic to miRNAs in cluster XIII, in which they 
observed that clusters I and V had the opposite effect on the same set of mRNAs 
compared to cluster XIII (Hua et al. 2013). ORCA also identified significant 
overrepresentation of correlations (which were predominantly negative correlation 
coefficients) between cluster pairs I/XIII and V/XIII in one of microarray data sets 
[Liu et al. (2010)]. Figure 4.9 shows the correlation coefficients between the cluster 
pairs I/XIII and V/XIII. ORCA can detect functional antagonism by using only 
microRNA expression data set alone unlike the follow-up study, which highlighted 
the potential of this method. 
 
Figure 4.9 Correlation coefficients between cluster pairs I/XIII and V/XIII. Most 
of the correlation coefficients between these cluster pairs were predominantly 
negative correlation, which suggests that miRNAs in clusters I and V might be 
working against miRNAs in cluster XIII. 
 
4.4 Discussion 
ORCA has a potential to be used as a pathway analysis tool as well, but the research 
question that need to be asked will be different from existing pathway or gene set 
analysis methods. Currently, most pathway analysis methods identify pathways that 
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are significantly enriched or depleted through the genes that deemed differentially 
expressed in a certain biological condition. However, ORCA could identify associated 
pathways through correlations between the genes within the pathways. Although the 
examples presented in this chapter were not pathway analysis, ORCA could be 
applied to any type of pathway or gene set in order to determine the associated 
pathways. OCRA could address some limitations of existing pathway analysis 
methods outlined by Khatri et al. (2012). First, pathway analysis tools using ORA do 
not take into account the actual levels of variables (such as gene expression or 
metabolite levels). ORCA takes these values into account through correlation 
coefficient calculations, albeit indirectly, which in effect ORCA does not weigh the 
variables equally. Second, ORCA does not assume that the variables are independent, 
which usually is an important assumption of typical pathway analysis tools that 
implementing ORA. Third, classical ORA only use variables, such as mRNAs or 
miRNAs, which are deemed differentially expressed in a certain condition. ORCA, on 
the other hand, uses all the variables in the calculation. Fourth, ORA-based pathway 
analysis tools usually apply multiple hypothesis testing for p-value correction, which 
has an assumption on the independence of the pathways tested. However, ORCA has 
the opposite assumption and seeks to find the association between two groups of 
variables.  
ORCA is based on the hypergeometric distribution, therefore it could be argued that 
this method violates the assumption of independence of each data point because the 
use of correlation coefficient in the p-value calculation, which may lead to inaccurate 
p-value calculations. A simulation study by Goeman & Bühlmann (2007) have shown 
that when hypergeometric test was used in correlated data, the p-values calculated 
from the test were found to be underestimated. There are, however, means to correct 
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the underestimated p-values by using the multiple comparison procedures, such as 
Bonferroni correction or Benjamini-Hochberg FDR correction (which was used in 
this study). The alpha level of the p-value can also be selected from a table of nominal 
alpha level for correlated data from (Goeman & Bühlmann 2007) to match the 
correlation coefficient threshold used in the analysis. Note that in the simulation study 
previously mentioned, correlated data have the same correlation coefficient in every 
data points. Wilcoxon rank-sum test could also be used instead of hypergeometric test 
when the comparison is between the numbers of correlation coefficients in one group 
pair against all other group pairs. 
ORCA can be applied as a pathway analysis tool, but the information from the 
analysis will be related specifically to the pathway interactions. For example, ORCA 
can calculate the correlation coefficients between the mRNAs or metabolites from 
pathways, and then identify the pathway pairs with higher correlation coefficients that 
pass a certain threshold (determined by either the threshold selection method or by 
other means) than expected by chance.  
This version of ORCA requires the data sets to have exclusive group memberships for 
the variables, i.e. each variable can belong to only one group. Therefore, at present 
ORCA cannot be used with pathway data where variables are overlapped in two or 
more pathways. This is a subject for the future work.  
In conclusion, ORCA is a novel method that combines correlation analysis with 
overrepresentation analysis, which has potential to reveal associations between sets of 
variables that might not be uncovered by conventional statistical methods in a wide 
variety of biological data sets. ORCA has clear application in  “-omics” data analysis, 
however, it will be profitable in any circumstance where an association network can 
be constructed between variables that can be classified into meaningful sets. 
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5.1 Conclusions 
This thesis presented novel utilisation of various statistical methods for exploring the 
roles of miRNAs on metabolism. In the second chapter a specific miRNA, miR-22 
was studied from several independent breast cancer data sets with patient survival 
data. Spearman’s Rank correlation analysis was used to assess the potential of the 
miR-22 host gene expression, MIR22HG, as a surrogate marker for mature miR-22 
expression. Correlation and survival analyses were also used to evaluate the 
association between miR-22 and the three metabolic target genes, MTHFD2, 
ELOVL6, and ACLY, previously identified in the Keun group laboratory, in vivo. 
Correlation between miR-22 and the two target genes, MTHFD2 and ELOVL6, were 
found to be statistically significant. Survival analyses on the relapse-free of breast 
cancer patient data were performed using miR-22 and the three metabolic target genes 
as the predictors. It was found that the expression of miR-22, MTHFD2, and 
ELOVL6, affected the survival outcome of the breast cancer patients. High expression 
of miR-22 was beneficial to the survival outcome of the breast cancer patients, while 
the high expression of the metabolic target genes, i.e. MTHFD2 and ELOVL6, 
exhibited the opposite effects. The second chapter concluded with the effect 
modification analysis of miR-22 on the three metabolic target genes using Cochran-
Armitage trend test. The survival outcomes of breast cancer patients with low 
expression of MTHFD2 and EVOLV6 were modified to be better by the high 
expression of miR-22 than the target genes alone.  
The third chapter was the global analysis on the predicted metabolic target genes of 
miRNA families from the TargetScan miRNA target prediction database. This chapter 
applied weighted Jaccard index to overlapped predicted metabolic target genes of 
every miRNA family pair to create a weighted Jaccard distance matrix for 
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hierarchical clustering analysis. The miRNA families were then classified into six 
different clusters, and the predicted metabolic target genes in these clusters were 
analysed by pathway enrichment analysis. Three clusters yielded several enriched 
pathways in metabolism, cancer-specific and cancer-related pathways.  
The fourth chapter described a novel statistical method that was created by combining 
two classical statistical methods, called over-representation of correlation analysis 
(ORCA). This new statistical analysis was invented to identify association between 
two sets of variables through correlation coefficients between the variables in the two 
sets. The method was applied to two problems: one problem was to identify 
associations between chemotherapeutic drugs by using drug sensitivity data on NCI-
60 cancer cell line panel; another problem was to verify miRNA clusters previously 
identified by an independent study. In conclusion, combinations of classical 
statistical methods can be used to reveal novel insights and provide a better 
understanding of miRNA biology from publicly available data sets. 
5.2 Future work 
The main limitation in the miR-22 analysis was the usage of MIR22HG expression as 
the surrogate marker for mature miR-22 expression. Although the high degree and 
statistically significant results of positive correlation between the host gene and 
mature species were observed, the actual measurement of active miRNA species is 
definitely better than a surrogate. This could be achieved when the high-throughput 
mature miRNA data sets are more widely available. Another drawback was lying in 
the survival analysis. Breast cancer survival outcomes are heavily affected by the 
hormone receptors status in the tumours. The survival analysis in this thesis did not 
stratify the patients by any hormone receptor status in order to gain the highest 
number of samples possible. Again, with more data available, complete with hormone 
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receptors status, the reanalysis can be performed to determine the roles of the 
hormone receptors.  
In global analysis of predicted metabolic target genes of miRNA families, the main 
drawback is that only one predicted target genes database was used, in which only 
two main features of miRNA target prediction were used. To increase the sensitivity 
of the analysis, a new way to integrate other main features for miRNA target gene 
prediction is needed in order to widen the predicted metabolic target genes. For a 
specificity issue, experimentally validated targets could be used for reanalysis to weed 
out spuriously enriched pathways. Another extension of the work would be to include 
the gene expression of specific pathways or conditions to confirm the findings.  
For the chapter on ORCA, this method had been applied to the cluster verification 
problem. It should be used to verify the findings in the global predicted target genes 
analysis. Another extension of the method that could be implemented is to use other 
association metric other than the correlation, such as Jaccard index or other distance 
metrics. One big limitation of the method is the exclusive groupings requirement in 
the data used in the analysis. When the method can accept overlapped variables 
between two groups, this method could be applied more widely on the pathway level 
data, in which the variables usually overlapped between the sets. 
 
  
143 
References 
Alexiou, P. et al., 2009. Lost in translation: an assessment and perspective for 
computational microRNA target identification. Bioinformatics (Oxford, 
England), 25(23), pp.3049–55. 
Ameres, S.L. & Zamore, P.D., 2013. Diversifying microRNA sequence and function. 
Nature reviews. Molecular cell biology, 14(8), pp.475–88. 
Armitage, P., 1955. Tests for linear trends in proportions and frequencies. Biometrics, 
11(3), pp.375–386. 
Bargonetti, J., Champeil, E. & Tomasz, M., 2010. Differential toxicity of DNA 
adducts of mitomycin C. Journal of nucleic acids, 2010. 
Bartel, D., 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. cell, 
116, pp.281–297. 
Baskerville, S. & Bartel, D.P., 2005. Microarray profiling of microRNAs reveals 
frequent coexpression with neighboring miRNAs and host genes. RNA, 11(3), 
pp.241–247. 
Beissbarth, T. & Speed, T.P., 2004. GOstat: find statistically overrepresented Gene 
Ontologies within a group of genes. Bioinformatics (Oxford, England), 20(9), 
pp.1464–5. 
Benjamini, Y. & Hochberg, Y.B., 1995. Controlling the False Discovery Rate!: A 
Practical and Powerful Approach to Multiple Testing. Journal of the Royal 
Statistical Society , Series B, 57(1), pp.289–300. 
Biasiolo, M. et al., 2011. Impact of host genes and strand selection on miRNA and 
miRNA* expression. PloS one, 6(8), p.e23854. 
Bioinformatics and research computing, 2012. TargetScan. Available at: 
http://www.targetscan.org/cgi-bin/targetscan/data_download.cgi?db=vert_61 
[Accessed October 7, 2013]. 
Blower, P.E. et al., 2007. MicroRNA expression profiles for the NCI-60 cancer cell 
panel. Molecular cancer therapeutics, 6(5), pp.1483–91. 
Borchert, G.M., Lanier, W. & Davidson, B.L., 2006. RNA polymerase III transcribes 
human microRNAs. Nature structural & molecular biology, 13(12), pp.1097–
101. 
Boross, G., Orosz, K. & Farkas, I.J., 2009. Human microRNAs co-silence in well-
separated groups and have different predicted essentialities. Bioinformatics 
(Oxford, England), 25(8), pp.1063–9. 
References 
 
144 
Bullard, J.H. et al., 2010. Evaluation of statistical methods for normalization and 
differential expression in mRNA-Seq experiments. BMC bioinformatics, 11, 
p.94. 
Bushman, B.J. & Wang, M.C., 1995. A procedure for combining sample correlation 
coefficients and vote counts to obtain an estimate and a confidence interval for 
the population correlation coefficient. Psychological Bulletin, 117(3), pp.530–
546. 
Cairns, R. a, Harris, I.S. & Mak, T.W., 2011. Regulation of cancer cell metabolism. 
Nature reviews. Cancer, 11(2), pp.85–95. 
Carthew, R.W. & Sontheimer, E.J., 2009. Origins and Mechanisms of miRNAs and 
siRNAs. Cell, 136(4), pp.642–55. 
Cavill, R. et al., 2011. Consensus-Phenotype Integration of Transcriptomic and 
Metabolomic Data Implies a Role for Metabolism in the Chemosensitivity of 
Tumour Cells G. Tucker-Kellogg, ed. PLoS Computational Biology, 7(3), 
p.e1001113. 
Chang, T.-C. et al., 2008. Widespread microRNA repression by Myc contributes to 
tumorigenesis. Nature genetics, 40(1), pp.43–50. 
Chen, B. et al., 2012. Roles of microRNA on cancer cell metabolism. Journal of 
translational medicine, 10(1), p.228. 
Cochran, W.G., 1954. The Combination of Estimates from Different Experiments. 
Biometrics, 10(1), pp.101–129. 
Dang, C. V, 2013. MYC, metabolism, cell growth, and tumorigenesis. Cold Spring 
Harbor perspectives in medicine, 3(8). 
Davis, B.N. & Hata, A., 2009. Regulation of MicroRNA Biogenesis: A miRiad of 
mechanisms. Cell communication and signaling!: CCS, 7, p.18. 
Davison, A.C. & Hinkley, D.V., 1997. Bootstrap methods and their application 9th 
ed., New York: Cambridge University Press. 
Dillies, M.-A. et al., 2013. A comprehensive evaluation of normalization methods for 
Illumina high-throughput RNA sequencing data analysis. Briefings in 
bioinformatics, 14(6), pp.671–83. 
Dória, M.L. et al., 2014. Fatty acid and phospholipid biosynthetic pathways are 
regulated throughout mammary epithelial cell differentiation and correlate to 
breast cancer survival. FASEB journal!: official publication of the Federation of 
American Societies for Experimental Biology, pp.1–18. 
Duarte, N.C. et al., 2007. Global reconstruction of the human metabolic network 
based on genomic and bibliomic data. Proceedings of the National Academy of 
Sciences of the United States of America, 104(6), pp.1777–82. 
References 
 
145 
Dumortier, O., Hinault, C. & Van Obberghen, E., 2013. MicroRNAs and metabolism 
crosstalk in energy homeostasis. Cell metabolism, 18(3), pp.312–24. 
Elton, T.S. et al., 2013. Regulation of the MIR155 host gene in physiological and 
pathological processes. Gene, 532(1), pp.1–12. 
Esquela-Kerscher, A. & Slack, F.J., 2006. Oncomirs - microRNAs with a role in 
cancer. Nature reviews. Cancer, 6(4), pp.259–69. 
Eulalio, A., Huntzinger, E. & Izaurralde, E., 2008. Getting to the root of miRNA-
mediated gene silencing. Cell, 132(1), pp.9–14. 
Farazi, T. a et al., 2011. MicroRNA sequence and expression analysis in breast 
tumors by deep sequencing. Cancer research, 71(13), pp.4443–53. 
Friedman, R.C. et al., 2009. Most mammalian mRNAs are conserved targets of 
microRNAs. Genome research, 19(1), pp.92–105. 
Garmire, L.X. & Subramaniam, S., 2012. Evaluation of normalization methods in 
mammalian microRNA-Seq data. RNA (New York, N.Y.), 18(6), pp.1279–88. 
Garzon, R., Calin, G. a & Croce, C.M., 2009. MicroRNAs in Cancer. Annual review 
of medicine, 60, pp.167–79. 
Gaur, A. et al., 2007. Characterization of microRNA expression levels and their 
biological correlates in human cancer cell lines. Cancer research, 67(6), 
pp.2456–68. 
Gennarino, V.A. et al., 2009. MicroRNA target prediction by expression analysis of 
host genes. Genome research, 19(3), pp.481–90. 
Goeman, J.J. & Bühlmann, P., 2007. Analyzing gene expression data in terms of gene 
sets: methodological issues. Bioinformatics (Oxford, England), 23(8), pp.980–7. 
Guo, M.-M. et al., 2013. miR-22 is down-regulated in gastric cancer, and its 
overexpression inhibits cell migration and invasion via targeting transcription 
factor Sp1. Medical oncology (Northwood, London, England), 30(2), p.542. 
Ha, M. & Kim, V.N., 2014. Regulation of microRNA biogenesis. Nature reviews. 
Molecular cell biology, 15(8), pp.509–524. 
Hammell, M., 2010. Computational methods to identify miRNA targets. Seminars in 
cell & developmental biology, 21(7), pp.738–44. 
Hanahan, D. & Weinberg, R. a, 2011. Hallmarks of cancer: the next generation. Cell, 
144(5), pp.646–74. 
Hanahan, D. & Weinberg, R.A., 2000. The Hallmarks of Cancer. , 100, pp.57–70. 
References 
 
146 
Hanai, J.-I. et al., 2013. ATP citrate lyase knockdown impacts cancer stem cells in 
vitro. Cell death & disease, 4(6), p.e696. 
Hausser, J. & Zavolan, M., 2014. Identification and consequences of miRNA-target 
interactions - beyond repression of gene expression. Nature reviews. Genetics, 
15(9), pp.599–612. 
He, L. & Hannon, G.J., 2004. MicroRNAs: small RNAs with a big role in gene 
regulation. Nature reviews. Genetics, 5(7), pp.522–31. 
Heiden, M.G. Vander, Cantley, L.C. & Thompson, C.B., 2009. Understanding the 
Warburg effect: the metabolic requirements of cell proliferation. Science (New 
York, N.Y.), 324(5930), pp.1029–33. 
Hinske, L.C.G. et al., 2010. A potential role for intragenic miRNAs on their hosts’ 
interactome. BMC genomics, 11, p.533. 
Hua, Y. et al., 2013. miRConnect 2.0: identification of oncogenic, antagonistic 
miRNA families in three human cancers., 
Hua, Y. et al., 2011. miRConnect: Identifying Effector Genes of miRNAs and 
miRNA Families in Cancer Cells L. Zhang, ed. PLoS ONE, 6(10), p.e26521. 
Huang, Z.-P. et al., 2013. MicroRNA-22 regulates cardiac hypertrophy and 
remodeling in response to stress. Circulation research, 112(9), pp.1234–43. 
John, B. et al., 2004. Human MicroRNA targets. PLoS biology, 2(11), p.e363. 
Jovicic, A. et al., 2013. MicroRNA-22 (miR-22) overexpression is neuroprotective via 
general anti-apoptotic effects and may also target specific Huntington’s disease-
related mechanisms. PloS one, 8(1), p.e54222. 
Kanehisa, M. & Goto, S., 2000. KEGG: kyoto encyclopedia of genes and genomes. 
Nucleic acids research, 28(1), pp.27–30. 
Karolchik, D. et al., 2014. The UCSC Genome Browser database: 2014 update. 
Nucleic acids research, 42(Database issue), pp.D764–70. 
Kendall, M. & Gibbons, J.D., 1990. Rank correlation methods, Oxford University 
Press. 
Kertesz, M. et al., 2007. The role of site accessibility in microRNA target recognition. 
Nature genetics, 39(10), pp.1278–84. 
Khatri, P., Sirota, M. & Butte, A.J., 2012. Ten years of pathway analysis: current 
approaches and outstanding challenges. PLoS computational biology, 8(2), 
p.e1002375. 
Kim, V.N., 2005. MicroRNA biogenesis: coordinated cropping and dicing. Nature 
reviews. Molecular cell biology, 6(5), pp.376–85. 
References 
 
147 
Kim, V.N., Han, J. & Siomi, M.C., 2009. Biogenesis of small RNAs in animals. 
Nature reviews. Molecular cell biology, 10(2), pp.126–39. 
Kleinbaum, D.G. & Klein, M., 2005a. Kaplan–Meier Survival Curves and the Log–
Rank Test. In Survival analysis!: a self-learning text. Springer, pp. 45–82. 
Kleinbaum, D.G. & Klein, M., 2005b. The Cox Proportional Hazards Model and Its 
Characteristics. In Survival analysis!: a self-learning text. Springer, pp. 83–130. 
Kong, L.-M. et al., 2014. A regulatory loop involving miR-22, Sp1, and c-Myc 
modulates CD147 expression in breast cancer invasion and metastasis. Cancer 
research, 74(14), pp.3764–78. 
Koppenol, W.H., Bounds, P.L. & Dang, C. V, 2011. Otto Warburg’s contributions to 
current concepts of cancer metabolism. Nature reviews. Cancer, 11(5), pp.325–
37. 
Kozomara, A. & Griffiths-Jones, S., 2014. miRBase: annotating high confidence 
microRNAs using deep sequencing data. Nucleic acids research, 42(Database 
issue), pp.D68–73. 
Krek, A. et al., 2005. Combinatorial microRNA target predictions. Nature genetics, 
37(5), pp.495–500. 
Lagos-Quintana, M. et al., 2002. Identification of tissue-specific microRNAs from 
mouse. Current biology!: CB, 12(9), pp.735–9. 
Langfelder, P., Zhang, B. & Horvath, S., 2008. Defining clusters from a hierarchical 
cluster tree: the Dynamic Tree Cut package for R. Bioinformatics (Oxford, 
England), 24(5), pp.719–20. 
Larose, D.T., 2005. Discovering knowledge in data: an introduction to data mining, 
John Wiley & Sons. 
Lee, R.C., Feinbaum, R.L. & Ambros, V., 1993. The C. elegans heterochronic gene 
lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 75(5), 
pp.843–54. 
Lehtinen, L. et al., 2013. High-throughput RNAi screening for novel modulators of 
vimentin expression identifies MTHFD2 as a regulator of breast cancer cell 
migration and invasion. Oncotarget, 4(1), pp.48–63. 
Lenkala, D. et al., 2014. The impact of microRNA expression on cellular 
proliferation. Human genetics, 133(7), pp.931–8. 
Leonard, T., 2000. A course in categorical data analysis, Chapman & Hall/CRC. 
Di Leva, G. et al., 2010. MicroRNA cluster 221-222 and estrogen receptor alpha 
interactions in breast cancer. Journal of the National Cancer Institute, 102(10), 
pp.706–21. 
References 
 
148 
Levandowsky, M. & Winter, D., 1971. Distance between sets. Nature, 234, pp.34–35. 
Li, J. et al., 2010. An inhibitory effect of miR-22 on cell migration and invasion in 
ovarian cancer. Gynecologic oncology, 119(3), pp.543–8. 
Li, X. et al., 2014. miR-22 targets the 3’ UTR of HMGB1 and inhibits the HMGB1-
associated autophagy in osteosarcoma cells during chemotherapy. Tumour 
biology!: the journal of the International Society for Oncodevelopmental Biology 
and Medicine, 35(6), pp.6021–8. 
Li, Y. et al., 2014. Mirsynergy: detecting synergistic miRNA regulatory modules by 
overlapping neighbourhood expansion. Bioinformatics (Oxford, England), 
(2011), pp.1–9. 
Ling, B. et al., 2012. Tumor suppressor miR-22 suppresses lung cancer cell 
progression through post-transcriptional regulation of ErbB3. Journal of cancer 
research and clinical oncology, 138(8), pp.1355–61. 
Liu, F. et al., 2014. Increased MTHFD2 expression is associated with poor prognosis 
in breast cancer. Tumour biology!: the journal of the International Society for 
Oncodevelopmental Biology and Medicine, 35(9), pp.8685–90. 
Liu, H. et al., 2010. mRNA and microRNA expression profiles of the NCI-60 
integrated with drug activities. Molecular cancer therapeutics, 9(5), pp.1080–91. 
Liu, J., 2008. Control of protein synthesis and mRNA degradation by microRNAs. 
Current opinion in cell biology, 20(2), pp.214–21. 
Malumbres, M., 2013. miRNAs and cancer: an epigenetics view. Molecular aspects 
of medicine, 34(4), pp.863–74. 
Martinez-Sanchez, A. & Murphy, C.L., 2013. MicroRNA Target Identification-
Experimental Approaches. Biology, 2(1), pp.189–205. 
Melamed, Z. et al., 2013. Alternative splicing regulates biogenesis of miRNAs 
located across exon-intron junctions. Molecular cell, 50(6), pp.869–81. 
Melo, S. a & Esteller, M., 2011. Dysregulation of microRNAs in cancer: playing with 
fire. FEBS letters, 585(13), pp.2087–99. 
Migita, T. et al., 2014. Inhibition of ATP citrate lyase induces triglyceride 
accumulation with altered fatty acid composition in cancer cells. International 
journal of cancer. Journal international du cancer, 135(1), pp.37–47. 
Miller, D.M. et al., 2012. c-Myc and cancer metabolism. Clinical cancer research!: 
an official journal of the American Association for Cancer Research, 18(20), 
pp.5546–53. 
References 
 
149 
Miranda, K.C. et al., 2006. A pattern-based method for the identification of 
MicroRNA binding sites and their corresponding heteroduplexes. Cell, 126(6), 
pp.1203–17. 
Mogilyansky, E. & Rigoutsos, I., 2013. The miR-17/92 cluster: a comprehensive 
update on its genomics, genetics, functions and increasingly important and 
numerous roles in health and disease. Cell death and differentiation, 20(12), 
pp.1603–14. 
Morozova, N. et al., 2012. Kinetic signatures of microRNA modes of action. RNA 
(New York, N.Y.), 18(9), pp.1635–55. 
Mortazavi, A., Williams, B. & McCue, K., 2008. Mapping and quantifying 
mammalian transcriptomes by RNA-Seq. Nature methods, 5, pp.621–628. 
Nam, J.-W. et al., 2014. Global analyses of the effect of different cellular contexts on 
microRNA targeting. Molecular cell, 53(6), pp.1031–43. 
National Cancer Institute, 2014. Molecular Target Data. Available at: 
https://wiki.nci.nih.gov/display/NCIDTPdata/Molecular+Target+Data [Accessed 
April 24, 2014]. 
Nilsson, R. et al., 2014. Metabolic enzyme expression highlights a key role for 
MTHFD2 and the mitochondrial folate pathway in cancer. Nature 
communications, 5, p.3128. 
Pandey, D.P. & Picard, D., 2009. miR-22 inhibits estrogen signaling by directly 
targeting the estrogen receptor alpha mRNA. Molecular and cellular biology, 
29(13), pp.3783–90. 
Pasquinelli, a E. et al., 2000. Conservation of the sequence and temporal expression 
of let-7 heterochronic regulatory RNA. Nature, 408(6808), pp.86–9. 
Patel, J.B. et al., 2011. Control of EVI-1 oncogene expression in metastatic breast 
cancer cells through microRNA miR-22. Oncogene, 30(11), pp.1290–301. 
Pawelek, P.D. & MacKenzie, R.E., 1998. Methenyltetrahydrofolate cyclohydrolase is 
rate limiting for the enzymatic conversion of 10-formyltetrahydrofolate to 5,10-
methylenetetrahydrofolate in bifunctional dehydrogenase-cyclohydrolase 
enzymes. Biochemistry, 37(4), pp.1109–15. 
Peter, M.E., 2010. Targeting of mRNAs by multiple miRNAs: the next step. 
Oncogene, 29(15), pp.2161–4. 
Peterson, S.M. et al., 2014. Common features of microRNA target prediction tools. 
Frontiers in genetics, 5(February), p.23. 
Pillai, R.S., Bhattacharyya, S.N. & Filipowicz, W., 2007. Repression of protein 
synthesis by miRNAs: how many mechanisms? Trends in cell biology, 17(3), 
pp.118–26. 
References 
 
150 
Polioudakis, D. et al., 2013. A Myc-microRNA network promotes exit from 
quiescence by suppressing the interferon response and cell-cycle arrest genes. 
Nucleic acids research, 41(4), pp.2239–54. 
Pomyen, Y. et al., 2014. Over-representation of correlation analysis (ORCA): a 
method for identifying associations between variable sets. Bioinformatics, pp.1–
7. 
Psathas, J.N. & Thomas-Tikhonenko, A., 2014. MYC and the art of microRNA 
maintenance. Cold Spring Harbor perspectives in medicine, 4(8). 
Rajaram, S. & Oono, Y., 2010. NeatMap--non-clustering heat map alternatives in R. 
BMC bioinformatics, 11(1), p.45. 
Reczko, M. et al., 2012. Functional microRNA targets in protein coding sequences. 
Bioinformatics (Oxford, England), 28(6), pp.771–6. 
Rehmsmeier, M. et al., 2004. Fast and effective prediction of microRNA / target 
duplexes. , pp.1507–1517. 
Reinhart, B.J. et al., 2000. The 21-nucleotide let-7 RNA regulates developmental 
timing in Caenorhabditis elegans. Nature, 403(6772), pp.901–6. 
Resendis-Antonio, O. et al., 2015. Modeling metabolism: A window toward a 
comprehensive interpretation of networks in cancer. Seminars in cancer biology, 
30, pp.79–87. 
Ritchie, W. & Rasko, J.E.J., 2014. Refining microRNA target predictions: sorting the 
wheat from the chaff. Biochemical and biophysical research communications, 
445(4), pp.780–4. 
Robinson, M.D. & Oshlack, A., 2010. A scaling normalization method for differential 
expression analysis of RNA-seq data. Genome biology, 11(3), p.R25. 
Rodriguez, A. et al., 2004. Identification of mammalian microRNA host genes and 
transcription units. Genome Research, 14, pp.1902–1910. 
Rottiers, V. & Näär, A.M., 2012. MicroRNAs in metabolism and metabolic disorders. 
Nature reviews. Molecular cell biology, 13(4), pp.239–50. 
Rudolf, E., Rudolf, K. & Cervinka, M., 2011. Camptothecin induces p53-dependent 
and -independent apoptogenic signaling in melanoma cells. Apoptosis!: an 
international journal on programmed cell death, 16(11), pp.1165–76. 
Ruike, Y. et al., 2008. Global correlation analysis for micro-RNA and mRNA 
expression profiles in human cell lines. Journal of human genetics, 53(6), 
pp.515–23. 
Saito, T. & Saetrom, P., 2010. MicroRNAs--targeting and target prediction. New 
biotechnology, 27(3), pp.243–9. 
References 
 
151 
Sarkies, P. & Miska, E. a., 2014. Small RNAs break out: the molecular cell biology of 
mobile small RNAs. Nature Reviews Molecular Cell Biology, 15(8), pp.525–
535. 
Scherf, U. et al., 2000. A gene expression database for the molecular pharmacology of 
cancer. nature genetics, 24(3), pp.236–44. 
Selcuklu, S.D. et al., 2012. MicroRNA-9 inhibition of cell proliferation and 
identification of novel miR-9 targets by transcriptome profiling in breast cancer 
cells. The Journal of biological chemistry, 287(35), pp.29516–28. 
Sempere, L.F. et al., 2004. Expression profiling of mammalian microRNAs uncovers 
a subset of brain-expressed microRNAs with possible roles in murine and human 
neuronal differentiation. Genome biology, 5(3), p.R13. 
Sethi, P. & Alagiriswamy, S., 2010. Association rule based similarity measures for 
the clustering of gene expression data. The open medical informatics journal, 4, 
pp.63–73. 
Seyfried, T.N. et al., 2014. Cancer as a metabolic disease: implications for novel 
therapeutics. Carcinogenesis, 35(3), pp.515–27. 
Shankavaram, U.T. et al., 2007. Transcript and protein expression profiles of the NCI-
60 cancer cell panel: an integromic microarray study. Molecular cancer 
therapeutics, 6(3), pp.820–32. 
Shannon, C., 1948. A mathematical theory of communination. The bell system 
technical journal, 27(3), p.379. 
Shiau, a. L. et al., 2014. Elovl6 overexpression promotes liver carcinogenesis. 
European Journal of Cancer, 50, p.S75. 
Sikand, K., Slane, S.D. & Shukla, G.C., 2009. Intrinsic expression of host genes and 
intronic miRNAs in prostate carcinoma cells. Cancer Cell International, 9(1), 
p.21. 
Slezak-Prochazka, I. et al., 2013. Cellular localization and processing of primary 
transcripts of exonic microRNAs. PloS one, 8(9), p.e76647. 
Søkilde, R. et al., 2011. Global microRNA analysis of the NCI-60 cancer cell panel. 
Molecular cancer therapeutics, 10(3), pp.375–84. 
Song, S.J., Poliseno, L., et al., 2013. MicroRNA-antagonism regulates breast cancer 
stemness and metastasis via TET-family-dependent chromatin remodeling. Cell, 
154(2), pp.311–24. 
Song, S.J., Ito, K., et al., 2013. The oncogenic microRNA miR-22 targets the TET2 
tumor suppressor to promote hematopoietic stem cell self-renewal and 
transformation. Cell stem cell, 13(1), pp.87–101. 
References 
 
152 
Sun, W. et al., 2010. microRNA: a master regulator of cellular processes for 
bioengineering systems. Annual review of biomedical engineering, 12, pp.1–27. 
Sun, Z. & Zhu, Y., 2012. Systematic comparison of RNA-Seq normalization methods 
using measurement error models. Bioinformatics (Oxford, England), 28(20), 
pp.2584–91. 
Tavazoie, S. et al., 1999. Systematic determination of genetic network architecture. 
Nature genetics, 22(3), pp.281–5. 
Tenenbaum, D., 2013. KEGGREST: Client-side REST access to KEGG. 
The Cancer Genome Atlas Network, 2012. Comprehensive molecular portraits of 
human breast tumours. Nature, 490(7418), pp.61–70. 
The ENCODE Project Consortium, 2012. An integrated encyclopedia of DNA 
elements in the human genome. Nature, 489(7414), pp.57–74. 
Thomson, D.W., Bracken, C.P. & Goodall, G.J., 2011. Experimental strategies for 
microRNA target identification. Nucleic acids research, 39(16), pp.6845–53. 
Tibiche, C. & Wang, E., 2008. MicroRNA Regulatory Patterns on the Human 
Metabolic Network. The Open Systems Biology Journal, 1, pp.1–8. 
Ting, Y. et al., 2010. Differentiation-associated miR-22 represses Max expression and 
inhibits cell cycle progression. Biochemical and biophysical research 
communications, 394(3), pp.606–11. 
Tomasetti, M. et al., 2014. MicroRNA regulation of cancer metabolism: role in 
tumour suppression. Mitochondrion, 19, Part A, pp.29–38. 
Veronese, a et al., 2014. Allele-specific loss and transcription of the miR-15a/16-1 
cluster in chronic lymphocytic leukemia. Leukemia, (April), pp.1–10. 
Wang, J. et al., 2011. Microarray profiling of monocytic differentiation reveals 
miRNA-mRNA intrinsic correlation. Journal of cellular biochemistry, 112(9), 
pp.2443–53. 
Wang, W. et al., 2013. Integrative network-based Bayesian analysis of diverse 
genomics data. BMC bioinformatics, 14 Suppl 1(Suppl 13), p.S8. 
Ward, J.H., 1963. Hierarchical grouping to optimize an objective function. Journal of 
the American Statistical Association, 58(301), pp.236–244. 
Ward, P.S. & Thompson, C.B., 2012. Metabolic reprogramming: a cancer hallmark 
even warburg did not anticipate. Cancer cell, 21(3), pp.297–308. 
Whitlock, M.C., 2005. Combining probability from independent tests: the weighted 
Z-method is superior to Fisher’s approach. Journal of evolutionary biology, 
18(5), pp.1368–73. 
References 
 
153 
Wightman, B., Ha, I. & Ruvkun, G., 1993. Posttranscriptional regulation of the 
heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. 
elegans. Cell, 75(5), pp.855–62. 
Witkos, T.M., Koscianska, E. & Krzyzosiak, W.J., 2011. Practical Aspects of 
microRNA Target Prediction. Current molecular medicine, 11(2), pp.93–109. 
Xiong, J. et al., 2010. An estrogen receptor alpha suppressor, microRNA-22, is 
downregulated in estrogen receptor alpha-positive human breast cancer cell lines 
and clinical samples. The FEBS journal, 277(7), pp.1684–94. 
Xiong, J., Du, Q. & Liang, Z., 2010. Tumor-suppressive microRNA-22 inhibits the 
transcription of E-box-containing c-Myc target genes by silencing c-Myc binding 
protein. Oncogene, 29(35), pp.4980–8. 
Xu, D. et al., 2011. miR-22 represses cancer progression by inducing cellular 
senescence. The Journal of cell biology, 193(2), pp.409–24. 
Xu, J. et al., 2011. MiRNA-miRNA synergistic network: construction via co-
regulating functional modules and disease miRNA topological features. Nucleic 
acids research, 39(3), pp.825–36. 
Yoon, S. & De Micheli, G., 2005. Prediction of regulatory modules comprising 
microRNAs and target genes. Bioinformatics (Oxford, England), 21 Suppl 2, 
pp.ii93–100. 
Yoshimoto, N. et al., 2011. Distinct expressions of microRNAs that directly target 
estrogen receptor α in human breast cancer. Breast cancer research and 
treatment, 130(1), pp.331–9. 
Zeeberg, B.R. et al., 2003. GoMiner: a resource for biological interpretation of 
genomic and proteomic data. Genome biology, 4(4), p.R28. 
Zhang, G. et al., 2012. Clinical significance of miR-22 expression in patients with 
colorectal cancer. Medical oncology (Northwood, London, England), 29(5), 
pp.3108–12. 
Zhang, J. et al., 2010. microRNA-22, downregulated in hepatocellular carcinoma and 
correlated with prognosis, suppresses cell proliferation and tumourigenicity. 
British journal of cancer, 103(8), pp.1215–20. 
Zhang, Z. et al., 2009. MicroRNA miR-210 modulates cellular response to hypoxia 
through the MYC antagonist MNT. Cell cycle (Georgetown, Tex.), 8(17), 
pp.2756–68. 
Zhu, Y. et al., 2012. MicroRNA-26a/b and their host genes cooperate to inhibit the 
G1/S transition by activating the pRb protein. Nucleic acids research, 40(10), 
pp.4615–25. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendices 
 
Appendix A1 
 
Appendix A1 
Table A1.1 List of miRNA in cluster 1. 
miRNA in cluster1 
miR-451 
miR-551a 
miR-187 
miR-210 
 
Table A1.2 List of miRNA in cluster 2. 
miRNA in cluster 2 
miR-99ab/100 
miR-191 
miR-184 
miR-122/122a/1352 
miR-126-3p 
 
Table A1.2 List of miRNA in cluster 3. 
miRNA in cluster 3 
miR-499-5p 
miR-208ab/208ab-3p 
miR-18ab/4735-3p 
miR-383 
miR-193/193b/193a-3p 
miR-196abc 
miR-10abc/10a-5p 
miR-33a-3p/365/365-3p 
miR-455-5p 
miR-190/190ab 
miR-223 
miR-155 
miR-153 
miR-33ab/33-5p 
miR-375 
miR-142-3p 
miR-21/590-5p 
miR-139-5p 
miR-221/222/222ab/1928 
miR-219-5p/508/508-3p/4782-3p 
miR-216a 
miR-216b/216b-5p 
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Table A1.3 List of miRNA in cluster 4. 
miRNA in cluster 4 
miR-23abc/23b-3p 
miR-25/32/92abc/363/363-3p/367 
miR-26ab/1297/4465 
miR-30abcdef/30abe-5p/384-5p 
miR-101/101ab 
miR-132/212/212-3p 
miR-137/137ab 
miR-141/200a 
miR-144 
miR-181abcd/4262 
miR-194 
miR-200bc/429/548a 
miR-203 
miR-217 
 
Table A1.4 List of miRNA in cluster 5. 
miRNA in cluster 5 
miR-96/507/1271 
miR-182 
miR-148ab-3p/152 
miR-130ac/301ab/301b/301b-
3p/454/721/4295/3666 
miR-19ab 
miR-490-3p 
miR-146ac/146b-5p 
miR-34ac/34bc-5p/449abc/449c-5p 
miR-103a/107/107ab 
let-7/98/4458/4500 
miR-425/425-5p/489 
miR-31 
miR-183 
miR-205/205ab 
miR-192/215 
miR-140/140-5p/876-3p/1244 
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Table A1.5 List of miRNA in cluster 6. 
miRNA in cluster 6 
miR-1ab/206/613 
miR-7/7ab 
miR-9/9ab 
miR-15abc/16/16abc/195/322/424/497/1907 
miR-17/17-5p/20ab/20b-5p/93/106ab/427/518a-
3p/519d 
miR-22/22-3p 
miR-24/24ab/24-3p 
miR-27abc/27a-3p 
miR-29abcd 
miR-93/93a/105/106a/291a-
3p/294/295/302abcde/372/373/428/519a/520be/520acd-
3p/1378/1420ac 
miR-124/124ab/506 
miR-125a-5p/125b-5p/351/670/4319 
miR-128/128ab 
miR-129-5p/129ab-5p 
miR-133abc 
miR-135ab/135a-5p 
miR-138/138ab 
miR-143/1721/4770 
miR-145 
miR-150/5127 
miR-199ab-5p 
miR-204/204b/211 
miR-214/761/3619-5p 
miR-218/218a 
miR-338/338-3p 
miR-503 
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Table A1.6 Over-represented pathways in cluster 1. 
Pathway name Number of occurrences p-value Adjusted p-value 
Purine metabolism 1 0.35 0.35 
Rap1 signaling pathway 1 0.16 0.32 
cGMP-PKG signaling pathway 1 0.23 0.32 
cAMP signaling pathway 2 0.04 0.32 
Chemokine signaling pathway 1 0.31 0.34 
Adrenergic signaling in 
cardiomyocytes 1 0.11 0.32 
Platelet activation 1 0.10 0.32 
Glutamatergic synapse 1 0.21 0.32 
Cholinergic synapse 1 0.29 0.34 
Inflammatory mediator regulation of 
TRP channels 1 0.27 0.34 
Progesterone-mediated oocyte 
maturation 1 0.33 0.34 
Estrogen signaling pathway 1 0.23 0.32 
Oxytocin signaling pathway 1 0.17 0.32 
Pancreatic secretion 1 0.17 0.32 
Bile secretion 1 0.20 0.32 
Morphine addiction 1 0.21 0.32 
Chagas disease (American 
trypanosomiasis) 1 0.19 0.32 
Amoebiasis 1 0.23 0.32 
HTLV-I infection 1 0.19 0.32 
 
Table A1.7 Over-represented pathways in cluster 2. 
Pathway name Number of occurrences p.value Adjusted p-value 
Purine metabolism 1 0.46 0.46 
Arginine and proline metabolism 1 0.23 0.43 
Glycosaminoglycan biosynthesis - 
heparan sulfate / heparin 1 0.31 0.43 
Glycerolipid metabolism 1 0.37 0.43 
Glycerophospholipid metabolism 2 0.10 0.43 
Glycosphingolipid biosynthesis - 
ganglio series 1 0.15 0.43 
Drug metabolism - other enzymes 1 0.14 0.43 
Calcium signaling pathway 1 0.29 0.43 
cGMP-PKG signaling pathway 1 0.39 0.43 
cAMP signaling pathway 1 0.37 0.43 
Phosphatidylinositol signaling system 1 0.44 0.46 
Adrenergic signaling in 
cardiomyocytes 2 0.06 0.42 
Vascular smooth muscle contraction 1 0.24 0.43 
Gap junction 1 0.24 0.43 
Platelet activation 1 0.28 0.43 
Circadian entrainment 2 0.04 0.42 
Insulin secretion 1 0.27 0.43 
Thyroid hormone synthesis 1 0.31 0.43 
Oxytocin signaling pathway 1 0.26 0.43 
Salivary secretion 3 0.01 0.29 
Gastric acid secretion 1 0.31 0.43 
Pancreatic secretion 2 0.07 0.42 
Bile secretion 1 0.36 0.43 
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Table A1.8 Over-represented pathways in cluster 3. 
pathway name Number of occurrences p-value Adjusted p-value 
Purine metabolism 199 2.48E-12 4.76E-10 
Glycosphingolipid biosynthesis - lacto and 
neolacto series 104 9.36E-07 8.99E-05 
Morphine addiction 132 6.60E-06 0.0004 
Valine, leucine and isoleucine biosynthesis 61 3.68E-05 0.002 
Pantothenate and CoA biosynthesis 70 0.0001 0.005 
Glycosphingolipid biosynthesis - globo series 92 0.0002 0.006 
Pancreatic secretion 120 0.0002 0.006 
GABAergic synapse 104 0.0004 0.01 
cAMP signaling pathway 120 0.0006 0.01 
Salivary secretion 127 0.0006 0.01 
Lysine degradation 68 0.0007 0.01 
Phosphatidylinositol signaling system 141 0.002 0.02 
Valine, leucine and isoleucine degradation 102 0.002 0.03 
alpha-Linolenic acid metabolism 31 0.002 0.03 
Retinol metabolism 37 0.003 0.04 
Nicotinate and nicotinamide metabolism 41 0.006 0.07 
Other types of O-glycan biosynthesis 33 0.007 0.08 
Alanine, aspartate and glutamate metabolism 68 0.007 0.08 
Gap junction 70 0.01 0.13 
Biotin metabolism 13 0.02 0.19 
Glutamatergic synapse 104 0.02 0.20 
Peroxisome 46 0.03 0.25 
Cardiac muscle contraction 29 0.03 0.25 
Fatty acid degradation 73 0.04 0.31 
cGMP-PKG signaling pathway 112 0.04 0.31 
Circadian entrainment 78 0.04 0.32 
Protein digestion and absorption 37 0.04 0.32 
Bile secretion 102 0.05 0.34 
Chagas disease (American trypanosomiasis) 40 0.05 0.34 
Glycosaminoglycan biosynthesis - heparan 
sulfate / heparin 86 0.06 0.39 
FoxO signaling pathway 26 0.07 0.42 
Amoebiasis 38 0.07 0.42 
Pentose and glucuronate interconversions 9 0.08 0.47 
PPAR signaling pathway 53 0.09 0.47 
Inflammatory mediator regulation of TRP 
channels 67 0.09 0.47 
Estrogen signaling pathway 66 0.09 0.47 
Glycosylphosphatidylinositol(GPI)-anchor 
biosynthesis 33 0.09 0.49 
Glycerophospholipid metabolism 115 0.10 0.49 
Progesterone-mediated oocyte maturation 66 0.10 0.49 
Thyroid hormone synthesis 83 0.10 0.49 
Citrate cycle (TCA cycle) 12 0.12 0.54 
Aldosterone-regulated sodium reabsorption 38 0.12 0.55 
Insulin secretion 69 0.13 0.58 
Propanoate metabolism 23 0.15 0.64 
Cholinergic synapse 63 0.15 0.64 
Oocyte meiosis 27 0.16 0.68 
Nitrogen metabolism 15 0.17 0.71 
GnRH signaling pathway 48 0.21 0.83 
Melanogenesis 42 0.21 0.83 
Adrenergic signaling in cardiomyocytes 81 0.22 0.84 
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Table A1.9 Over-represented pathways in cluster 3. 
 
pathway name Number of occurrences p-value Adjusted p-value 
Proximal tubule bicarbonate reclamation 32 0.26 1.00 
Glycolysis / Gluconeogenesis 21 1.00 1.00 
Pentose phosphate pathway 15 0.74 1.00 
Fructose and mannose metabolism 18 0.89 1.00 
Galactose metabolism 4 1.00 1.00 
Ascorbate and aldarate metabolism 2 0.97 1.00 
Fatty acid biosynthesis 3 1.00 1.00 
Steroid biosynthesis 2 0.83 1.00 
Primary bile acid biosynthesis 1 0.99 1.00 
Steroid hormone biosynthesis 14 0.89 1.00 
Oxidative phosphorylation 17 0.99 1.00 
Caffeine metabolism 3 0.99 1.00 
Pyrimidine metabolism 64 0.49 1.00 
Glycine, serine and threonine metabolism 6 0.98 1.00 
Cysteine and methionine metabolism 23 1.00 1.00 
Lysine biosynthesis 2 1.00 1.00 
Arginine and proline metabolism 41 0.90 1.00 
Histidine metabolism 4 1.00 1.00 
Tyrosine metabolism 2 1.00 1.00 
Tryptophan metabolism 7 1.00 1.00 
Phenylalanine, tyrosine and tryptophan 
biosynthesis 1 1.00 1.00 
beta-Alanine metabolism 19 0.91 1.00 
Taurine and hypotaurine metabolism 1 0.86 1.00 
Selenocompound metabolism 16 0.84 1.00 
Cyanoamino acid metabolism 1 0.38 1.00 
D-Glutamine and D-glutamate metabolism 15 0.64 1.00 
Glutathione metabolism 4 0.78 1.00 
Starch and sucrose metabolism 21 0.57 1.00 
N-Glycan biosynthesis 51 0.76 1.00 
Other glycan degradation 1 0.67 1.00 
Mucin type O-Glycan biosynthesis 67 0.56 1.00 
Amino sugar and nucleotide sugar metabolism 53 0.34 1.00 
Butirosin and neomycin biosynthesis 1 1.00 1.00 
Glycosaminoglycan degradation 6 0.99 1.00 
Glycosaminoglycan biosynthesis - chondroitin 
sulfate / dermatan sulfate 20 1.00 1.00 
Glycosaminoglycan biosynthesis - keratan sulfate 11 1.00 1.00 
Glycerolipid metabolism 92 0.36 1.00 
Inositol phosphate metabolism 92 0.46 1.00 
Ether lipid metabolism 36 0.88 1.00 
Arachidonic acid metabolism 19 0.96 1.00 
Linoleic acid metabolism 5 0.92 1.00 
Sphingolipid metabolism 41 0.70 1.00 
Glycosphingolipid biosynthesis - ganglio series 20 0.99 1.00 
Pyruvate metabolism 14 0.97 1.00 
Glyoxylate and dicarboxylate metabolism 3 0.31 1.00 
Butanoate metabolism 13 0.95 1.00 
One carbon pool by folate 8 1.00 1.00 
Thiamine metabolism 5 0.56 1.00 
Riboflavin metabolism 2 0.73 1.00 
Vitamin B6 metabolism 10 0.83 1.00 
Folate biosynthesis 3 0.29 1.00 
Porphyrin and chlorophyll metabolism 5 0.85 1.00 
Terpenoid backbone biosynthesis 2 0.47 1.00 
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Table A1.9 Over-represented pathways in cluster 3. 
 
pathway name Number of occurrences p-value Adjusted p-value 
Metabolism of xenobiotics by cytochrome P450 3 0.98 1.00 
Drug metabolism - cytochrome P450 3 0.98 1.00 
Drug metabolism - other enzymes 6 1.00 1.00 
Biosynthesis of unsaturated fatty acids 13 0.88 1.00 
ABC transporters 1 1.00 1.00 
Protein export 1 0.83 1.00 
ErbB signaling pathway 9 0.94 1.00 
Ras signaling pathway 4 1.00 1.00 
Rap1 signaling pathway 24 1.00 1.00 
Calcium signaling pathway 48 0.99 1.00 
Chemokine signaling pathway 25 1.00 1.00 
HIF-1 signaling pathway 24 0.81 1.00 
Lysosome 7 0.99 1.00 
Phagosome 7 0.99 1.00 
mTOR signaling pathway 13 0.98 1.00 
AMPK signaling pathway 35 0.71 1.00 
Apoptosis 6 0.98 1.00 
Vascular smooth muscle contraction 56 0.38 1.00 
VEGF signaling pathway 10 1.00 1.00 
Osteoclast differentiation 5 0.66 1.00 
Focal adhesion 2 0.98 1.00 
Platelet activation 64 0.44 1.00 
Toll-like receptor signaling pathway 5 0.95 1.00 
Jak-STAT signaling pathway 4 0.49 1.00 
Natural killer cell mediated cytotoxicity 6 0.64 1.00 
T cell receptor signaling pathway 8 0.86 1.00 
B cell receptor signaling pathway 7 0.99 1.00 
Fc epsilon RI signaling pathway 10 0.98 1.00 
Fc gamma R-mediated phagocytosis 19 0.87 1.00 
TNF signaling pathway 5 0.98 1.00 
Leukocyte transendothelial migration 8 0.61 1.00 
Long-term potentiation 12 0.91 1.00 
Synaptic vesicle cycle 10 1.00 1.00 
Neurotrophin signaling pathway 8 0.60 1.00 
Retrograde endocannabinoid signaling 45 0.60 1.00 
Serotonergic synapse 8 0.88 1.00 
Dopaminergic synapse 2 0.92 1.00 
Long-term depression 20 0.99 1.00 
Regulation of actin cytoskeleton 5 1.00 1.00 
Insulin signaling pathway 12 0.99 1.00 
Ovarian steroidogenesis 47 0.80 1.00 
Prolactin signaling pathway 6 1.00 1.00 
Thyroid hormone signaling pathway 42 0.67 1.00 
Adipocytokine signaling pathway 7 1.00 1.00 
Oxytocin signaling pathway 47 0.93 1.00 
Type II diabetes mellitus 6 1.00 1.00 
Non-alcoholic fatty liver disease (NAFLD) 16 0.80 1.00 
Endocrine and other factor-regulated calcium 
reabsorption 42 0.29 1.00 
Vasopressin-regulated water reabsorption 4 0.77 1.00 
Collecting duct acid secretion 5 1.00 1.00 
Gastric acid secretion 74 0.36 1.00 
Carbohydrate digestion and absorption 42 0.80 1.00 
Fat digestion and absorption 6 1.00 1.00 
Vitamin digestion and absorption 7 1.00 1.00 
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Table A1.9 Over-represented pathways in cluster 3. 
 
pathway name Number of occurrences p-value Adjusted p-value 
Mineral absorption 33 0.94 1.00 
Alzheimer's disease 14 0.99 1.00 
Parkinson's disease 7 1.00 1.00 
Amyotrophic lateral sclerosis (ALS) 36 0.40 1.00 
Huntington's disease 9 0.98 1.00 
Cocaine addiction 1 0.99 1.00 
Amphetamine addiction 1 0.99 1.00 
Alcoholism 1 0.64 1.00 
Bacterial invasion of epithelial cells 6 0.99 1.00 
Vibrio cholerae infection 11 1.00 1.00 
Epithelial cell signaling in Helicobacter pylori 
infection 7 1.00 1.00 
Toxoplasmosis 5 0.86 1.00 
Hepatitis C 5 0.66 1.00 
Hepatitis B 7 0.36 1.00 
Measles 5 0.66 1.00 
Influenza A 1 0.90 1.00 
HTLV-I infection 14 1.00 1.00 
Epstein-Barr virus infection 10 0.83 1.00 
Pathways in cancer 2 0.97 1.00 
Viral carcinogenesis 1 0.85 1.00 
Chemical carcinogenesis 3 1.00 1.00 
MicroRNAs in cancer 2 0.99 1.00 
Colorectal cancer 6 0.99 1.00 
Renal cell carcinoma 7 1.00 1.00 
Pancreatic cancer 12 0.92 1.00 
Endometrial cancer 13 0.98 1.00 
Glioma 16 0.97 1.00 
Prostate cancer 13 0.86 1.00 
Melanoma 13 0.97 1.00 
Chronic myeloid leukemia 6 0.99 1.00 
Acute myeloid leukemia 6 0.99 1.00 
Small cell lung cancer 13 0.96 1.00 
Non-small cell lung cancer 9 0.98 1.00 
Rheumatoid arthritis 6 0.91 1.00 
Dilated cardiomyopathy 31 0.61 1.00 
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Table A1.9 Over-represented pathways in cluster 4. 
 
Pathway name Number of occurrences p-value Adjusted p-value 
MicroRNAs in cancer 28 2.91E-11 5.74E-09 
Pyruvate metabolism 48 1.55E-07 1.02E-05 
Vibrio cholerae infection 57 1.50E-07 1.02E-05 
Citrate cycle (TCA cycle) 25 3.41E-07 1.68E-05 
Endometrial cancer 44 3.21E-06 0.0001 
Protein export 10 5.14E-06 0.0002 
Synaptic vesicle cycle 47 1.59E-05 0.0004 
Peroxisome 58 3.02E-05 0.0007 
Glycosylphosphatidylinositol(GPI)-anchor 
biosynthesis 46 6.31E-05 0.001 
mTOR signaling pathway 40 4.95E-05 0.001 
Collecting duct acid secretion 36 5.45E-05 0.001 
Protein digestion and absorption 48 6.53E-05 0.001 
Melanoma 37 0.0002 0.003 
Tyrosine metabolism 25 0.0003 0.004 
Focal adhesion 15 0.0003 0.004 
Glutathione metabolism 14 0.0006 0.007 
Starch and sucrose metabolism 36 0.001 0.01 
Small cell lung cancer 34 0.001 0.01 
Vitamin digestion and absorption 28 0.001 0.01 
Chemical carcinogenesis 20 0.001 0.01 
Glioma 39 0.001 0.01 
Adipocytokine signaling pathway 33 0.002 0.02 
Pathways in cancer 13 0.002 0.02 
Valine, leucine and isoleucine biosynthesis 51 0.003 0.02 
PI3K-Akt signaling pathway 9 0.003 0.02 
Other glycan degradation 5 0.004 0.03 
Phagosome 25 0.004 0.03 
Proximal tubule bicarbonate reclamation 42 0.004 0.03 
Primary bile acid biosynthesis 11 0.005 0.03 
Fat digestion and absorption 34 0.005 0.03 
Oxidative phosphorylation 42 0.005 0.03 
Glycolysis / Gluconeogenesis 51 0.005 0.03 
FoxO signaling pathway 30 0.006 0.04 
Serotonergic synapse 20 0.007 0.04 
Phenylalanine metabolism 12 0.007 0.04 
Histidine metabolism 22 0.009 0.05 
Hepatitis B 12 0.01 0.06 
VEGF signaling pathway 33 0.01 0.06 
D-Glutamine and D-glutamate metabolism 25 0.01 0.07 
Pantothenate and CoA biosynthesis 57 0.02 0.08 
Parkinson's disease 26 0.02 0.08 
Epithelial cell signaling in Helicobacter 
pylori infection 25 0.02 0.08 
Regulation of actin cytoskeleton 25 0.02 0.08 
Fatty acid degradation 73 0.02 0.09 
Ether lipid metabolism 55 0.02 0.10 
Steroid hormone biosynthesis 27 0.02 0.11 
Nitrogen metabolism 18 0.03 0.12 
Renal cell carcinoma 23 0.03 0.12 
Taurine and hypotaurine metabolism 5 0.04 0.14 
Glycosphingolipid biosynthesis - ganglio 
series 41 0.04 0.14 
Riboflavin metabolism 6 0.04 0.14 
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Table A1.10 Over-represented pathways in cluster 4. 
 
Pathway name Number of occurrences p-value Adjusted p-value 
TNF signaling pathway 16 0.04 0.17 
Propanoate metabolism 25 0.05 0.18 
Cocaine addiction 9 0.05 0.20 
Drug metabolism - cytochrome P450 12 0.06 0.20 
Phenylalanine, tyrosine and tryptophan 
biosynthesis 11 0.06 0.22 
Rheumatoid arthritis 14 0.07 0.25 
HIF-1 signaling pathway 35 0.07 0.25 
Glycine, serine and threonine metabolism 17 0.09 0.29 
Porphyrin and chlorophyll metabolism 11 0.09 0.29 
Metabolism of xenobiotics by cytochrome 
P450 11 0.09 0.29 
Tryptophan metabolism 31 0.10 0.31 
ABC transporters 15 0.10 0.31 
Viral carcinogenesis 4 0.10 0.32 
p53 signaling pathway 1 0.11 0.33 
PPAR signaling pathway 50 0.12 0.33 
Insulin signaling pathway 26 0.11 0.33 
Colorectal cancer 17 0.11 0.33 
Acute myeloid leukemia 17 0.12 0.34 
Cysteine and methionine metabolism 51 0.13 0.38 
Galactose metabolism 17 0.16 0.45 
Non-small cell lung cancer 20 0.17 0.46 
Lysine biosynthesis 16 0.19 0.52 
Prostate cancer 20 0.20 0.52 
Pentose and glucuronate interconversions 7 0.24 0.59 
Ascorbate and aldarate metabolism 7 0.24 0.59 
Valine, leucine and isoleucine degradation 79 0.25 0.59 
N-Glycan biosynthesis 59 0.24 0.59 
Apoptosis 14 0.23 0.59 
Fc epsilon RI signaling pathway 20 0.24 0.59 
Aldosterone-regulated sodium 
reabsorption 34 0.24 0.59 
Chronic myeloid leukemia 15 0.23 0.59 
Protein processing in endoplasmic 
reticulum 1 0.26 0.62 
Huntington's disease 18 0.26 0.62 
ErbB signaling pathway 16 0.28 0.64 
Glyoxylate and dicarboxylate metabolism 3 0.29 0.66 
Proteoglycans in cancer 4 0.29 0.66 
Non-alcoholic fatty liver disease (NAFLD) 21 0.30 0.67 
Carbohydrate digestion and absorption 49 0.31 0.69 
Bacterial invasion of epithelial cells 14 0.31 0.69 
NF-kappa B signaling pathway 1 0.34 0.73 
Nicotine addiction 1 0.34 0.73 
Alanine, aspartate and glutamate 
metabolism 51 0.35 0.74 
Arginine and proline metabolism 50 0.36 0.74 
B cell receptor signaling pathway 15 0.36 0.74 
Steroid biosynthesis 4 0.37 0.74 
beta-Alanine metabolism 26 0.37 0.74 
Toll-like receptor signaling pathway 10 0.38 0.74 
Prolactin signaling pathway 15 0.37 0.74 
Influenza A 3 0.38 0.74 
Pancreatic cancer 18 0.37 0.74 
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Table A1.10 Over-represented pathways in cluster 4. 
 
Pathway name Number of occurrences p-value Adjusted p-value 
Inositol phosphate metabolism 90 0.39 0.76 
Synthesis and degradation of ketone 
bodies 3 0.40 0.76 
Amphetamine addiction 5 0.40 0.76 
Retinol metabolism 23 0.44 0.83 
AMPK signaling pathway 37 0.48 0.90 
Biosynthesis of unsaturated fatty acids 17 0.50 0.91 
Endocrine and other factor-regulated 
calcium reabsorption 37 0.51 0.93 
Arachidonic acid metabolism 26 0.52 0.93 
Thiamine metabolism 5 0.53 0.93 
Fc gamma R-mediated phagocytosis 23 0.52 0.93 
Folate biosynthesis 2 0.54 0.95 
Lysine degradation 43 0.55 0.96 
Vasopressin-regulated water reabsorption 5 0.57 0.98 
Dopaminergic synapse 4 0.57 0.98 
Glutamatergic synapse 80 0.59 1.00 
Pentose phosphate pathway 6 1.00 1.00 
Fructose and mannose metabolism 18 0.86 1.00 
Fatty acid biosynthesis 8 0.89 1.00 
Purine metabolism 89 0.99 1.00 
Caffeine metabolism 1 1.00 1.00 
Pyrimidine metabolism 45 0.99 1.00 
Selenocompound metabolism 18 0.63 1.00 
Mucin type O-Glycan biosynthesis 56 0.89 1.00 
Other types of O-glycan biosynthesis 7 1.00 1.00 
Amino sugar and nucleotide sugar 
metabolism 46 0.63 1.00 
Butirosin and neomycin biosynthesis 2 0.99 1.00 
Glycosaminoglycan degradation 10 0.80 1.00 
Glycosaminoglycan biosynthesis - 
chondroitin sulfate / dermatan sulfate 31 0.76 1.00 
Glycosaminoglycan biosynthesis - keratan 
sulfate 11 1.00 1.00 
Glycosaminoglycan biosynthesis - heparan 
sulfate / heparin 64 0.77 1.00 
Glycerolipid metabolism 73 0.92 1.00 
Glycerophospholipid metabolism 84 0.94 1.00 
Linoleic acid metabolism 5 0.90 1.00 
alpha-Linolenic acid metabolism 6 1.00 1.00 
Sphingolipid metabolism 36 0.86 1.00 
Glycosphingolipid biosynthesis - lacto and 
neolacto series 57 0.72 1.00 
Glycosphingolipid biosynthesis - globo 
series 45 0.98 1.00 
Butanoate metabolism 6 1.00 1.00 
One carbon pool by folate 14 0.99 1.00 
Nicotinate and nicotinamide metabolism 23 0.75 1.00 
Biotin metabolism 1 1.00 1.00 
Drug metabolism - other enzymes 21 0.90 1.00 
Ras signaling pathway 10 0.64 1.00 
Rap1 signaling pathway 29 0.95 1.00 
Calcium signaling pathway 31 1.00 1.00 
cGMP-PKG signaling pathway 76 0.96 1.00 
cAMP signaling pathway 66 0.99 1.00 
Chemokine signaling pathway 28 0.96 1.00 
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Table A1.10 Over-represented pathways in cluster 4. 
 
Pathway name Number of occurrences p-value Adjusted p-value 
Phosphatidylinositol signaling system 90 0.94 1.00 
Oocyte meiosis 6 1.00 1.00 
Lysosome 10 0.92 1.00 
Cardiac muscle contraction 13 0.95 1.00 
Adrenergic signaling in cardiomyocytes 52 0.99 1.00 
Vascular smooth muscle contraction 36 0.99 1.00 
Osteoclast differentiation 3 0.91 1.00 
Gap junction 31 1.00 1.00 
Platelet activation 46 0.98 1.00 
Jak-STAT signaling pathway 3 0.68 1.00 
Natural killer cell mediated cytotoxicity 3 0.95 1.00 
T cell receptor signaling pathway 10 0.61 1.00 
Leukocyte transendothelial migration 6 0.83 1.00 
Circadian entrainment 35 1.00 1.00 
Long-term potentiation 8 0.99 1.00 
Neurotrophin signaling pathway 6 0.82 1.00 
Retrograde endocannabinoid signaling 33 0.97 1.00 
Cholinergic synapse 40 0.97 1.00 
GABAergic synapse 62 0.88 1.00 
Long-term depression 23 0.94 1.00 
Phototransduction 1 0.69 1.00 
Inflammatory mediator regulation of TRP 
channels 37 1.00 1.00 
Insulin secretion 32 1.00 1.00 
GnRH signaling pathway 17 1.00 1.00 
Ovarian steroidogenesis 45 0.80 1.00 
Progesterone-mediated oocyte maturation 41 0.97 1.00 
Estrogen signaling pathway 34 1.00 1.00 
Melanogenesis 17 1.00 1.00 
Thyroid hormone synthesis 41 1.00 1.00 
Thyroid hormone signaling pathway 36 0.87 1.00 
Oxytocin signaling pathway 48 0.85 1.00 
Type II diabetes mellitus 20 0.60 1.00 
Salivary secretion 63 1.00 1.00 
Gastric acid secretion 42 1.00 1.00 
Pancreatic secretion 69 0.95 1.00 
Bile secretion 65 0.98 1.00 
Mineral absorption 26 0.99 1.00 
Alzheimer's disease 21 0.73 1.00 
Amyotrophic lateral sclerosis (ALS) 15 1.00 1.00 
Morphine addiction 77 0.84 1.00 
Chagas disease (American 
trypanosomiasis) 22 0.93 1.00 
Toxoplasmosis 6 0.71 1.00 
Amoebiasis 20 0.96 1.00 
Hepatitis C 3 0.91 1.00 
Measles 3 0.91 1.00 
HTLV-I infection 26 0.68 1.00 
Epstein-Barr virus infection 11 0.69 1.00 
Dilated cardiomyopathy 13 1.00 1.00 
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Table A1.10 Over-represented pathways in cluster 5. 
Pathway name Number of occurrences p-value Adjusted p-value 
Glycolysis / Gluconeogenesis 1 0.35 0.69 
Fructose and mannose metabolism 1 0.24 0.69 
Galactose metabolism 1 0.15 0.69 
Fatty acid degradation 1 0.50 0.69 
Oxidative phosphorylation 1 0.28 0.69 
Purine metabolism 1 0.75 0.75 
Pyrimidine metabolism 1 0.52 0.69 
Alanine, aspartate and glutamate 
metabolism 1 0.44 0.69 
Cysteine and methionine metabolism 1 0.41 0.69 
Valine, leucine and isoleucine degradation 1 0.59 0.69 
Valine, leucine and isoleucine 
biosynthesis 1 0.34 0.69 
Lysine degradation 1 0.41 0.69 
Arginine and proline metabolism 1 0.44 0.69 
beta-Alanine metabolism 1 0.25 0.69 
Starch and sucrose metabolism 1 0.22 0.69 
Mucin type O-Glycan biosynthesis 1 0.55 0.69 
Amino sugar and nucleotide sugar 
metabolism 1 0.44 0.69 
Butirosin and neomycin biosynthesis 1 0.08 0.69 
Glycosaminoglycan degradation 1 0.14 0.69 
Glycosaminoglycan biosynthesis - 
chondroitin sulfate / dermatan sulfate 1 0.34 0.69 
Glycosaminoglycan biosynthesis - 
heparan sulfate / heparin 1 0.57 0.69 
Glycerolipid metabolism 1 0.65 0.69 
Glycerophospholipid metabolism 1 0.70 0.71 
Ether lipid metabolism 1 0.40 0.69 
Arachidonic acid metabolism 1 0.27 0.69 
Sphingolipid metabolism 1 0.40 0.69 
Glycosphingolipid biosynthesis - lacto and 
neolacto series 1 0.52 0.69 
Glycosphingolipid biosynthesis - globo 
series 1 0.52 0.69 
Glycosphingolipid biosynthesis - ganglio 
series 1 0.31 0.69 
One carbon pool by folate 1 0.26 0.69 
Nicotinate and nicotinamide metabolism 1 0.27 0.69 
Pantothenate and CoA biosynthesis 1 0.40 0.69 
Retinol metabolism 1 0.23 0.69 
Drug metabolism - other enzymes 1 0.28 0.69 
cGMP-PKG signaling pathway 1 0.67 0.69 
cAMP signaling pathway 1 0.65 0.69 
HIF-1 signaling pathway 1 0.28 0.69 
Lysosome 1 0.16 0.69 
Adrenergic signaling in cardiomyocytes 1 0.58 0.69 
Vascular smooth muscle contraction 1 0.46 0.69 
VEGF signaling pathway 1 0.23 0.69 
Gap junction 1 0.46 0.69 
Platelet activation 1 0.52 0.69 
Circadian entrainment 1 0.53 0.69 
Glutamatergic synapse 1 0.63 0.69 
GABAergic synapse 1 0.58 0.69 
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Table A1.11 Over-represented pathways in cluster 5. 
 
Pathway name Number of occurrences p-value Adjusted p-value 
Long-term depression 1 0.31 0.69 
Ovarian steroidogenesis 1 0.46 0.69 
Thyroid hormone synthesis 1 0.57 0.69 
Thyroid hormone signaling pathway 1 0.40 0.69 
Oxytocin signaling pathway 1 0.49 0.69 
Type II diabetes mellitus 1 0.22 0.69 
Aldosterone-regulated sodium 
reabsorption 1 0.30 0.69 
Proximal tubule bicarbonate reclamation 1 0.28 0.69 
Salivary secretion 1 0.67 0.69 
Gastric acid secretion 1 0.56 0.69 
Pancreatic secretion 1 0.63 0.69 
Carbohydrate digestion and absorption 1 0.42 0.69 
Fat digestion and absorption 1 0.22 0.69 
Bile secretion 1 0.64 0.69 
Mineral absorption 1 0.39 0.69 
Amyotrophic lateral sclerosis (ALS) 1 0.33 0.69 
Morphine addiction 1 0.65 0.69 
Vibrio cholerae infection 1 0.28 0.69 
Pancreatic cancer 1 0.18 0.69 
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Table A1.11 Over-represented pathways in cluster 6. 
Pathway name Number of occurrences p-value 
Adjusted p-
value 
Type II diabetes mellitus 161 1.56E-16 3.22E-14 
Butanoate metabolism 144 6.41E-15 6.60E-13 
Insulin signaling pathway 145 2.91E-12 2.00E-10 
Regulation of actin cytoskeleton 120 5.74E-12 2.96E-10 
Prolactin signaling pathway 105 1.93E-11 7.94E-10 
Bacterial invasion of epithelial cells 94 1.37E-10 4.71E-09 
Chronic myeloid leukemia 94 1.98E-10 5.10E-09 
Acute myeloid leukemia 96 1.89E-10 5.10E-09 
Colorectal cancer 95 2.53E-10 5.80E-09 
B cell receptor signaling pathway 100 5.59E-10 1.07E-08 
Vitamin digestion and absorption 109 5.70E-10 1.07E-08 
Renal cell carcinoma 105 1.37E-08 2.34E-07 
Glycine, serine and threonine metabolism 86 4.12E-08 6.53E-07 
Non-small cell lung cancer 106 1.16E-07 1.70E-06 
Tyrosine metabolism 82 1.98E-07 2.72E-06 
Apoptosis 80 2.20E-07 2.84E-06 
Vitamin B6 metabolism 86 3.23E-07 3.91E-06 
AMPK signaling pathway 205 1.02E-06 1.16E-05 
Pancreatic cancer 105 1.13E-06 1.23E-05 
Glycosaminoglycan biosynthesis - keratan sulfate 145 1.28E-06 1.32E-05 
Proteoglycans in cancer 28 1.44E-06 1.42E-05 
Fc epsilon RI signaling pathway 107 1.53E-06 1.43E-05 
Epstein-Barr virus infection 82 3.96E-06 3.54E-05 
Lysine biosynthesis 83 4.44E-06 3.81E-05 
Caffeine metabolism 56 4.63E-06 3.82E-05 
beta-Alanine metabolism 140 7.92E-06 6.27E-05 
Aldosterone-regulated sodium reabsorption 168 8.64E-06 6.59E-05 
Fatty acid biosynthesis 75 1.84E-05 0.00013541 
Propanoate metabolism 105 2.48E-05 0.000175891 
Pentose phosphate pathway 100 2.91E-05 0.000199533 
Nicotine addiction 8 3.22E-05 0.000213921 
Terpenoid backbone biosynthesis 17 3.50E-05 0.000225309 
Tryptophan metabolism 137 4.03E-05 0.000246234 
ErbB signaling pathway 84 4.18E-05 0.000246234 
Viral carcinogenesis 19 4.10E-05 0.000246234 
Phenylalanine, tyrosine and tryptophan 
biosynthesis 47 5.21E-05 0.00029824 
Sphingolipid metabolism 220 8.43E-05 0.000469127 
Non-alcoholic fatty liver disease (NAFLD) 107 8.69E-05 0.000471063 
HIF-1 signaling pathway 148 9.99E-05 0.000527423 
Influenza A 20 0.000318179 0.001638624 
Ras signaling pathway 66 0.000480099 0.002412204 
Jak-STAT signaling pathway 27 0.00056637 0.002777909 
Toll-like receptor signaling pathway 55 0.000656828 0.003146664 
Phenylalanine metabolism 36 0.001131254 0.00517863 
HTLV-I infection 146 0.001115401 0.00517863 
Histidine metabolism 73 0.001218231 0.005455557 
VEGF signaling pathway 116 0.001260968 0.005526796 
Mineral absorption 203 0.001347207 0.005781764 
Fructose and mannose metabolism 119 0.001505351 0.006328617 
Endometrial cancer 110 0.002226267 0.009172221 
Carbohydrate digestion and absorption 222 0.002449239 0.009893004 
Lysosome 81 0.002776239 0.010998178 
mTOR signaling pathway 107 0.00341812 0.013285525 
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Table A1.12 Over-represented pathways in cluster 6. 
 
Pathway name Number of occurrences p-value 
Adjusted p-
value 
Butirosin and neomycin biosynthesis 44 0.003524148 0.013443973 
Ascorbate and aldarate metabolism 33 0.003736629 0.013995374 
Melanoma 103 0.003841056 0.014129599 
Phototransduction 11 0.004646859 0.016793913 
TNF signaling pathway 57 0.004897168 0.017393389 
Lysine degradation 210 0.005475571 0.019118095 
Ubiquinone and other terpenoid-quinone 
biosynthesis 7 0.00628012 0.021489529 
Chemokine signaling pathway 185 0.006363404 0.021489529 
ABC transporters 58 0.007543879 0.025065147 
Galactose metabolism 70 0.009571577 0.030882798 
Drug metabolism - other enzymes 134 0.009594656 0.030882798 
T cell receptor signaling pathway 58 0.010157899 0.032192726 
Folate biosynthesis 14 0.010814755 0.033755144 
Fc gamma R-mediated phagocytosis 115 0.011164135 0.03432555 
Prostate cancer 84 0.011900869 0.036052633 
Glioma 116 0.012907729 0.038536118 
Focal adhesion 32 0.01606941 0.047289978 
Thyroid hormone signaling pathway 201 0.017511931 0.050809265 
Natural killer cell mediated cytotoxicity 36 0.019701765 0.05636894 
Fat digestion and absorption 104 0.020457311 0.057728849 
Nicotinate and nicotinamide metabolism 125 0.025886533 0.07206251 
Hepatitis C 31 0.026728798 0.072449111 
Measles 31 0.026728798 0.072449111 
Linoleic acid metabolism 43 0.02901022 0.07713219 
Osteoclast differentiation 31 0.029205392 0.07713219 
Toxoplasmosis 39 0.030264107 0.078916533 
Glycosphingolipid biosynthesis - ganglio series 144 0.036050981 0.092831277 
Phagosome 70 0.040111535 0.102012052 
Leukocyte transendothelial migration 42 0.062715543 0.15755368 
Porphyrin and chlorophyll metabolism 36 0.070215487 0.174269763 
Amoebiasis 131 0.071958416 0.17646945 
Glycolysis / Gluconeogenesis 159 0.076619093 0.185688626 
alpha-Linolenic acid metabolism 80 0.084589609 0.201821539 
Rap1 signaling pathway 173 0.08523531 0.201821539 
FoxO signaling pathway 86 0.089434414 0.209357834 
Parkinson's disease 78 0.091759038 0.212386087 
Arginine and proline metabolism 210 0.097974921 0.224253708 
Hepatitis B 29 0.10057449 0.227646204 
Small cell lung cancer 89 0.101667237 0.227646204 
Neurotrophin signaling pathway 40 0.102786542 0.227677716 
Proximal tubule bicarbonate reclamation 123 0.125319565 0.274636493 
Pyruvate metabolism 96 0.13476915 0.292236262 
Tuberculosis 1 0.15314939 0.328633066 
PI3K-Akt signaling pathway 16 0.156250325 0.331830588 
Alanine, aspartate and glutamate metabolism 208 0.191666093 0.398820355 
Chagas disease (American trypanosomiasis) 129 0.191386218 0.398820355 
Sulfur metabolism 5 0.209649621 0.431878218 
Glycosaminoglycan degradation 56 0.236120488 0.481592283 
African trypanosomiasis 6 0.250705321 0.506326433 
Glycosaminoglycan biosynthesis - chondroitin 
sulfate / dermatan sulfate 149 0.258902437 0.517804875 
Alzheimer's disease 102 0.274502233 0.543725578 
Sulfur relay system 2 0.292228895 0.573325261 
Mucin type O-Glycan biosynthesis 274 0.324411645 0.630460367 
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Table A1.12 Over-represented pathways in cluster 6. 
 
Pathway name Number of occurrences p-value 
Adjusted p-
value 
Selenocompound metabolism 82 0.333733786 0.642515514 
Biotin metabolism 29 0.340716218 0.649884637 
D-Arginine and D-ornithine metabolism 1 0.392678335 0.742126028 
Metabolism of xenobiotics by cytochrome P450 30 0.397206094 0.743858686 
Other types of O-glycan biosynthesis 84 0.405717482 0.752953165 
Taste transduction 3 0.409516052 0.753217024 
Collecting duct acid secretion 74 0.424899616 0.774595759 
Amyotrophic lateral sclerosis (ALS) 136 0.451319791 0.81554278 
Synthesis and degradation of ketone bodies 10 0.461165197 0.818965781 
Cysteine and methionine metabolism 179 0.458705847 0.818965781 
Biosynthesis of unsaturated fatty acids 69 0.46759626 0.823289141 
D-Glutamine and D-glutamate metabolism 64 0.471760733 0.823582297 
Leishmaniasis 1 0.48569122 0.840776398 
Huntington's disease 62 0.522624161 0.897171477 
Starch and sucrose metabolism 84 0.529215019 0.900977636 
Drug metabolism - cytochrome P450 29 0.551000808 0.930378414 
Adipocytokine signaling pathway 77 0.580407052 0.972063843 
Citrate cycle (TCA cycle) 21 0.989016848 1 
Pentose and glucuronate interconversions 19 0.691239621 1 
Fatty acid elongation 1 0.735491808 1 
Fatty acid degradation 205 0.978868298 1 
Steroid biosynthesis 10 0.825068593 1 
Primary bile acid biosynthesis 15 0.8082639 1 
Steroid hormone biosynthesis 59 0.973214863 1 
Oxidative phosphorylation 98 0.937508113 1 
Purine metabolism 320 1 1 
Pyrimidine metabolism 244 0.654217573 1 
Valine, leucine and isoleucine degradation 235 0.999983818 1 
Valine, leucine and isoleucine biosynthesis 88 0.999999774 1 
Taurine and hypotaurine metabolism 6 0.78166927 1 
Cyanoamino acid metabolism 1 0.863966596 1 
Glutathione metabolism 15 0.935263098 1 
N-Glycan biosynthesis 212 0.70812518 1 
Other glycan degradation 3 0.824627683 1 
Amino sugar and nucleotide sugar metabolism 187 0.759169198 1 
Glycosaminoglycan biosynthesis - heparan 
sulfate / heparin 268 0.872180286 1 
Glycerolipid metabolism 301 0.997575256 1 
Inositol phosphate metabolism 304 0.99914439 1 
Glycosylphosphatidylinositol(GPI)-anchor 
biosynthesis 84 0.977458871 1 
Glycerophospholipid metabolism 315 0.999999402 1 
Ether lipid metabolism 144 0.98637289 1 
Arachidonic acid metabolism 100 0.751472878 1 
Glycosphingolipid biosynthesis - lacto and 
neolacto series 181 0.999999646 1 
Glycosphingolipid biosynthesis - globo series 189 0.999976096 1 
Glyoxylate and dicarboxylate metabolism 2 0.997535887 1 
One carbon pool by folate 91 0.834253522 1 
Thiamine metabolism 18 0.689700478 1 
Riboflavin metabolism 9 0.698728878 1 
Pantothenate and CoA biosynthesis 140 0.997837279 1 
Retinol metabolism 76 0.955025159 1 
Nitrogen metabolism 43 0.643988329 1 
Protein export 3 0.976598686 1 
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Table A1.12 Over-represented pathways in cluster 6. 
 
Pathway name Number of occurrences p-value 
Adjusted p-
value 
PPAR signaling pathway 164 0.738301332 1 
Calcium signaling pathway 244 0.75496893 1 
cGMP-PKG signaling pathway 292 0.999998931 1 
cAMP signaling pathway 284 0.999944176 1 
Phosphatidylinositol signaling system 319 1 1 
Oocyte meiosis 73 0.952265731 1 
Peroxisome 112 0.986158822 1 
Cardiac muscle contraction 67 0.930870018 1 
Adrenergic signaling in cardiomyocytes 280 0.768262888 1 
Vascular smooth muscle contraction 143 0.999999955 1 
Gap junction 134 0.999999999 1 
Platelet activation 225 0.932542962 1 
Circadian entrainment 182 0.999999745 1 
Long-term potentiation 42 0.99965287 1 
Synaptic vesicle cycle 78 0.992034958 1 
Retrograde endocannabinoid signaling 152 0.99381721 1 
Glutamatergic synapse 247 0.999999973 1 
Cholinergic synapse 207 0.760697635 1 
Serotonergic synapse 21 0.999989187 1 
GABAergic synapse 234 0.999929233 1 
Dopaminergic synapse 10 0.974207111 1 
Long-term depression 85 0.999982444 1 
Inflammatory mediator regulation of TRP 
channels 202 0.935563957 1 
Insulin secretion 188 0.999789044 1 
GnRH signaling pathway 118 0.999992243 1 
Ovarian steroidogenesis 170 0.997814437 1 
Progesterone-mediated oocyte maturation 196 0.966332987 1 
Estrogen signaling pathway 199 0.929106075 1 
Melanogenesis 107 0.999837625 1 
Thyroid hormone synthesis 229 0.999857341 1 
Oxytocin signaling pathway 209 0.881350998 1 
Endocrine and other factor-regulated calcium 
reabsorption 139 0.858187332 1 
Vasopressin-regulated water reabsorption 14 0.959785337 1 
Salivary secretion 275 0.999999994 1 
Gastric acid secretion 226 0.999768006 1 
Pancreatic secretion 251 0.999999972 1 
Protein digestion and absorption 97 0.883510573 1 
Bile secretion 269 0.999993071 1 
Cocaine addiction 13 0.967899923 1 
Amphetamine addiction 10 0.981830901 1 
Morphine addiction 246 1 1 
Vibrio cholerae infection 87 0.99435115 1 
Epithelial cell signaling in Helicobacter pylori 
infection 56 0.877884507 1 
Pathways in cancer 18 0.812574211 1 
Chemical carcinogenesis 31 0.921443354 1 
MicroRNAs in cancer 14 0.997061505 1 
Rheumatoid arthritis 33 0.782752456 1 
Dilated cardiomyopathy 103 0.990994669 1 
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ABSTRACT
Motivation: Often during the analysis of biological data, it is of import-
15 ance to interpret the correlation structure that exists between vari-
ables. Such correlations may reveal patterns of co-regulation that
are indicative of biochemical pathways or common mechanisms of
response to a related set of treatments. However, analyses of correl-
ations are usually conducted by either subjective interpretation of the
20 univariate covariance matrix or by applying multivariate modeling tech-
niques, which do not take prior biological knowledge into account.
Over-representation analysis (ORA) is a simple method for objectively
deciding whether a set of variables of known or suspected biological
relevance, such as a gene set or pathway, is more prevalent in a set of
25 variables of interest than we expect by chance. However, ORA is
usually applied to a set of variables differentiating a single experimen-
tal variable and does not take into account correlations.
Results: Over-representation of correlation analysis (ORCA) is a novel
combination of ORA and correlation analysis that provides ameans to
30 test whether more associations exist between two specific groups of
variables than expected by chance. The method is exemplified by
application to drug sensitivity and microRNA expression data from a
panel of cancer cell lines (NCI60). ORCA highlighted a previously
reported correlation between sensitivity to alkylating anticancer
35 agents and topoisomerase inhibitors. We also used this approach to
validate microRNA clusters predicted by mRNA correlations. These
observations suggest that ORCA has the potential to reveal novel
insights from these data, which are not readily apparent using
classical ORA.
40 Availability and implementation: The R code of the method is avail-
able at https://github.com/ORCABioinfo/ORCAcode
Supplementary information: Supplementary data are available at
Bioinformatics online.
Received on June 10, 2014; revised on August 13, 2014; accepted on
45 August 26, 2014
1 INTRODUCTION
High-throughput biological techniques such as gene expression
microarray or high-throughput sequencing have become a rou-
tine for most research laboratories in life sciences. Thousands of
50 biomolecules in different conditions, e.g. mRNAs, microRNAs,
proteins or metabolites, can be measured simultaneously.
In complex diseases, such as cancer, these biomolecules in a
group (such as a pathway or a gene set) are often altered to-
gether. Two conventional, but contrasting, approaches for ana-
55lyzing coordinated responses in molecular profile data are
correlation analysis and pathway analysis. In correlation or co-
variance analysis (and its multivariate extensions such as princi-
pal components analysis and canonical correlation analysis),
there is a focus on quantitatively estimating the explanatory
60power of one variable over another to infer some fundamental
link between the observed biomolecules. In pathway analysis,
however, the objective is to use prior knowledge about interact-
ing or otherwise related sets of biomolecules and to test specific
hypotheses about the relationship between a particular set of
65those biomolecules (the ‘pathway’) and a given experimental con-
dition. A conventional approach for pathway analysis of high-
throughput biological data is over-representation analysis
(ORA). To perform ORA, firstly, the biomolecules, such as
mRNA, proteins or microRNA, considered ‘differentially ex-
70pressed’ in two or more conditions are identified. Secondly, the
number of differentially expressed biomolecules in each pathway
is determined. Finally, for each pathway, a probability value (P-
value) of obtaining the number of differentially expressed bio-
molecules against the background list of all biomolecules mea-
75sured is calculated using a hypergeometric distribution. The first
implementation of ORA was by Tavazoie et al. (1999) where
transcriptional regulatory subnetworks in yeast were identified
by using mRNA microarray profiling. Most implementations of
ORA are used to perform pathway analysis based on pathway
80information, such as Kyoto Encyclopedia of Genes and
Genomes (KEGG) or other pathway databases (Cavill et al.,
2011), or to infer important biological functions of two different
conditions from biological categories, such as Gene Ontology
(GO; Beissbarth and Speed, 2004; Zeeberg et al., 2003).
85We introduce a novel method called Over-Representation of
Correlation Analysis (ORCA) that seeks to combine both con-
ventional approaches for analysis of coordinated biological re-
sponses and provide a new means to test for an unexpectedly
high prevalence of informative associations between two sets of
90variables, which could be mRNA, microRNA or proteins, that
comprise pathways/groups deemed of importance a priori. The
method first calculates the correlation coefficients between all the
variables in the dataset, in which the variables can be divided
into groups according to pre-defined criteria (exclusive group-
95ings). Then, as an analogy to counting ‘differentially’ expressed*To whom correspondence should be addressed.
! The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com 1
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genes in ORA (which might be below or above a certain thresh-
old of P-values or other metrics), ORCA defines the number of
correlation coefficients that are ‘above’ a certain threshold within
each group. Finally, the probability of association between any
5 two-group pair is calculated in a similar fashion to the calcula-
tion of over-representation in the conventional ORA. This prob-
ability value is calculated from the number of correlation
coefficients that pass a threshold against the background
number of correlation coefficients of the two-group pairs and
10 overall correlation coefficients by using the hypergeometric
test. The correlation coefficient threshold can be empirically
chosen or calculated by a Shannon’s entropy-based threshold
selection. The method was applied to several biological datasets
to demonstrate the concept and implications of ORCA in biolo-
15 gical data analysis.
2 METHODS
To apply ORCA, the variables (such as genes, microRNA or proteins) of
the dataset must be divided into sets according to relevant criteria, such as
GO annotations, KEGG pathways or groups, resulting from unsuper-
20 vised classification techniques such as hierarchical clustering. There
should also be as many data points available for an accurate correlation
coefficient as possible between two variables.
All statistical calculations and plots were made using R statistical
packages version 2.12. The P-values were all adjusted by Benjamini–
25 Hochberg false discovery rate (FDR) procedure (Benjamini and
Hochberg, 2009).
2.1 Over-representation of correlation analysis
A schematic representation of ORCA is shown in Figure 1. Firstly, the
method starts with calculation of the correlation coefficients between
30 all n variables, yielding a symmetric correlation matrix (n! n matrix).
We chose Spearman’s rank correlation coefficients in this study to
avoid the assumption of a Normal distribution. Secondly, variables
are sorted into sets or groups according to a priori information,
such as pathways, GO (sets 1–6 in Fig. 1). Correlation coefficients
35 between variables in the same group are called within-group correl-
ations, whereas the ones between different groups are called between-
group correlations. Thirdly, all correlation coefficients are labelled as
above or below a certain threshold previously established by empirical
means or a threshold selection method (see Section 2.2). The associ-
40 ation between sets or groups is then quantified by the number of
correlation coefficients between those two groups that are above the
threshold.
To determine the significance of the association between groups, we
introduce ORCA. The total number of correlation coefficients in the
45 correlation matrix of the dataset (N) in the analysis can be categorized
in two ways:
(i) correlation coefficients that are above the threshold (X of Venn
diagram in Fig. 1)
(ii) correlation coefficients that link members of a particular pair of
50 groups (M of Venn diagram in Fig. 1)
For any association between two groups, these criteria define four
different categories of correlation coefficients (see contingency table in
Fig. 1). The number of correlation coefficients that are both above the
threshold and are members of a particular pair of groups (k in contin-
55 gency table in Fig. 1) is the determinant of association between the pair of
groups being calculated (we used association between sets 1 and 6 as an
example in Fig. 1).
Finally, we calculate the P-value of obtaining, by chance, the number
of correlation coefficients that pass the threshold and are present in
60each set of between-group correlations (Supplementary Fig. S1). This
can be calculated by the hypergeometric distribution:
p n4kð Þ=1$
Xk
i=0
M
i
 !
N$M
X$ i
 !
N
X
 ! ð1Þ
where
t
u
 !
=
t!
u! t$uð Þ! is the binomial coefficient, M is the number of
between-group correlation coefficients, N is the total number of correl-
65ation coefficients in the correlation matrix (excluding within-group
correlations), X is the total number of between-group correlation
coefficients that pass the threshold and k is the number of correlation
coefficients in the between-group set of interest that pass the threshold.
The reason for excluding within-group correlation coefficients that
70pass the threshold is that these tend to have high correlation coefficients
and will cause an underestimation of the P-value calculating from be-
tween-group correlation. The P-values for within-group correlations were
separately calculated using the same equation but including within-group
correlations in N, M and X.
752.2 Threshold selection
To select a threshold of correlation coefficient that yields the most infor-
mation from the data, a selection method based on Shannon’s entropy
(Shannon, 1948) was developed. Briefly, a score is calculated for a range
Fig. 1. The concept of over-representation of correlation. A correlation
matrix of correlation coefficients calculated from a dataset is divided into
sets or groups. Correlation coefficients are represented by rectangles in
each group pair. Non-filled and crosshatch-filled rectangles represent cor-
relation coefficients that do not pass and do pass a certain threshold,
respectively. The contingency table in the bottom right explains the vari-
ables required to calculate the probability value of having a certain
number of correlation coefficients that pass the threshold in each group
pair by chance alone via the hypergeometric distribution (Equation 1)
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of correlation coefficient thresholds based on the P-values from ORCA
for all group pairs using the equation (2):
H Xð Þ=#
XJ
i=1
p xið Þlog epðxiÞ ð2Þ
where H(X) is a Shannon entropy-like score, P(xi) is a P-value of a
5 within- or between-group association calculated by hypergeometric test,
J is the total number of within- and between-group pairs [if the total
number of groups is n then J= n(n– 1)/2+ n] and loge is the natural
logarithm. The correlation coefficient that yields the highest Shannon
entropy-like score is selected for the ORCA threshold.
10 2.3 Permutation analysis
As the variables in the correlation matrix are not necessarily independent,
permutation analysis was used to determine the null distribution of the
P-values obtained by the hypergeometric test for a given data matrix.
Specifically the group membership of each variable in the dataset was
15 permuted, but the group structure (i.e. the number of groups and the
number of variables within each group) together with the overall distri-
bution of correlations was retained. For each dataset, one million per-
mutations were performed, and the empirical P-values of each between
and within groups were calculated by using the following equation
20 (Davison and Hinkley, 1997):
P=
ðr+1Þ
ðn+1Þ ð3Þ
where P is the empirical P-value, r is the number of times that the hyper-
geometric P-values from permutation test are equal or less than the actual
P-values from ORCA and n is the total number of permutation used in
25 the test.
3 RESULTS
3.1 ORCA reveals an association between the sensitivity
of tumour cells to alkylating agents and topoisomerase
inhibitors
30 To demonstrate the concept and potential of ORCA, we exam-
ined publicly available phenotypic profiles from the National
Cancer Institute cell line panel (NCI-60 panel). This dataset
meets the basic requirements of ORCA: the variables can be
divided into groups and each variable has multiple data points
35 for correlation analysis. This dataset consists of drug sensitivity
data associated with the NCI-60 cell panel: profiles of 58 cancer
cell lines treated with a range of drug compounds (Scherf et al.,
2000). The effect of a drug on a cell line was represented by the
concentration of the drug that lead to 50% growth inhibition
40 (GI50). We selected a collection of well-validated results for 116
chemotherapeutic drugs and divided them into nine groups ac-
cording to their mechanisms of action, i.e. the molecular targets
of the drugs. Our objective was to determine whether there
was similarity between different groups of drugs in terms of the
45 sensitivity pattern across the cell lines. The dataset is detailed in
Supplementary data files S1 and S2 and Supplementary Figure S2.
Despite a wide range of different mechanisms of action, some
of the drugs from different classes have an apparently high
degree of similarity in the observed sensitivity profile, as
50 observed in the correlation matrix of the GI50 data (Fig. 2).
We used ORCA to determine whether any two drug classes,
defined by independent modes of action, have more common
correlations that are above an informative threshold than we
would expect between them by chance. For this dataset, our
55threshold selection method identified a correlation coefficient
of 0.79 to produce the highest Shannon entropy-like score,
i.e. to be the most informative (Supplementary Fig. S3). Using
this threshold, ORCA was then applied to generate a matrix of
P-values for obtaining the observed number of high correlations,
60between every possible pair of groups of drugs (Table 1). The
analysis revealed that the similarity in sensitivity profile across
the NCI-60 panel between alkylating agents (group 1) and topo-
isomerase inhibitors (group 8) was much higher than expected by
chance (q=1e-6, Benjamini-Hochberg FDR). This finding has
65not previously been reported and could result in part by the fact
that both sets of compounds are likely to lead to single and
double-stranded DNA breaks in rapidly dividing cells, which
leaves the cells reliant on a common set of DNA repair pathways
for survival (Bargonetti et al., 2010; Rudolf et al., 2011). Another
70pair of drug classes exhibiting higher than expected association
was DNA synthesis inhibitor (group 5) and ribonucleotide
reductase inhibitor (group 6), albeit at a lesser extent than alky-
lating agents and topoisomerase inhibitors.
3.2 Verification of microRNA cluster significance
75The second and third datasets used in this study are microRNA
expression profiles of NCI-60 cell panel from Liu et al. (2010)
Fig. 2. Correlation matrix of drug sensitivity data from the NCI-60 cell
panel. Circles and squares represent positive and negative correlation
coefficients between two drugs, respectively. The sizes of circles and
squares reflect the strength of correlation. The filled circles and squares
are correlation coefficients that pass the threshold of 0.79. The lines
divide drugs into their groups according to their mechanisms of actions.
The number labels are NSC numbers (NCI’s sample accession number)
of the drugs. The drug names are given in Supplementary Material. Note
the unusually high number of positive correlations between alkylating
agents (group 1) and topoisomerase inhibitors (group 8)
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and Søkilde et al. (2011). The datasets measured baseline
microRNA expression of the 60 cancer cell lines. The primary
objective for using these datasets in ORCA is to verify the group-
ings (clusters) generated in miRConnect study (Hua et al., 2011).
5The secondary objective is to identify any interaction between
these clusters.
The miRConnect study attempted to cluster microRNAs using
a new correlation scheme (summed Pearson Correlation coeffi-
cient or sPCC) between baseline microRNA expression profiles
10and gene expression profiles from the same cell line panel. The
study divided 136 microRNAs into 13 clusters according to the
correlation patterns between microRNAs and gene expression of
selected gene signatures. We focused on the microRNAs, which
overlapped in both datasets, resulting in 124 microRNAs for this
15analysis.
Although the two datasets have the same structure, the data
were generated using different microarray technologies, thus re-
sulting in different microRNA profiles (see Supplementary files
S3 and S4; Supplementary Figure S4 and S5). The threshold
20selection method determined correlation coefficient thresholds
for Liu et al. (2010) and Søkilde et al. (2011) to be 0.29 and
0.61, respectively. Figure 3 shows correlation matrices of the
two datasets and Tables 2 and 3 show FDR-adjusted P-values
resulting from ORCA of the correlation matrices corresponding
25to the correlation matrices for Liu et al. (2010) and Søkilde et al.
(2011) datasets, respectively.
At the thresholds identified previously for the two datasets,
ORCA confirmed that several clusters as proposed by Hua et al.
(2011) were determined to contain significant within-group over-
30representation of correlations at an FDR-adjusted significance
level of 0.05 in both datasets, which are clusters I, IV, V, X
Fig. 3. Correlation matrices of two microRNA datasets characterizing the NCI-60 cell panel. Circles and squares represent positive and negative
correlation coefficients between two microRNAs, respectively. The sizes of circles and squares reflect the strength of correlation. The lines divide
microRNAs into their clusters according to the miRConnect study. The arrows indicate the clusters and a cluster pair that are significant according to
adjusted P-values from ORCA in both datasets. Note that the correlation thresholds for two datasets are different
Table 1. (A) Benjamini–Hochberg FDR-adjusted (lower half) and em-
pirical (upper half) P-value table for drug sensitivity dataset; (B) P-values
from diagonal (within-group correlation coefficients)
A)
Drug
Group 1 2 3 4 5 6 7 8 9 
Drug
Group
1 0.94 0.82 0.82 0.29 0.70 0.87 1E-6 0.99 1
2 1.00 0.59 0.59 0.66 0.58 0.60 0.92 0.91 2
3 1.00 1.00 0.58 0.68 0.42 0.64 0.78 0.79 3
4 1.00 1.00 1.00 0.11 0.42 0.64 0.78 0.79 4
5 1.00 1.00 1.00 0.33 0.01 0.62 0.24 0.86 5
6 1.00 1.00 1.00 1.00 0.01 0.47 0.64 0.62 6
7 1.00 1.00 1.00 1.00 1.00 1.00 0.81 0.81 7
8 1E-57 1.00 1.00 1.00 1.00 1.00 1.00 0.99 8
9 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 9
Drug
Group 1 2 3 4 5 6 7 8 9
Drug
Group
B)
Drug
Group 1 2 3 4 5 6 7 8 9 
Empirical
P-value 5E-5 0.03 0.31 0.007 0.21 1E-6 0.11 1E-6 0.01
FDR-adjusted 
P-value 9E-21 0.01 0.41 0.001 0.31 0 0.56 2E-37 0.26
Notes: P-values in grey-shaded cells are the group pairs that have the number of
correlation coefficients higher than expected that pass the threshold of 0.79 (FDR-
adjusted and empirical P-value50.05).
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and XIII. Considering associations between clusters, ORCA iden-
tified several cluster pairs where between-group correlations were
overrepresented, but only one cluster pair had over-representation
of correlations in both datasets: cluster pair X/XIII.
5The finding that clusters I, IV, V, X and XIII contain over-
representation of correlation as seen by ORCA supports the hy-
pothesis that miRNAs within these clusters are controlled by the
same transcription factors, located at the same chromosomal
regions or involved in the same processes or pathways.
10The significant association of cluster pair X/XIII could be
explained by the fact that several of the miRNAs in the two
clusters possess similar seed sequences, i.e. let-7 family, mir-23
family, mir-27 family, mir-125 family and mir-99/100 family
(Lewis et al., 2005). This fact was not reported in the original
15study and might suggest that these two clusters be best con-
sidered as a single superfamily of miRNAs.
Other potentially related clusters we identified by ORCA, i.e.
cluster pairs II/IV and V/VI, were less easy to be rationalized,
as clusters 2 and 6 did not exhibit significant within-group
Table 2. (A) Benjamini–Hochberg FDR-adjusted (lower half) and em-
pirical (upper half) P-value table for Liu et al. (2010) microRNA dataset;
(B) P-values from diagonal (within-group correlations)
Notes: P-values in grey-shaded cells are the group pairs that have the number of
correlation coefficients higher than expected that pass the threshold of 0.29 (FDR-
adjusted and empirical P-value50.05). P-values in bold are the clusters and cluster
pair that passed the threshold and overlapped with another microRNA dataset (also
correspond to the arrows on left panel in Fig. 3). P-values in left-slanted cells cor-
respond to the Figure 4.
Table 3. (A) Benjamini–Hochberg FDR-adjusted (lower half) and em-
pirical P-value (upper half) table for Søkilde et al. (2011) microRNA
dataset; (B) P-values from diagonal (within-group correlations)
Notes: P-values in grey-shaded cells are the group pairs that have the number of
correlation coefficients higher than expected that pass the threshold of 0.61 (FDR-
adjusted and empirical P-value50.05). P-values in bold are the clusters and cluster
pair that passed the threshold and overlapped with another microRNA dataset (also
correspond to the arrows on right panel in Fig. 3).
Fig. 4. Parts of the correlation matrix between the expression of selected
miRNAs from the Liu et al. (2010) dataset (cluster pairs I/XIII and V/
XIII). Circles and squares represent positive and negative correlation
coefficients between two microRNAs, respectively. The sizes of circles
and squares reflect the strength of correlation. Correlation threshold
identified by threshold selection method for this dataset is 0.29. This
result is consistent with the finding from Hua et al. (2013) that the
microRNAs in cluster I and V are the antagonists of microRNAs in
cluster XIII
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over-representation of correlation suggest possible misclassifica-
tion in the original clustering of these miRNA families.
Interestingly, a follow-up study Hua et al. (2013) observed that
clusters I and V appeared to be functionally antagonistic to
5 miRNAs in cluster XIII, i.e. had the opposite effect on the
same set of mRNAs. ORCA was able to identify significant
over-representation of (predominantly negative) correlations be-
tween clusters I and XIII and between clusters V and XIII in one
of the microarray datasets (Fig. 4). This highlighted the potential
10 of ORCA to detect such functional antagonism by analysis of
miRNA co-expression alone.
4 DISCUSSION
ORCA can be used as pathway analysis tool, but the research
question will be different from existing pathway or gene set ana-
15 lysis methods. Current methods identify pathways that are sig-
nificantly enriched or depleted with respect to genes associated to
a biological condition, while ORCA can identify pathways that
are associated through correlations. Although the examples
given here were not of typical pathways, ORCA can be applied
20 to any type of pathway or gene set to determine pathways that
are associated. In terms of pathway analysis, ORCA addresses
some limitations of existing pathway analysis methods that were
presented by Khatri et al. (2012). First, whereas ORA does not
take the actual levels of variables (such as gene expression or
25 metabolite levels) into consideration, ORCA can take these
values into account, although indirectly, through the correlation
coefficient calculation, which means that ORCA does not weigh
the variables equally. Second, by using correlation, ORCA does
not assume that the variables are independent, which is usually
30 an important assumption in typical ORA implementations.
Third, classical ORA only uses variables, such as mRNAs or
microRNAs, that are deemed most differentially expressed, while
ORCA uses all the data in the calculation. Fourth, pathway
analysis tools based on ORA use multiple testing corrections
35 that assume independence of each pathway. ORCA, on the
other hand, assumes the opposite and looks for the association
between two sets of variables. Because our method is based on
the hypergeometric test, it could be argued that ORCA violates
the assumptions of the independence of each data point by using
40 correlation coefficients as the source data. This may lead to in-
accurate P-value calculations from the test. Goeman and
B €uhlmann (2007) have shown in simulated data that when hyper-
geometric test was used in correlated datasets, the calculated
P-values will be underestimated. Possible remedies for the under-
45 estimated P-values could be multiple comparisons procedures,
such as Bonferroni correction or Benjamini–Hochberg FDR cor-
rection (which was applied in this study). A table showing the
nominal alpha level for correlated data from Goeman and
B €uhlmann (2007) can also be used to select a suitable alpha
50 level according to a correlation threshold. A limitation of this
approach is that in the simulation experiment mentioned above,
all the data points have the same correlation coefficient. An al-
ternative test that could be used instead of the hypergeometric
test is the Wilcoxon rank-sum test, where the comparison is
55 between the number of correlation coefficients in one group-
pair and all other group-pairs.
ORCA can be used in pathway analysis in the same way as
tools based on ORA. However, the information that will be
derived from ORCA relates specifically to the pathway inter-
60actions. For pathway or gene set analysis, ORCA can calculate
the correlation coefficients between genes or metabolites and
then find the pathway-pairs that have more correlation coeffi-
cients that pass a certain threshold (determined by the threshold
selection method or by other means) than expected.
65Our version of ORCA requires group membership of variables
to be mutually exclusive. Therefore, it cannot yet be used with
pathway data where group members overlap, i.e. variables
can not belong to more than one group. This is the subject of
future work.
70Recently gene co-function networks were used to identify
cross-category association between different GO classes
(CroGo, Peng et al., 2013). However, CroGO does not explicitly
include gene expression values into the analysis and, therefore,
could miss actual association between GO categories in the real
75biological context. In this regard, ORCA can be a crucial down-
stream analysis to CroGO to highlight associations between GO
categories that are of greatest importance, using gene expression
to complement the associations identified by CroGO.
In conclusion, ORCA is a new method that combines analysis
80of correlation with ORA, and has the potential to reveal other-
wise obscured associations between sets of variables, whether
they are genes, proteins, metabolites or other molecular signals,
in a wide variety of biological datasets. Although the method has
clear application in ‘-omics’ data analysis, ORCA can be profit-
85able in any circumstance where an association network can be
constructed between variables that can be classified into mean-
ingful sets.
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